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Summary 
Epstein-Barr virus (EBV) infects over 90% of the human population and persists in 
the infected individual lifelong without further complications. However, EBV is associated 
with several malignancies including Burkitt’s lymphoma (BL), which is endemic in the Sub-
Saharan African region and affects children around 5 years of age. Nevertheless, the 
contribution of EBV to the development of BL remains elusive. Other factors in addition to 
EBV have been identified, e.g., the malaria pathogen Plasmodium falciparum. P. falciparum 
was shown to have multiple effects on the human innate immune system including the 
triggering of the germ line encoded Toll-like receptor 9 (TLR9). Importantly, as ligands of 
TLR9 were shown to affect EBV-induced transformation, we aimed to investigate the effect 
of TLRs on EBV-associated malignancies.  
The work presented here focused on the impact of innate immunity (TLRs) towards 
EBV. We hypothesized that triggering TLR9 inhibits EBV lytic gene expression and thereby 
reduces the probability that EBV will undergo reactivation from latency. As latency is a 
prerequisite for transformation, a clear understanding of the factors that regulate lytic 
infection is critical. To investigate TLR9 stimulation, its subsequent signaling pathways, and 
its effects on EBV in more detail, we used EBV-positive BL cell lines as a model system. 
Expression of TLRs and the effects of TLR triggering on cell growth and cytokine expression 
were assessed. Most importantly, signaling pathways triggered by TLR9 were investigated, 
with a focus on the regulation of the switch between lytic and latent EBV.  
The data presented here provide new insights concerning the regulation of EBV gene 
expression in the context of TLR engagement. This markedly contributes to the 
understanding of how EBV and chronic innate immune stimulation, as seen in malaria, may 
affect BL development by forcing EBV to stay latent. Most importantly, our data argue that 
acetylation and phosphorylation on histones is the key step in the TLR9-induced suppression 
of EBV lytic gene expression. The novelty of how TLR9 affects viral promoter activation 
will be of great benefit for evaluating the role of TLR9 in cancer onset and development.  
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Zusammenfassung 
Das B-lymphotropische Epstein-Barr Virus (EBV) findet sich bei über 90% der 
humanen Weltbevölkerung wider. Nach Primärinfektion etabliert EBV eine lebenslang 
andauernde latente Infektion in den Gedächtnis B-Zellen des Wirtes. Unter bestimmten 
Bedingungen entwickelt sich die latente Infektion zu einem EBV-assoziierten Tumor wie 
zum Beispiel dem endemischen Burkitt’s Lymphom (BL), welcher vor allem in Afrika 
südlich der Sahara bei Kindern um die 5 Jahren auftritt. Welchen Einfluß EBV bei der 
Tumorentstehung jedoch hat, ist ungewiss. Eine Rolle in der Entstehung des BL könnten 
weitere Faktoren spielen: das Malaria Pathogen Plasmodium falciparum stimuliert auf 
mehrfache Weise das angeborene Immunsystem, insbesondere den Toll-like Rezeptors 9 
(TLR9). Unhabhängig davon wurde gezeigt, dass die Aktivierung von TLR9 einen Einfluß 
auf die in vitro Transformation durch EBV hat. Aufgrunddessen richteten wir unsere 
Untersuchungen auf die Auswirkungen von TLRs in Bezug auf EBV-assoziierte Tumoren.  
Die hier dargestellte Arbeit konzentriert sich auf die Konsequenzen der TLR-
aktivierten Signalwege bezüglich der Genexpression von EBV. Da EBV in latenter Phase 
eine Vorraussetzung für die Transformation der Zelle darstellt, ist ein Verständnis der 
Faktoren welche die lytische Phase regulieren von enormer Bedeutung. Die Untersuchungen 
der TLR9 Aktivierung, seiner Signalwege und Auswirkungen auf EBV wurden in EBV-
positiven BL Zelllinien durchgeführt. Dabei wurden ebenfalls die TLR Expression in BL 
Zelllinien und der Einfluß der TLR Aktivierung auf das Zellwachstum und die Zytokin 
Produktion analysiert.  
Diese Arbeit trägt wesentlich zum Verständnis bei, wie EBV und chronische 
Immunstimulierung, ähnlich wie bei Malaria, einen Einfluß auf die Entwicklung des BL 
nehmen können. Unsere Daten zeigen, daß eine Aktivierung von TLR9 zu Modifikationen in 
der Histonstruktur des lytischen EBV Promoters BZLF1 führt und die lytische Phase 
unterdrückt wird. Ein Verbleiben von EBV in der latenten Phase erhöht die 
Wahrscheinlichkeit, dass es zu einer onkogenen Mutation der Zellen kommt. Die hier 
dargestellten neuen Erkenntnisse dass TLR9 die Aktivierung eines viralen Promoters 
beeinflussen kann, werden von großer Bedeutung in der Beurteilung der Rolle von TLR9 bei 
der Tumorentstehung und Entwicklung sein. 
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Introduction 
Epstein-Barr virus 
Epstein-Barr virus and its life cycle 
The Epstein-Barr virus (EBV) is a double-stranded DNA virus and belongs to the 
group of the gamma herpesviruses of the Lymphocryptovirus (LCV) genus. It infects mainly 
B-cells and certain epithelial cells and is found in over 90% of the adult human population. 
Upon primary infection, the host remains a lifelong carrier of EBV. In developing countries, 
primary infection with EBV usually occurs in early childhood and is often asymptomatic. 
However, in developed countries, primary infection may be delayed until adolescence or 
adulthood, resulting in the characteristic clinical features of infectious mononucleosis (IM) in 
up to 50% of the cases. EBV is transmitted via saliva, and the virus gains access to B-cells 
within the lymphoid organs in the oropharynx. The virus persists in the host mainly as an 
asymptomatic latent infection of memory B-cells, which is characterized by only a limited 
viral gene expression to avoid immune recognition. Occasionally, EBV will switch to its lytic 
form, which ultimately results in the production of new virus particles, death of the host cell, 
and infection of new susceptible cells (1, 2). Upon switch to the lytic form, the EBV 
immediate-early genes BZLF1 (and its protein Zta) and BRLF1 (and its protein Rta) are the 
first viral products expressed. They encode transcription factors that lead to an ordered 
cascade of early and late lytic gene expression (3). 
The physiological stimuli that control the switch between latent and lytic EBV in B-
cells are not completely understood. In vivo, reactivation of the latent EBV into lytic 
replication to allow shedding and transmission of the virus probably occurs as memory B-
cells differentiate further, e.g., into plasma cells in response to antigen stimulation (3, 4). 
However, there are several mechanisms known to induce EBV lytic gene expression in vitro. 
These include cross-linking of the B-cell receptor (BCR) with an anti-Ig, treatment with 
transforming growth factor beta 1 (TGFβ1), addition of Ca2+ ionophores or activators of 
protein kinase C (PKC), like phorbol 12-myristate 13-acetate (PMA) or 12-O-
tetradecanoylphorbol-13-acetate (TPA), and infection with human herpesvirus 6 (5-10). All 
these inducing agents are believed to operate by different mechanisms and different signaling 
pathways, exemplified by the different duration of stimulus and response time needed for 
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activation of EBV BZLF1 and BRLF1 expression (11). Moreover, these agents exhibit a 
considerable variability in the degree of activation of lytic EBV infection in established cell 
lines. 
 
Regulation of the EBV immediate early lytic promoter BZLF1  
Initiating EBV lytic gene expression by various stimuli involves the activation of the 
BZLF1 promoter. The BZLF1 gene encodes a sequence-specific DNA-binding protein, Zta 
(also called Z, ZEBRA, or EB1), a member of the bZIP family of leucine-zipper 
transactivators. The activities of Zta include directly participating in EBV replication via 
binding to the viral DNA origin of lytic replication, ori-Lyt, down-regulating the latency-
associated promoters Cp and Wp, and serving as a transcriptional transactivator of his own 
promoter, other EBV lytic promoters including the BRLF1 promoter, Rp, and several cellular 
promoters (3, 12). The BRLF1 gene encodes a second viral transcription factor, Rta (also 
called R). Acting together, Zta and Rta play multiple roles in the lytic replication of EBV (3, 
12). 
Cross-linking of the BCR in Akata cells with anti-human immunoglobulin G (IgG) 
results in EBV lytic gene expression, starting with the transcription of BZLF1 (12). Viral 
gene expression then follows a temporal and sequential order. The immediate-early genes are 
followed by early and late genes. In EBV virology, these terms are used to describe stages of 
gene expression in reactivation (12). Viral immediate-early genes like BZLF1 and BRLF1 are 
induced directly by signal transduction from the BCR, independent of the expression of other 
proteins. BZLF1 appears to be the major immediate-early protein in EBV (12). Expression of 
BZLF1 alone is sufficient to trigger the entire lytic cascade (13, 14). The regulation of the 
BZLF1 promoter Zp has been investigated extensively. A great amount of data has been 
collected, still not all regulatory elements within the BZLF1 promoter have been identified. 
Most of the regulatory elements seem to be located within the nucleotide (nt) -221 region 
relative to the promoter’s transcription initiation site. In general, in an uninduced resting 
state, repressive factors bind the BZLF1 promoter leading to a repressive chromatin structure 
to keep Zp inactive. An important component is MEF-2D, which can associate with histone 
deacetylases (HDACs) or histone acetyltransferases (HATs) depending on the 
phosphorylation state of MEF-2D. For instance in Akata Burkitt’s lymphoma cells, BCR 
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signaling activates a signal transduction pathway which can dephosphorylate MEF-2D, 
reduce its association with HDACs (HDAC4 and HDAC5 of the class II HDACs), and 
promote its association with HATs (such as CBP or p300) (15, 16). Histone acetylation by 
HATs is generally associated with open chromatin structure allowing transcription-
responsible enzymes to access the promoter. Thus, initial amounts of Zta are generated. The 
induction of the EBV lytic form requires an initial activation signal of sufficient magnitude to 
allow expression of enough Zta to feedback, bind and autoactivate its own promoter Zp. In 
addition, Zta activates the adjacent gene BRLF1. Together, Zta and Rta activate most of the 
early genes in the next phase of the lytic infection. This two-step induction model would 
prevent spurious activation of the lytic form by signals of insufficient magnitude (17).  
 
Figure 1. Proposed model for the regulation of Zp by Zta (adapted from (18)). Shown are the main 
regulatory elements located within the nt -221 relative to the promoter’s transcription initiation site. In the 
absence of lytic cycle-inducing signals, suppressor factors such as MEF2D, ZIIR, or ZEB play a role in 
compacting the local chromatin structure to prevent binding of spuriously expressed Zta or inhibit the activation 
function of Zta. Induction of the lytic EBV form results in displacement of HDACs and the recruitment of HAT 
enzymes (co-activators). This leads to initial expression of Zta and opening of the chromatin structure or 
function. This model predicts that the relaxed chromatin structure allows for the binding or function of newly 
expressed Zta and a resulting high level of Zp activity and commitment to initiation of the lytic form. 
Most Zta protein is synthesized from mRNA initiated at Zp. The cis-acting elements 
of Zp sufficient for both basal and induced activity lie within the nt -221 to +12 region 
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relative to the promoter’s transcription initiation site (see table 1). However, within the Zp 
promoter other (mostly suppressive) regulatory elements upstream the nt -221 to +12 region 
have been identified. ZEB1 and MEF2D are the only repressors known to bind functionally 
within the nt -221 to +12 region of Zp. Within the Zp promoter other repressors that 
recognize silencing elements have been identified upstream of nt -221 (19, 20). Moreover, the 
more distal promoter Rp can initiate the transcription of a bicistronic mRNA including the 
BZLF1 mRNA, and thus lead to expression of Zta (17). 
 
 
Figure 2. Genomic structure of the responsible promoter regions encoding for Zta (adapted from (21)). 
Within the nt 221 to +12 region of Zp promoter lie the most important regulatory elements for Zta production. 
Nevertheless other regulator elements upstream nt -221 but within the Zp promoter have been identified. 
Besides transcription from the Zp promoter (red arrow), transcription can also start from Rp (blue arrow). Rp is a 
promoter region mainly responsible for the expression of the BRLF1 protein Rta but might also produce Zta due 
to transcription of a bicistronic mRNA containing BRLF1 and BZLF1. 
 
Table 1. BZLF1 promoter regions Zp, their locations and their functions (adapted from (22)). 
 
Name Motif Location Function 
ZI  
(A-D) 
AT-rich Within -221 to +12 region can bind the transcription factors Sp1, Sp3, 
and MEF2D 
ZII CRE-like 
motif 
Within -221 to +12 region Can bind CREB, ATF family members, 
C7EBPs, and the AP-1 family of 
transcription factors 
ZIII  Within -221 to +12 region Contains multiple binding sites for Zta itself 
ZIV  Within -551 to -222 region Transcriptional silencing element 
ZV  Within -221 to +12 region Transcriptional silencing element, binds 
ZEB1 
ZIIR  Within -221 to +12 region Transcriptional silencing element 
HIε  Within -221 to +12 region Transcriptional silencing element 
HIα-HIδ  Within -551 to -222 region Transcriptional silencing element 
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In addition to the regulatory elements and the autoactivation model of Zp, there is 
another regulatory mechanism for Zta expression. In anti-immunoglobulin (Ig)-treated Akata 
cells, Zta, which is produced at the initial stages of induction, may be modified (perhaps 
through BCR-mediated signaling) in a manner that equips it with a high DNA binding 
affinity (at least to binding sites within Zp). This idea is consistent with the autoactivation 
model because such a model requires that Zta plays a role in driving its own expression and 
not necessarily after high levels of Zta have already been produced (18). 
 
EBV-associated malignancies 
Burkitt’s lymphoma (BL) was first described by the English surgeon Denis Burkitt in 
1958 in Uganda as a common cancer affecting children in equatorial Africa (23). The 
malignancy was found to be dependent on climatic and geographical conditions and this led 
to the suggestion that a vector-borne virus might be responsible (24, 25). The subsequent 
discovery of herpesvirus-like particles by electron microscopy in a cell line established from 
a BL biopsy by Epstein, Achong and Barr in 1964 (26), not only resulted in the initial 
discovery of EBV but also suggested that EBV is the responsible virus. Later, EBV was 
found to efficiently transform resting B-cells in vitro and induce tumors in nonhuman 
primates (27-29), confirming the transformation capacity of the virus. The later use of 
recombinant EBV lacking individual latent genes has confirmed the absolute requirement of 
EBNA2 an LMP1 in the in vitro transformation of B-cells, and has highlighted a critical role 
for EBNA-LP, EBNA3A and EBNA3C in this process (30). Moreover, EBV is associated 
with a variety of other human tumors including B-cell malignancies such as Hodgkin’s 
disease (31) and lymphoproliferative diseases arising in immuno-suppressed patients (32), 
some T-cell lymphomas, and epithelial tumors such as gastric cancer or undifferentiated 
nasopharyngeal carcinoma (33). All these tumors are characterized by the presence of 
multiple extrachromosomal copies of the circular EBV genome in the tumor cells and 
expression of EBV-encoded latent genes, which appear to contribute to the malignant 
phenotype (30). Different types of tumors are characterized by different patterns of EBV gene 
expression (see table 2). 
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Table 2. EBV gene expression in EBV-associated malignancies. 
 
Latency 
Program 
EBNA1 EBNA2-
6 
EBNA-
LP 
LMP1, 
LMP2A, 
LMP2B 
EBER1,  
EBER2 
BARTs Type of Tumor 
 
I 
+ - - + + Burkitt’s lymphoma  
II + - + + + Hodgkin’s disease, nasopharyngeal 
carcinoma 
III + + + + + Lymphoblastoid cell line, post-
transplant lymphoproliferative disease 
(PTLD), AIDS-associated lymphoma 
 
EBV-associated Burkitt’s lymphoma and the contribution of cofactors 
Latent EBV is strongly associated with the development of BL, the most common 
cancer of childhood in equatorial Africa (34). Typical BL is characterized by a chromosomal 
translocation leading to the deregulation of c-myc expression (35), a requirement for cell 
transformation (36, 37). A key molecular event in BL pathogenesis is the activation of MYC-
growth promoting activity (through translocation) and the inactivation of MYC apoptosis-
inducing activity (38). Cell lines derived from EBV-positive BL, such as the Akata cell line 
(39), are instrumental in understanding the factors that regulate the balance between EBV 
latency and lytic activation. In vivo, EBV is thought to contribute to the development of BL 
by promoting immune evasion, directly transforming lymphocytes, and increasing the 
chances of a c-myc translocation, which can be achieved by increasing the size and survival 
of the infected B-cell pool (37). In addition, EBV might also have a direct role in 
tumorigenesis as it might regulate c-myc expression, cooperate in the rearrangement of the c-
myc locus (37, 40, 41), and importantly, might support the inactivation of MYC apoptosis-
inducing activity, e.g., through Bim suppression (38). However, the precise role of EBV in 
the pathogenesis of BL remains to be established, although the detection of monoclonal EBV 
episomes in EBV-positive BL biopsies suggests that EBV infection preceded proliferation of 
the precursor B-cells (42). The apparent origin of BL in the germinal centre is based on 
phenotypic studies and is supported by the ability of BL risk factors such as holoendemic 
malaria and chronic HIV infection to stimulate proliferation of B-cells in the germinal centre 
(43). These cells are also programmed to undergo somatic mutation of Ig genes, and this 
event, in conjunction with the stimulation of germinal centre proliferation and EBV infection, 
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might be responsible for the generation and selection of B-cells carrying the c-myc 
translocation (30).  
The malaria parasite Plasmodium falciparum seems to be another crucial factor in the 
development of BL. Importantly, BL in Africa is restricted to areas where infection with P. 
falciparum malaria is holoendemic. The so-called ‘endemic’ form of BL occurs at an annual 
incidence of approximately 5-10 cases per 100,000 children in equatorial Africa and parts of 
Papua New Guinea. This contrasts sporadic cases of BL worldwide with a 50-fold lower 
frequency than the endemic form. Several studies indicate that the parasite burden correlates 
with EBV-positive BL incidence, and that consistent prophylaxis for malaria might lower the 
risk for EBV-positive BL (44). However, the parasites’ contribution to the establishment and 
survival of the lymphoma is not understood (37, 45), but probably involves multiple 
immunomodulatory effects and B-cell activation (34, 45). Most noteworthy, data from 
Parroche et al. (46) show that malaria parasite DNA, conjugated to malaria hemozoin, is a 
ligand for an innate immune receptor named Toll-like receptor 9 (TLR9). This finding 
becomes significant when one considers that in vitro B-cell transformation induced by EBV 
is efficiently increased in the presence of the TLR9 ligand ODN CpG2006 (47) or P. 
falciparum culture supernatant (48). Malaria parasite DNA might therefore increase EBV-
induced transformation in vivo. Aside from malaria parasite DNA, a P. falciparum membrane 
protein was recently reported to cause a weak, but detectible, increase in EBV genome copies 
in Akata cells and human peripheral blood mononuclear cells (PBMCs) by an unknown 
mechanism (49). P. falciparum may thus disturb the balance of latent and lytic EBV by 
multiple triggers including the parasite membrane protein and TLR9 ligands. The compound 
effects of these stimuli in vivo likely influence EBV pathogenesis and may promote the 
development of endemic BL. The importance of gaining a clear understanding of how these 
factors influence EBV-associated lymphomagenesis can not be overstated. 
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Toll-like receptors and its signaling in B-cells 
During my work on EBV and innate immunity, e.g. Toll-like receptors (TLRs), I 
drafted a review (see below) which we aim to submit in the near future. It covers all the 
necessary information on TLRs for the investigations described here. Additionally, the draft 
focuses on the often omitted but extremely important part of TLR9 and BCR interaction. The 
draft partly includes information about results I generated during the time span of my 
doctoral thesis and which can be found in the results and attachment section. 
Summary 
Toll-like receptors (TLRs) are under intensive investigation due to their great 
potential in pathogen and cancer therapy. As for TLR9, a huge amount of data has been 
generated concerning its way of function, its signaling and effects. However, most of these 
studies were performed in mice. As mice and humans comprise great differences in TLR 
expression, it must be assumed that differences in TLR signaling and function are indeed 
tremendous. Thus, detailed investigations in the human system are a prerequisite for an 
accurate understanding of TLRs in pathogen and cancer therapy. Further, most investigations 
on TLR9 focus on dendritic cells and macrophages, but detailed analyses on TLR9 signaling 
and its effects in B-cells are often neglected. The scope of this review is to outline human 
TLR9 signaling and function, with a focus on B-cells including TLR9 – B-cell receptor 
interaction. 
 
Pattern recognition receptors and Toll-like receptors 
Upon encountering a pathogen, the human immune system is equipped with a variety 
of innate immune receptors in order to eliminate the intruder. This first line of defense is 
mainly based on the family of the pattern recognition receptors (PRR). They recognize 
molecules that are broadly shared by pathogens but distinguishable from host molecules. The 
PRRs include the C-type lectin receptors (CLR) for detecting fungi, the cytosolic RIG-I-like 
receptors (RLR) and DNA-dependent activator of interferon-regulated factors (DAI) for 
sensing viral nucleic acid, the nucleotide-binding domain LRR-containing family (NLR) for 
bacterial products, and the TLRs. In humans, 10 TLRs have been identified so far and ligands 
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have been established except for TLR10. TLR1-9 recognize specific pathogen-associated 
molecular patterns (PAMPs) leading to an ordered signal cascade and resulting in gene 
expression to fight the invading pathogen. The Toll protein, identified previously for its role 
in dorso-ventral embryo patterning in the fruit fly Drosophila melanogaster, was shown to be 
critical in an anti-fungal response in adult flies in 1996 (50). However, the Toll protein in 
Drosophila does not directly recognize microbial ligands (51). In 1997, the first human 
homologue of the Toll protein was identified which is now known as TLR4 (52). TLR4 is 
also the most studied and to date with the most papers published in the Toll field, in contrast 
to TLR10 which has very few papers published (according to NCBI PubMed, TLR4 with 
4751 papers and TLR10 with 63 papers published until 13th October 2009).  
In this review we attempted to incorporate the most contemporary and salient findings 
in the field of TLR9, including (i) expression profiles and way of receptor function, (ii) 
activated signaling pathways and effects on gene expression including histone modulation, 
and (iii) implications on cancer development. Importantly, we aimed to review TLR9 and B-
cell receptor (BCR) signaling interaction, as they are crucial for B-cell development as well 
as for pathogen elimination.  
 
Toll-like receptor expression and signaling 
Multiple factors affect the expression patterns of TLRs in the human and mouse system 
Human B-cells are characterized by high expression levels of TLR1, 6, 7, 9, and 10 
(53-55). However, expression patterns can vary depending on the B-cell subset, the 
developmental stage of the B-cell, their tissue environment and in B-cell malignancies ((56), 
(123), and manuscript 3). For instance, naïve human B-cells are barely responsive to TLR 
stimulation and express only low levels of TLRs (in contrast to mouse naïve B-cells), while 
memory B-cells are more reactive and more prone to proliferate and differentiate into plasma 
blasts upon TLR stimulation (53, 54). Further, in the human body the local environment 
seems to shape the TLR repertoire: TLR9 expression and responsiveness towards the ligand 
is increased in B-cells isolated from tonsils when compared to those isolated from peripheral 
blood (57). Importantly, there are distinct differences in TLR expression in mouse cells 
compared to human cells. Human (non-malignant) B-cells lack TLR4 in contrast to mouse B-
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cells. Moreover, in humans only plasmacytoid dendritic cells and B-cells respond to TLR9 
ligands whereas in mice B-cells, monocytes, and probably all dendritic cells subsets express 
TLR9 (58, 59). This differential TLR9 expression pattern in turn affects signaling pathways 
and results in a unique cytokine and chemokine expression profile. Thus, experimental results 
from mice cannot easily be extrapolated to humans (51, 60).  
Location and signaling of Toll-like receptors 
Toll-like receptors can be segregated into two groups due to their cellular location 
where they recognize their ligands. TLR1, 2, 4, 5, 6 are located on the surface of the cell 
membrane. Thus, they are designed to recognize structural components of the invading 
organism, e.g., bacterial cell wall components like proteins, lipoproteins, lipopeptids and 
lipopolysaccharides. By contrast, TLR 3, 7, 8, 9 are located in the endosomal / lysosomal 
compartment within the cell. They recognize the less readily accessible nucleotides, e.g., 
pathogenic RNA and DNA. 
In general, TLR engagement by its microbial ligands leads to the interaction with the 
Toll/IL-R (TIR) domain-containing adaptor proteins, which link activated receptors to 
downstream kinases that define a given signaling pathway. Depending on which adaptor 
protein is recruited, different TLRs are able to trigger different signaling pathways. For 
example, MyD88 and TIRAP function to activate a mitogen-activated protein kinase 
(MAPK) and nuclear factor-κB (NF-κB) leading to a pro-inflammatory response. TRIF-
related adaptor molecule (TRAM) and TIR domain-containing adaptor protein inducing IFNβ 
(TRIF) activate TANK-binding kinase 1 (TBK1) and IκB kinase-ε (IKKε) to induce type I 
IFN production. Together with the expression of costimulatory molecules such as CD40, 
CD80 and CD86, this leads to the activation of innate immunity and finally to the 
development of adaptive immunity (61, 62). Moreover, TLRs induce expansion, 
immunoglobulin class switch recombination and immunoglobulin secretion in human B-cells 
(63). Interestingly, TLR ligands are known to induce cell-type-specific responses, but how 
this is achieved is only beginning to reveal. If cell-type specific factors are involved or the 
subcellular positioning of certain adaptor molecules play a role, is partly unknown (64). 
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Regulation of TLR9 activation 
TLR9 ligands and inhibitors 
The DNA-containing unmethylated CpG (cytosine-phosphate-guanine) motif is 
binding and activating endosomal TLR9. Synthetic oligonucleotides (ODNs) containing the 
CpG motif are used nowadays to stimulate TLR9-expressing cells in experiments. B-cells can 
be best stimulated with ODN CpG class B (or K) which have multiple CpG motifs and a 
phosphorothioate backbone (60). In contrast, dendritic cells are best stimulated with CpG 
class A (or D) which have mixed phosphodiester-phosphorothioate backbones and contain a 
single hexameric purine-pyrimidine-CG-puinre-pyrimidine motif flanked by self-
complementary bases and induce type I IFNs (65). 
In addition to engaging bacterial and viral DNA, TLR9 also recognizes the malaria 
pathogen Plasmodium falciparum, but whether the ligand is hemozoin, a metabolic product 
of the parasite, or the DNA of the parasite itself is still a matter of debate (46, 66). 
Endogenous ligands released in the context of tissue damage, cellular stress, or cell death 
may also be recognized by TLRs. These danger-associated molecular patterns (DAMPS) 
represent host-derived TLR ligands. These endogenous TLR ligands are involved in solid 
tumor progression (56). For TLR9, known endogenous ligands are HMGB1 or Ig-DNA 
complexes. Of note, mammalian self DNA is degraded extracellular by secretion of DNase I 
into the serum and is therefore not taken up by immune cells for TLR9 engagement.  
Besides ligands for TLR9, there are also inhibitors for TLR9 activation known. 
Inhibitors like chloroquine block TLR9 activation (and TLR3, TLR7, TLR8) by disrupting 
the acidic milieu in the endosomes (or their maturation) and thus interfere with the activation 
of all endosomal TLRs (67, 68). This observation has to be evaluated in the context of 
deactivating proteases and thus interfering in the cleavage of TLR9 to generate a functional 
receptor. Moreover, short ODNs containing a GGGG motif are able to bind to TLR9, but 
instead of conformational change and activation of TLR9, the inhibitor blocks TLR9 
activation. Thus, they do not interfere with ODN CpG cell binding or internalization (69, 70). 
Some of these inhibitors are found to act on nanomolar level, although the inhibitors in our 
hands need to be used in micromolar concentration similar or higher than the concentration 
for the TLR9 ligands. Stimulatory (CpG), control (GpC) or inhibitory (GGGG) DNA have 
the similar affinities for TLR9, but only DNA-containing CpG leads to allosteric changes in 
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the TLR9 cytoplasmic signaling domains and thus activation of TLR9 signaling in the 
endosomes (71). 
TLR9 and its way of function 
Toll-like receptors consists of extracellular leucine-rich repeats (LRRs), a 
transmembrane domain and a cytoplasmic Toll/interleukin-1 receptor homology (TIR) 
domain. TLR9 initially resides in the endoplasmatic reticulum (ER) of B-cells, dendritic cells 
and macrophages (in mice), but upon oligonucleotide (ODN) uptake it translocates to the 
same ODN CpG-containing lysosomal / endosomal compartment for ligand binding and 
signal transduction (67, 68). Initially, it was thought that TLR9 does not travel through the 
Golgi but is recruited directly to endo-lysosomes from the ER, bypassing the classical 
secretory pathway (67). However, recent studies showed that the full-length TLR9 protein is 
sorted in the ER, traffics through the Golgi and is routed to the endo-lysosome, where it is 
cleaved by resident proteases (72). 
TLR9 is a preformed, inactive homodimer, in which the TIR domains remain 
separated so that the signaling adaptor, which is MyD88 in the case of TLR9, is not recruited 
(73). The TLR9 ligand CpG is binding to the endo-lysosomal TLR9 and thus leading to a 
close apposition of the cytoplasmatic TIR signaling domains (71). These allosteric changes 
are probably required for the recruitment of MyD88 (71). Moreover, not only receptor 
binding but also the sequence of potential DNA ligands dictates the quantity and quality of 
conformational change and subsequent activation of TLR9. Indeed, it is conceivable that 
ligand secondary and/or tertiary structures as well as binding valency, further influence the 
receptor response, as noted with the various classes of CpG DNA (71). Of note, other reports 
have shown that ODN DNA without CpG motifs can be a biologically active ligand for 
TLR9. Thus, TLR9 recognizes not just CpG motifs, but DNA itself with certain structures 
(63). 
Discrimination of self and non-self TLR9 ligands 
The TLR9 ligand consists of a motif found in bacterial and viral DNA. However, 
most of the approximately 29.000 CpG-rich islands in mammalian cells are unmethylated, 
which - in theory - make them also suitable to trigger TLR9 (74). Thus, discriminating self 
and non-self DNA is an important factor in launching immune responses against pathogens 
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and avoiding immune responses against self-molecules. An interesting study came form 
Barton et al. (75) who described the chimeric TLR9 receptor TLR9N4C that localized to the 
cell surface and responded normally to synthetic TLR9 ligands but not to viral nucleic acids. 
This ‘relocated’ chimeric TLR9 receptor was able to recognize self DNA, which does not 
stimulate wild-type TLR9. Thus, intracellular localization of TLR9 is required for 
discriminating between self and nonself nucleic acid – it controls the access of the receptor to 
different sources of DNA - but not for ligand recognition (75). Moreover, there is a 
requirement for capsid degradation by lysosomal proteases so that nucleic acids of the viruses 
become accessible for endosomal TLR9. Purified viral DNA is a poor inducer of TLR9 
compared with intact virus. 
Another strategy for TLR9 to prevent responding to self nucleic acids involves 
cleavage of TLR9 to create a functional receptor. The ectodomains of TLR9 (and TLR7) are 
cleaved in the endo-lysosome, such that no full-length protein is detectable in the 
compartment where ligand is recognized. Although both the full-length and cleaved forms of 
TLR9 are capable of binding ligand, only the processed form recruits MyD88 on activation, 
indicating that this truncated receptor, rather than the full-length form is functional (72). The 
ectodomain cleavage represents a strategy to restrict receptor activation to endo-lysosomal 
compartments and prevent TLRs from responding to self nucleic acids. TLR9 receptors found 
on the cell surface may be prevented from responding inappropriately to self nucleic acid 
ligands (72). Thus, a low pH seems not to be necessary for TLR9 activation by CpG DNA, as 
the chimeric TLR9N4C responded to CpG DNA in the presence of chloroquine or 
bafilomycin A1, but might be necessary for the proteases-induced TLR9 cleavage to generate 
the functional short receptor form.  
 
Toll-like receptor 9, its signaling pathways and effects in human B-cells 
Sequence-specific recognition of CpG DNA is believed to occur in the endo-
lysosomes after non-specific DNA uptake into the cells. The uptake into lymphocytes is 
energy and temperature dependent and greatly increased by cell activation (60). Moreover, it 
was suggested that different classes of Phosphatidylinositol 3-kinases (PI3K) are involved in 
uptake / vesicular trafficking of CpG DNA to the endosomal compartment, whereas other 
PI3K classes might participate as a signaling component as well (63, 76). For example, PI3K 
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delta functions in influencing the type of B-cell cytokine production and differentiation 
response induced by TLR4 and TLR9 ligands (77). Importantly, PI3K is known to activate 
the AKT (PKB) pathway. During an infection, endocytosis of microbial nucleic acids, which 
may occur upon bacterial disintegration or cellular infection via cell-surface receptor-
mediated uptake, is necessary (56). Nevertheless, after ligand binding in the endosomes, 
TLR9 is induced to conformational changes and thus recruits the myeloid differentiation 
marker 88 (MyD88). Signaling of TLR9 in B-cells proceeds only through MyD88 (73), 
which then activates the IL-1R-associated kinase 1 (IRAK1), the TNF-receptor-associated 
factor 6 (TRAF6), and the TGFβ-activated kinase 1 (TAK1) pathway (78, 79). TAK1 
phosphorylation leads to the activation of the nuclear factor-κB (NF-κB) transcription factor 
(see Figure 3 on page 20). TAK1 also signals through mitogen-activated protein kinases 
(MAPKs), such as p38 and the c-Jun NH2-terminal kinase (JNK), leading to the activation of 
activating protein-1 (AP-1) complexes (78). Thus, NF-κB and AP-1 complexes are able to 
translocate into the cell nucleus where they promote the expression of genes involved in B-
cell activation, proliferation and production of inflammatory cytokines as a part of the 
immune response against pathogens (79). Moreover, activation of CCAAT/enhancer binding 
protein (C/EBP), cAMP-responsive element-binding protein (CREB) and the Ras-ERK 
pathway after TLR9 engagement could also be observed (56, 79). Another class of 
transcription factors, the family of interferon-regulated factors (IRFs, e.g. IRF3, IRF5, IRF7) 
is activated after TLR engagement, interacts with MyD88 and translocates to the nucleus 
where they promote the expression of type I interferons (of note, IRF5 induces expression of 
proinflammatory cytokines). However, reports indicate that TLR9-induced ERKs and IRFs 
play less prominent roles in B-cells than in (mice) macrophages or dendritic cells where they 
promote IL10 and type I IFN expression, respectively (79, 80).  
Although human B-cells are generally considered poor cytokine producers, 
stimulation with TLR7 or TLR9 ligands results in the secretion of pro-inflammatory 
cytokines like IL-1β , IL-2, IL-6, IL-8, and to the release of immune regulatory cytokines that 
might limit the intensity of the inflammatory response, such as IL10 (56). Further, TLR7/9 
stimulation in naïve and transitional human B-cells induces differentiation in the absence of 
significant proliferation in these B-cell subsets. A proliferative response to TLR7/9 ligands is 
predominantly observed in IgM+ memory B-cells (123). Moreover, TLR triggering of 
terminally differentiated plasma cells augments Ig production (see manuscript 3). Finally, 
TLR9 plays a role in the induction of T helper 1 (Th1) acquired immune response (63).  
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The differential activity of the ODN different classes of the TLR9 ligands on immune 
cells and how the signals are transduced can not be explained fully to date. Although it is 
known that different IRFs are activated depending on the type of CpG used, we do not know 
how the different effects and activated proteins are produced from the same TLR. An 
interesting study came from Guiducci et al. who demonstrated in plasmacytoid dendritic cells 
that the differential higher order structure and the endosomal location of the ODN classes 
determines the biological response (IFNα production versus maturation) of the cells towards 
TLR9 ligands (81). Moreover, additional factors / receptors might also be involved in shaping 
the diverse signaling and outcome of TLR9 engagement (65). 
 
Signaling interaction of Toll-like receptor 9 and the B-cell receptor (BCR) 
The BCR in immature and mature B-cells  
Besides germ line-encoded PPRs like the TLRs, B-cells express clonally rearranged 
antigen (Ag)-specific receptors on their surface. The BCR has two main roles. The first is to 
transmit signals that regulate B-cell fate decisions. The second is to mediate antigen 
processing, leading to the presentation of antigen to T-cells, which allow full activation of B-
cells in the effector phase.  
In pre-B-cells, rearrangements of the Ig light chain are completed. An important role 
of the BCR at the later immature B-cell stage is to induce efficient elimination of the 
potentially harmful, self-reactive B-cells, which can be achieved in three ways: immature B-
cells are eliminated through negative selection (BCR-induced cell death), they are inactivated 
(anergy), or they revise the specificity of their BCRs (receptor editing) (82). Immature B-
cells that have passed successfully through developmental checkpoints in the bone marrow 
emigrate subsequently to the spleen as transitional B-cells, which then become mature B-
cells. Mature B-cells are classified into subsets, e.g., follicular B-cells or marginal-zone B-
cells. Depending on the developmental stage, the BCR mediates distinct cell-fate decisions at 
the immature and mature stages of B-cell development leading to receptor editing/cell death 
or activation/differentiation, respectively. Moreover, the physical form and/or the context of 
the Ag, the availability of T-cell help, different expression and activation levels of kinases, 
phosphatases and adaptor molecules, and involvement of co-receptors will contribute to the 
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diverse outcome of the BCR triggering (82). It might seem reasonable to expect signaling via 
BCR engagement on immature B-cells to differ from mature B-cells (83). Indeed, a number 
of variations in the signaling cascade of immature and mature B-cells have been identified 
and invoked to explain differences in cellular outcomes. Gene chip analysis has also revealed 
increases in distal signaling molecules (NF-κB, JAKs, MAP kinases), anti-apoptotic 
molecules (Bcl-2, A1), and inhibitory co-receptors (CD22, FcγRIIB) expression as cells 
mature (84). Of note, BCR translocation of lipid rafts is non-functional in immature primary 
B-cells and immature B-cell lines compared with mature B-cells (85, 86). Differential 
recruitment to rafts might result in qualitative differences in downstream signaling profiles. 
Instead of inducing proliferation or differentiation, immature B-cells respond to BCR cross-
linking by increasing expression of genes involved in receptor editing and/or apoptosis (87, 
88). For instance, protein kinase C (PKC), which prevents BCR-induced apoptosis of mature 
B-cells is impaired selectively in BCR-activated primary immature B-cells (89, 90). 
BCR-induced signaling pathways 
If the BCR is engaged by an antigen, BCRs will form signaling active microclusters, 
followed by a conformational change to an ‘open form’ (44, 91). The first signaling events 
consist of recruitment of Lyn and Syk (which phosphorylates the cytoplasmatic signaling 
domain of the BCR) to the BCR microcluster, and Ca2+ release. The four major signaling 
pathways activated include phospholipase C (PLC), the Rho family of GTPases like VAV1-3, 
Ras, and phophatidylinositol-3-kinase (PI3K) (92, 93). They lead to the activation of MAP 
kinase signaling cascades and of transcription factors like NF-κB, and thus to transcription of 
a variety of genes depending on the maturation state of the cell (see Figure 3 on page 20). 
The activated MAP kinases - consisting of extracellular signal-regulated kinase (ERK), c-Jun 
NH2-terminas kinase (JNK/SAPK) and p38 MAPK - phosphorylate different sets of 
transcriptions factors including Elk1 and c-Myc by ERK, c-Jun and ATF2 by JNK, and ATF2 
and MAX by p38 MAPK. Studies have shown both positive (survival/proliferation) and 
negative (apoptosis/deletion) roles for ERK depending on the maturational state and 
activation status of the B-cell (90). In addition, the BCR is internalized and thus efficiently 
transports antigens to a MHC-class II-containing, multivesicular, intracellular compartment 
in which the antigens are proteolytically cleaved and the resulting peptides are assembled 
with MHC class II molecules into complexes for recognition by helper T-cells (94). 
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BCR and its interaction with co-receptors 
BCR signaling is regulated and fine tuned by several co-receptors. These include the 
B-cell inhibitory receptor FcγRIIb (recognizes immune complexes) and the stimulatory co-
receptor complex CD19/CD21 (recognizes complement-coupled antigens). However, the 
family of the TLRs seems to be a new player in the field. During an infection, B-cells will 
most probably receive signals through both TLRs and BCRs. Investigations how these 
receptors and their signaling interact are crucial for the understanding of the human immune 
system towards a pathogen and, importantly, autoimmune diseases like systemic lupus 
erythematodes. The synergistic engagement of TLR9 and BCR in response to DNA-
containing antigens has been implicated in the activation of autoimmune B-cells (95). 
Moreover, TLR9 has been shown to play a critical role in regulating DNA-specific 
autoantibody production in mouse models of lupus by mechanisms that involve the 
simultaneous engagement of TLR9 and the BCR (96).  
The diverse outcome of BCR – TLR9 interactions is dependent on the maturation state 
of the B-cell 
TLR9 signaling has the ability to interfere with BCR signaling, leading to synergistic 
or blocking effect depending on the maturation step of the B-cell (97). In immature, B-cells, 
TLR9 and BCR synergize with cytokines production (like IL10, IL6, TNFα), but TLR9 
blocks BCR mediated growth arrest and apoptosis (by interfering with the regulation of c-
myc and bcl-xl) (98-100). In mature B-cells, TLR9 and BCR synergize in B-cell proliferation 
and production of cytokines and Ig production (101, 102). 
Little is known on the molecular events integrating TLR signaling into the classical 
BCR-mediated signaling cascades. Only a few studies attempted to distinguish BCR- from 
TLR signaling. TLR9 engagement seems not to interfere with the early signaling pathway 
induced by surface Ig cross-linking ((103) and manuscript 1), but may work through an 
intracellular pathway at a later stage. As with the BCR, the TLR9-initiated signaling 
pathways ultimately result in phosphorylation of MAP kinases, activation of PI3K, and 
activation of transcription factors like NF-κB and AP1. However, these TLR9–initiated 
signaling pathways are partly distinct from those triggered by the BCR (92, 93, 104). Indeed, 
BCR and TLR9 co-stimulation induced synergistic activation of the MAP kinase p38 and 
JNK for cytokine production in immature B-cells, but ERK is not enhanced (97). This is in 
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contrast to the synergistic activation of ERK in addition to p38, JNK for the induction of 
mature B-cell proliferation. Moreover, TLR9 and BCR engagement seem to activate different 
sets of MAPK and transcription factors via distinct signaling pathways. BCR-mediated 
signals strongly activate MEK1/2, MKK3, MKK6 and its downstream targets ERK and p38 
(but have little effect on MKK4, and JNK). Moreover, MAP kinases have differential 
regulatory roles for CpG-mediated cytokine versus cell proliferation depending on the 
maturity of the B-cells (60). In summary, although interaction of signaling pathways of TLR9 
and BCR at the level of NF-κB and MAPKs have been observed, one has to consider that 
different sets of MAPKs and NF-κB subunits are involved which might explain the diverse 
outcome depending on the maturation state of the B-cell. Activation of ERK is important in 
BCR signaling but less important in TLR9 signaling in B-cells; and JNK has a less prominent 
role in BCR triggering than in TLR9 activation. However, the relatively few studies 
concerning the signaling interaction of BCR and TLR9 limit the validity of the herein stated 
conclusions.  
 
 
Figure 3. TLR9- and BCR-induced signaling cascades. The main important signaling pathways are shown. 
Cross-talk between signaling components of the single TLR9 or BCR pathway exists: The PLC-Ca2+/PKC axis 
can induce MAP Kinases (JNK, p38, ERK); DAG cross-talks to RAS-RAF-ERK; PI3K/AKT cross-talks to 
IKK-NF-κB; the PI3K can induce Ras activation. Possible interactions between TLR9 and BCR signaling might 
take place at the MAPK and NF-κB level (highlighted by red dashed lines), but also downstream of the MAPKs 
in the nucleus like CREB or ATF-2. Of note, the TLR9-induced signaling pathway to IRFs and Ras-ERK1/2 
seems to be less prominent in B-cells, but important in pDCs and mouse macrophages. However, activation of 
ERK is important in BCR signaling. JNK has a less prominent role in BCR triggering than in TLR9 activation. 
Abbreviations are as followed: CaMK, calcium-modulin-dependent kinase; ERK, extracellular signal-regulated 
kinase; GSK3, glycogen synthase kinase 3; IKK, inhibitor of NF-κB kinase; JNK, c-JUN NH2-terminal kinase; 
MAPK, mitogen-activated protein kinase; MEK1/2, MAPK/ERK kinase 1/2; MEKK, MAPK/ERK kinase 
kinase; MKK 3/4/6/7, MAPK kinase 3/4/6/7; NFAT, nuclear factor of activated T-cells; NF-κB, nuclear factor-
κB; NIK, NF-κB-inducing kinase; PI3K, Phosphatidylinositol 3-kinase; PKC, protein kinase C; PLC, 
phospholipase C; PTK, protein tyrosine kinases. 
Introduction 
21 
TLR9 and BCRs meet at the autophagosomes in mature B-cells 
The next obvious question is how signaling interaction between TLR9 and BCR can 
occur as TLR9 and the BCR initiate signaling from two spatially distinct sites, the TLR9 
from endosomes, and the BCR from the plasma membrane. A study from Chaturvedi et al. 
(105) demonstrated that upon antigen binding, the BCR in mouse B-cells initiates signaling at 
the plasma membrane and continues to signal to activate MAP kinases as it traffics to 
autophagosome-like compartments. Further, the internalized BCR signals to recruit TLR9-
containing endosomes to the BCR-containing autophagosome where hyperactivation of MAP 
kinases occurs. Thus, TLR9 and BCR signaling appears to synergize in autophagosome-like 
structures and hyperactivate signaling through to p38 and JNK (105). Of note, engagement of 
BCR and TLR9 can be achieved by individual triggering of the receptors, or by CpG linked 
to protein antigen. Recently it was demonstrated that CpG linked to protein antigen gain 
selective entry into Ag-specific B-cells through BCR-mediated endocytosis, allowing 
engagement of intracellular TLR9, and resulting in enhanced B-cell proliferation and 
production of antigen-specific class-switch antibodies in vivo (106). The individual triggering 
of BCR and TLR versus triggering of the receptors with CpG linked to protein antigen might 
not only yield in differential activated signaling pathways but also in effector function. In the 
case of TLR4, studies in mouse B-cells showed that simultaneous stimulation of TLR4 and 
BCR additively elevates B-cell activation, but co-engagement of TLR4 and BCR by antigen-
coupled LPS synergistically enhances activation of B-cells (107). Thus, depending on the 
nature of the trigger, there can be different outcomes due to differences in activation of 
signaling pathways. 
The BCR in the context of TLR Tolerance 
Another interesting aspect of signaling interaction between TLR9 and BCR was 
observed recently and involves TLR tolerance. TLR tolerance is defined as a temporary 
hypo-responsiveness of immune cells to TLR ligands following repeated or chronic 
stimulation through the same or different TLRs. (108). For instance, pre-stimulation of TLR7 
reduces the response of a subsequent stimulation of TLR7 or TLR9 in human and mouse 
cells. Importantly, triggering the BCR rescues B-cells from TLR tolerance (109). Of note, 
TLR tolerance is not affecting all TLR-mediated functions. This might be partly explained by 
a recent study, which proposed that repeated TLR stimulation and its effect on selected but 
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not all TLR-responsive promoters might be regulated at the level of histone modifications of 
individual promoters (110), which will be discussed later in the text. 
Expression interference of BCR and TLR9 
As TLR9 and BCR can interfere with each others signaling, they can also interfere 
with each others expression. Human naïve B-cells express most TLRs at low to undetectable 
levels, but expression of TLR9 and 10 is rapidly induced following BCR triggering (54). 
Memory B-cells express several TLRs at constitutively high levels. The differential 
expression of TLR9 correlates with its responsiveness to its agonist, CpG. Thus, human 
memory B-cells proliferate and differentiate to Ig secreting cells in response to CpG, while 
naïve cells only do so if simultaneously triggered through the BCR. 
 
Toll-like receptor 9, regulation of gene expression and histone 
modifications 
Transcription factors like NF-κB, AP1, IRFs and others are crucially important to 
transduce the signal from the TLR9 to the promoters and thus leading to changes in gene 
expression. The regulation of NF-κB activation and other transcription factors have been 
intensively reviewed and will not be summarized here. 
In addition to activation of transcription factors, host gene expression can be initiated 
or modified by the architecture of the chromatin, e.g., DNA or histone modifications. Nuclear 
DNA is packed into nucleosomes, which consist of a histone octamer core around which 
DNA (approximately 143bp) is wrapped. The core histones are reversibly modified by 
acetylation, methylation, ubiquitination, biotinylation and phosphorylation. Modifications 
occur on the N- and C-terminal tails of the core histones, and more recently analyses of 
histone modifications by mass spectrometry have revealed several modifications (acetylation 
and methylation) in the histone fold (111). Among the N-terminal histone tail modifications, 
acetylation is perhaps the most characterized and has been found associated with actively 
transcribed regions of chromatin (111). Histone acetylation is the covalent addition of acetyl 
groups on lysine residues of histones and non-histone proteins that renders chromatin 
accessible to DNA binding proteins. 
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TLR signaling results in the general activation of transcription factors such as AP-1 
and NF-κB. Histone regulation might be a possibility of how gene expression due to TLR-
mediated transcription factor activation can be specifically modified to adapt to the invading 
organism or to avoid excessive inflammation.  
TLR-induced chromatin remodeling on the IL12p40 promoter has been described, 
indicating that chromatin remodeling is an additional level of TLR signaling specificity (112, 
113). Recently, Foster et al found out that individual host gene promoters can be targeted and 
modulated in its histone architecture after TLR engagement (110). Repeated triggering of 
TLRs was shown to repress activation of selected TLR-responsive promoters (TLR 
tolerance), while other TLR-responsive promoters were not affected (110). This adaptation of 
gene expression includes host genes promoters from cytokines, but TLRs also directly 
interfere with histone structure of pathogen gene promoters. Recently, our group provided 
strong evidence that TLR9 is changing the acetylation and phosphorylation states of histones 
on the B-cell tropic Epstein-Barr virus (EBV) lytic gene promoter BZLF1 leading to a 
suppression in lytic gene expression (see manuscript 1). Thus, TLRs can interfere with lytic 
activation of a chronic pathogen like EBV residing in its latent form via alteration of histones 
on the viral gene promoter.  
However, no study has identified the exact mechanism by which histone remodeling 
occurs. It can only be speculated how TLR9 induces changes in the histone architecture. TLR 
engagement strongly induces distinct sets of MAP kinase kinases (MKKs/MEKs) as well as 
MAPK phosphatases, e.g. DUSP1 (MAPK phosphatase 1) (114). In turn, these enzymes are 
able to differentially regulate the activity of the AGC kinase family members, e.g., MSK1/2 
and RSK2, which are known to affect histone phosphorylation (114, 115). In the context of 
histone acetylation, TLR9 might affect the recruitment of co-activators which have histone 
deacetylase (HDAC) or histone acetyl-transferase (HAT) activities (like p300/CBP), leading 
to chromatin remodeling on host and viral promoters and subsequent changes in gene 
expression. Importantly, MSKs, HDACs and HATs are known to modify a range of other 
non-histone proteins including transcription factors such as CREB, ATF-1, and NF-κB. Thus, 
detailed investigations about their effect on transcription factor activation versus histone 
modification are needed. 
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Toll-like receptor 9: friend or foe in cancer development and treatment 
Carcinogenesis is a progression of events resulting from alterations in the processing 
of the genetic information. These alterations result from stable genetic changes (mutations) 
and potentially reversible epigenetic changes, including DNA methylation and histone 
modifications (111). The clinical interest for TLRs in cancer research is increasingly 
growing. Among TLR ligands those engaging TLR9 are the most intensively studied as they 
can be relatively simply manufactured, administrated through any drug route e.g., 
intramuscular, subcutaneous or orally, and have very low side but very strong adjuvant 
effects that polarize helper T-cell responses to Th1 (63, 79). Th1 immune activation is 
optimized for fighting intracellular infections such as viruses and involves the activation of 
natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) that can lyse infected cells. 
This type of immune activation is the most highly desired for cancer therapy, as the same 
defenses (activation of NK cells, monocytes and macrophages and induction of cytokines 
with direct or indirect antitumor activities) can be directed to kill tumor cells (60). TLR 
activation might enhance cancer immunotherapy by activation of tumor-specific CTLs which 
in principle can eradicate even metastatic tumor cells. Thus, for the TLR9 agonist ODN CpG 
there are several phase II and phase III clinical trials as adjuvants to cancer vaccines and in 
combination with conventional chemotherapy and other therapies being tested (60). 
Having a great potential in cancer therapy, TLR stimulation due to excessive pathogen 
encounter might lead to a high inflammation process over a long period. As inflammation is 
one of the reasons for a cell to become malignant, TLR activation might not only be 
beneficial but detrimental for humans (116). In humans, chronic active infection and 
inflammation are considered two of the most important epigenetic and environmental factors 
contributing to tumorigenesis and tumor progression (117, 118). Tumor environment contains 
significant amount of immune infiltrates and has all the characteristics of an ongoing 
inflammatory process (119). Moreover, when a tumor is already established, TLRs might 
induce tumor promoting factors and tumor immune evasion; for example, IL12 induces 
resistance of tumor cells to CTL and NK cell attack and evasion from immune surveillance 
and matrix metalloproteinase promotes cell invasion. The transcription factor NF-κB 
upregulates the expression of many pro-inflammatory cytokines, chemokines, growth factors, 
matrix metalloproteinases, adhesion molecules and, more importantly, anti-apoptotic proteins 
like c-FLIP and XIAP, and is able to inhibit pro-apoptotic proteins such as Bax and Caspase 
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9 (120). These cellular events may lead to chemo-resistance (119). Moreover, in cancer cells, 
certain genes required for development or for apoptosis are silenced in the transformation 
process of the cells, leading to uncontrolled proliferation. The change of gene expression 
partly relies on enzymes like histone-deacetylases (HDACs), inducing chromatin remodeling 
processes and leading to differentially expressed genes (121). That histone modification can 
induce proliferation of cells to cause leukemia is well known in the case of thyroid hormone 
receptor. As TLRs are known to induce histone modification, TLRs might be beneficial or 
detrimental in tumor development and has to be evaluated for the specific case. Inhibiting 
certain TLRs in inflammation-associated cancers might therefore yield new therapies (121). 
The use of histone-deacetylases (HDAC) inhibitors might therefore counteract the 
detrimental triggering of TLRs. Our group has shown that TSA could reverse the effect of 
TLR9 on human and viral gene expression (see manuscript 1). That HDAC inhibitors – 
beside our findings – have great potential in cancer therapy is widely accepted. Although 
both normal and tumor cells become enriched in acetylated histones, sensitivity to HDAC 
inhibitors is ten-fold higher in tumor cells (111). 
 
Toll-like receptor 9: future directions 
Although TLRs seem to have great potential in cancer therapies due to their ability of raising 
or enhancing immune responses against malignant cells, TLRs might as well play a 
supportive role in tumor development and progression via expression of tumor promoting 
factors regulating apoptosis. Indeed, chronic active infection and inflammation are assumed 
to stimulate B-cell tumor development. A model from Chiron and colleagues (56) proposed 
that repeated polyclonal activation of leukemic B-cells by microbial molecules during natural 
infection or inflammation is the initial step in the oncogenic process that lowers the threshold 
for outgrowth of malignant cell clones. Evaluating if TLR9 has a positive or negative effect 
in tumor onset and progression has to be done on the cell type, maturation of the cell, whether 
an infection is present, and other factors separately. Investigation on TLR9-activated 
signaling pathways – sub-pathways, strength and duration of activation – may give important 
information whether TLRs might have beneficial or detrimental effects on tumor 
development. In this matter, TLR triggering gives a ‘signaling fingerprint’, which has to be 
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carefully examined as it might contain the key for the understanding of the diverse outcome 
of TLR engagement. 
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Subject of Investigation 
As my work deals with TLRs and EBV gene expression, the following topics were 
subjected for investigation: 
1) TLR9 triggering induces suppression of EBV lytic gene expression via histone 
modification (manuscript 1) 
In this (first authorship) paper I characterized and revealed the mechanism of how 
TLR9 triggering suppresses EBV lytic gene expression in Akata BL cells. Moreover, TLR9 
was found to suppress EBV in Mutu BL cells and MHV-68 in S11 cells, indicating a general 
effect of TLR9 on gamma herpesviruses from different species and in distinct cellular 
backgrounds. This manuscript is the main part of my work and thus will be the essential part 
in the discussion and outlook section. 
2) Immune activation suppresses initiation of lytic Epstein-Barr virus infection 
(manuscript 2) 
The paper describes the initial discovery that triggering the innate immune system 
affects EBV gene expression. My contribution to this crucial finding was that, in the Akata 
cell line, TLR9 suppresses BCR-induced EBV lytic gene expression. Thus, I established the 
Akata cell line as a model system for the TLR9-induced suppression of EBV, which was used 
throughout the following investigations. 
3) Plasma cell Toll-like receptor (TLR) expression differs from that of B-cells and 
plasma cell TLR triggering enhances immunoglobulin production (manuscript 3) 
As the differential expression of the TLRs correlates with its responsiveness to its 
agonists, we investigated the expression patterns of TLRs in primary B-cells and B-cell lines. 
Using quantitative real-time PCR we measured mRNA expression of the Toll-like receptors 
in B-cell lines (not shown in this publication) and primary B-cells. This helped to shed light 
on the different expression patterns in B-cells depending on the developmental stage and the 
tissue environment, and showed for the first time that triggering of plasma cell TLRs 
enhances immunoglobulin production.  
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4) Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-
Barr virus infection (manuscript 4) 
Inducing EBV lytic gene expression in the model cell line Akata starts with B-cell 
receptor cross-linking. My project involved identifying the first steps of BCR signaling and 
whether they are affected upon TLR9 triggering. Therefore, I designed experiments for 
investigating the first steps of BCR signaling including Ca2+ flux measurements which I also 
performed in this publication. Thus, we could show EBV’s LMP2B counteracting LMP2A’s 
function by restoring BCR-induced calcium mobilization. Our findings suggest that LMP2B 
negatively regulates the function of LMP2A in preventing the switch from latent to lytic EBV 
replication. 
5) Burkitt’s lymphoma cell lines as a model B-cell system for investigating TLR 
engagement and interaction with the BCR 
Here, I investigated the outcome of TLR triggering in BL cell lines in the context of 
proliferation and cytokine expression. Importantly, effects of TLR9 and BCR signaling 
interaction were studied using microarray and quantitative PCR analysis to identify 
overlapping and segregated gene expression profiles for BCR and TLR9 engagement. This 
(first-authorship) manuscript is in preparation.  
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Results 
TLR9 triggering induces suppression of EBV lytic gene expression via histone 
modification  
 
Ludwig Zauner, Gregory T. Melroe, Markus P. Rechsteiner, Marcus Dorner, Martina Arnold, 
Christoph Berger, Michele Bernasconi, Beat W. Schaefer, Roberto F. Speck, David Nadal 
Manuscript submitted for publication. 
 
Abstract 
By recognizing numerous pathogen-associated DNA sequences, Toll-like receptor 9 
(TLR9) causes a strong innate immune response resulting in cytokine secretion and 
costimulatory molecule expression. Immune activation with a TLR9 ligand was shown to 
suppress the initiation of EBV lytic replication in primary human B-cells. Here, we show that 
the suppression of EBV lytic gene expression is dependent on functional TLR9 and MyD88 
signaling in the Akata cell line. Furthermore, TLR9 activation suppresses not only human but 
also murine gamma herpesvirus lytic gene expression, independently of the pathway involved 
in reactivating the virus. Finally, suppression of EBV lytic gene expression due to TLR9 
activation in Akata cells involves histone modifications impacting on the activation of a viral 
lytic gene promoter. The suppression of EBV lytic gene expression, thus EBV hiding in 
latency, via histone modifications may have evolved to protect the virus against a TLR9-
induced immune response. 
 
For detailed information see attached manuscript 1. This manuscript is the main part 
of my work and thus will be the essential part in the discussion and outlook section.  
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Immune activation suppresses initiation of lytic Epstein-Barr virus infection 
 
Kristin Ladell, Marcus Dorner, Ludwig Zauner, Christoph Berger, Franziska Zucol, Michele 
Bernasconi, Felix K. Niggli, Roberto F. Speck and David Nadal1 (2007) Cell Microbiol., 
Aug;9(8):2055-69. 
 
Abstract 
Primary infection with Epstein-Barr virus (EBV) is asymptomatic in children with 
immature immune systems but may manifest as infectious mononucleosis, a vigorous 
immune activation, in adolescents or adults with mature immune systems. Infectious 
mononucleosis and chronic immune activation are linked to increased risk for EBV-
associated lymphoma. Here we show that EBV initiates progressive lytic infection by 
expression of BZLF1 and the late lytic genes gp85 and gp350/220 in cord blood mononuclear 
cells (CBMC) but not in peripheral blood mononuclear cells (PBMC) from EBV-naive adults 
after EBV infection ex vivo. Lower levels of proinflammatory cytokines in CBMC, used to 
model a state of minimal immune activation and immature immunity, than in PBMC were 
associated with lytic EBV infection. Triggering the innate immunity specifically via Toll-like 
receptor-9 in B-cells substantially suppressed BZLF1 mRNA expression in acute EBV 
infection ex vivo and in anti-IgG-stimulated chronically latently EBV-infected Akata Burkitt 
lymphoma cells. This was mediated in part by IL12 and IFNγ. These results identify immune 
activation as critical factor for the suppression of initiation of lytic EBV infection. We 
hypothesize that immune activation contributes to EBV-associated lymphomagenesis by 
suppressing lytic EBV and in turn promotes latent EBV with transformation potential. 
 
For detailed information see attached manuscript 2. 
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Plasma cell Toll-like receptor (TLR) expression differs from that of B-cells and 
plasma cell TLR triggering enhances immunoglobulin production 
 
Marcus Dorner, Simone Brandt, Marianne Tinguely, Franziska Zucol, Jean-Pierre Bourquin, 
Ludwig Zauner, Christoph Berger, Michele Bernasconi, Roberto F. Speck, and David Nadal; 
in press; doi: 10.1111/j.1365-2567.2009.03143.x 
 
Abstract 
Toll-like receptors (TLRs) are key receptors of the innate immune system and show 
cell-subset specific expression. We investigated the mRNA expression of TLR genes in 
human haematopoietic stem cells (HSC), naïve B-cells, memory B-cells and plasma cells 
from palatine tonsils and plasma cells from peripheral blood. HSC and plasma cells showed 
unrestricted expression of TLR1-TLR9, contrasting B-cells which lacked TLR3, TLR4 and 
TLR8 but expressed mRNA of all other TLRs. We demonstrate for the first time that TLR 
triggering of terminally differentiated plasma cells augments immunoglobulin production. 
Thus, boosting immediate antibody response by plasma cells upon pathogen recognition may 
point to a novel role of TLRs. 
 
For detailed information see attached manuscript 3. 
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Latent membrane protein 2B regulates susceptibility to induction of lytic 
Epstein-Barr virus infection 
 
Markus P. Rechsteiner, Christoph Berger, Ludwig Zauner, Jürg A. Sigrist, Matthias Weber, 
Richard Longnecker, Michele Bernasconi, and David Nadal (2008) J. Virol., Feb;82(4):1739-
47. 
 
Abstract 
The B-lymphotropic Epstein-Barr virus (EBV) encodes two isoforms of latent 
membrane protein 2 (LMP2), LMP2A and LMP2B, which are expressed during latency in B-
cells. The function of LMP2B is largely unknown, whereas LMP2A blocks B-cell receptor 
(BCR) signaling transduction and induction of lytic EBV infection, thereby promoting B-cell 
survival. Transfection experiments on LMP2B in EBV-negative B-cells and the silencing of 
LMP2B in EBV-harboring Burkitt's lymphoma-derived Akata cells suggest that LMP2B 
interferes with the function of LMP2A, but the role of LMP2B in the presence of functional 
EBV has not been established. Here, LMP2B, LMP2A, or both were overexpressed in EBV-
harboring Akata cells to study the function of LMP2B. The overexpression of LMP2B 
increased the magnitude of EBV switching from its latent to its lytic form upon BCR cross-
linking, as indicated by a more-enhanced upregulation and expression of EBV lytic genes and 
significantly increased production of transforming EBV compared to Akata vector control 
cells or LMP2A-overexpressing cells. Moreover, LMP2B lowered the degree of BCR cross-
linking required to induce lytic EBV infection. Finally, LMP2B colocalized with LMP2A as 
demonstrated by immunoprecipitation and immunofluorescence and restored calcium 
mobilization upon BCR cross-linking, a signaling process inhibited by LMP2A. Thus, our 
findings suggest that LMP2B negatively regulates the function of LMP2A in preventing the 
switch from latent to lytic EBV replication. 
For detailed information see attached manuscript 4.
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Burkitt’s lymphoma cell lines as a model B-cell system for investigating TLR 
engagement and interaction with the BCR 
 
Ludwig Zauner, Gregory T. Melroe, Natascha Wuillemin, Martina Arnold, Christoph Berger, 
Michele Bernasconi, and David Nadal 
Manuscript in preparation. 
 
Abstract 
During an infection, B-cells will most probably receive signals through both TLRs 
and BCRs. Investigations of how these receptors of innate and adaptive immunity and their 
signaling interact, are crucial for the understanding of the human immune system towards a 
pathogen. Burkitt’s lymphoma cell lines are used as a model to study the switch of EBV 
latent to EBV lytic gene expression. As TLR9 was reported to suppress BCR-induced EBV 
lytic gene expression, we aimed to investigate in more detail the effects of TLR9 on host 
gene expression and proliferation. Importantly, we focused on the effects of TLR9 and BCR 
triggering to shed light on the signaling interactions between these two receptors. We could 
show that TLR9 induces cytokine expression in BL cells peaking in the sequential order IL8 / 
TNFα, followed by IFNγ and IL10. Interestingly TLR9 engagement does not affect 
proliferation rates of Akata cells. Moreover, BCR triggering results in either a synergistic or 
suppressive effect on TLR9-induced cytokine production depending on the investigated 
cytokine. Finally, microarray analysis was performed to identify overlapping and segregated 
gene expression profiles for BCR and TLR9 engagement in the BL cell line Akata. 
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Discussion and Outlook 
Burkitt’s lymphoma cell lines are essential for investigating the switch from EBV 
latent to lytic gene expression. As the EBV-mediated transformation of B-cells takes place 
during EBV latency, it is crucial to study the regulatory mechanisms of latent EBV versus 
lytic EBV gene expression. Moreover, as lytic gene expression results in the death of the host 
cell, the switch to lytic EBV gene expression has oncolytic potential as it might destroy 
specifically tumor cells harboring EBV. Only little is known about how EBV contributes to 
tumor formation. In vitro, the latent genes necessary for the remarkable transforming 
capability of EBV are LMP1 and EBNA1, EBNA3B and EBNA3C. In vivo, however, EBV is 
not equally efficient in transforming cells, reflected by the fact that 90% of the adult human 
population is carrier of the virus. Consequently, other factors must play important 
pathogenetic roles. Importantly, the malaria pathogen Plasmodium falciparum or HIV are 
known to enhance the incidence of EBV-associated malignancies. 
EBV reactivation from latency or the contribution of EBV to malignancies cannot be 
investigated in a mouse model due to the narrow host range of EBV. Mice cannot be infected 
with EBV. Consequently, researchers often use MHV-68 as a surrogate. Although EBV 
shares great homology with MHV-68, there are differences - e.g. MHV-68 does not have 
transformation capability – which makes it difficult to predict the behavior of EBV in humans 
by extrapolating results from MHV-68 in mice. Moreover, there are distinct differences in 
TLR expression in mouse compared to human. In humans, only plasmacytoid dendritic cells 
and B-cells respond to TLR9 ligands. The limited expression of TLR9 in humans contrasts 
the expression in mice in which B-cells, monocytes, and probably all dendritic cells subsets 
express TLR9 (58, 59). Consequently, TLR9 triggering leads to a unique cytokine and 
chemokine expression profile, which differs between humans and mice (60). This differential 
TLR9 expression pattern affects the validity of the mouse model if one wants to assess 
experimental murine results for potential applicability in humans (51, 60). Thus, human B-
cell lines are important tools for investigating the effect of the TLRs on EBV gene 
expression. 
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As it was found that TLR9 ligands strongly enhance EBV-induced immortalization of 
B-cells (47), and in addition, that Plasmodium falciparum, a factor epidemiologically linked 
to the development of BL, triggers TLR9 (46, 66), we aimed to investigate TLR9 in EBV-
positive BL cell lines. In this work, we could show that TLR9 triggering activates several 
signaling pathway components including PI3K, MAPK and NF-κB, resulting in a distinct 
cytokine profile in BL cell lines. However, TLR9 engagement does not have a significant 
effect on proliferation although other reports on non-BL cell lines described enhanced 
proliferation or apoptosis in B-cells due to TLR9 stimulation. Nevertheless, TLR9 triggering 
leads to a significant suppression of EBV lytic gene expression, which could be shown at the 
mRNA and protein level (see manuscript 1). Moreover, TLR9 does not inhibit the initial steps 
of BCR signaling. That BCR signaling can be inhibited in the first signaling steps is 
exemplified by the interference of EBV’s LMP2 with the BCR-induced Ca2+ flux (for 
detailed information see manuscript 4). However, suppression of EBV lytic reactivation is 
independent of the inducing agent as TLR9 suppresses both BCR- and TPA-induced EBV 
lytic gene expression (see manuscript 1). Importantly, although NF-κB has a well-established 
role in affecting gamma herpesvirus gene expression, this transcription factor seems not to be 
involved in the TLR9-induced suppression of lytic EBV. A milestone in this work is the 
finding that TLR9 affects lytic EBV gene expression in the Akata BL cell line as well as in 
the EBV-infected BL cell line Mutu I and in the MHV-68-infected cell line S11 (see 
manuscript 1). However, this general effect of TLR9 seems not to be reflected by a general 
mechanism. In Akata cells, histone modifications induced by TLR9 seem to be the 
responsible mechanism as investigated with the HDAC inhibitor Trichostatin A and the 
chromatin immunoprecipitation assay (see manuscript 1). As the efficiencies for gamma 
herpesvirus reactivation in Mutu I or S11 cells are not as high as in Akata cells, we could not 
determine enriched phosphorylated or acetylated histones in sufficient quantities on the lytic 
promoter upon BCR or TPA induction in these cell lines, respectively. Thus, two contrasting 
conclusions for Mutu and S11 cells can be drawn from here: First, the less efficient 
reactivation results in histone modifications in such a low amount that cannot be detected in a 
whole population of cells. Second, a different mechanism might be responsible for TLR9-
induced suppression of gamma herpesvirus in Mutu I and S11 cells. 
This “same-effect-but-different-mechanism” model seems not only to be applicable to 
cell lines infected with EBV or MHV-68. Part of the work presented here, describes the 
TLR9-induced suppression of EBV lytic gene expression in ex-vivo infected cord blood 
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mononuclear cells (CBMCs) (manuscript 2). This suppression was mediated in part by the 
TLR9-induced expression of IL12 and IFNγ. Moreover, treatment with recombinant 
cytokines was able to influence EBV lytic gene expression in ex-vivo infected cord blood 
mononuclear cells (CBMCs). However, we could not detect any inhibition of BZLF1 
expression in Akata cells treated with recombinant IFNγ and IL12 (data not shown). Thus, 
the suppression of EBV lytic gene expression upon TLR9 triggering is differentially 
regulated in chronically EBV-infected BL Akata cells compared to acutely EBV-infected 
CBMCs.  
Humans encounter multiple pathogens during daily life and thus evolved multiple 
ways of innate and adaptive defense responses. Very successful viruses like the gamma 
herpesvirus Epstein-Barr virus (EBV), which establishes a life long latent B-cell infection in 
over 90% of the world’s adult population, must have developed mechanisms in order to hide 
from immune responses triggered by other similar pathogens. Interestingly, a study from 
Martin et al. showed that EBV has the potential to manipulate the innate immune pathway of 
toll-like-receptor 7 in order to establish EBV latent infection successfully (122). We could 
show here that EBV lytic gene expression is substantially suppressed upon engagement of 
Toll-like receptor 9 (TLR9). TLR9 recognizes DNA-containing CpG, a motif found in DNA 
of bacteria and viruses like the herpesviruses family. Thus, EBV developed a strategy to hide 
from the immune responses launched by the human body against EBV-similar pathogens by 
staying in latency with only few genes - or none - expressed to avoid immune recognition. 
We also showed that the responsible mechanism involves most probably TLR9-induced 
histone modifications on the EBV lytic promoter BZLF1. Histone modifications upon TLR 
engagement were previously shown to occur on individual host cytokine promoters in order 
to prevent excessive inflammation (110). Thus, it is tempting to speculate that EBV has 
adapted to use a host mechanism in order to prevent its own extinction. Moreover, gamma 
herpesviruses in cell lines other than Akata, like Mutu (EBV) or S11 (MHV-68), seem to 
have developed the same strategy of avoiding immune clearance. Nevertheless, this might be 
achieved by different mechanisms. Thus, depending on the virus and the background of the 
cell, the gamma herpesviruses have developed ways to avoid clearance by TLR9-induced 
immune responses through apparently different mechanisms.  
However, hiding in latency upon danger signals from TLRs might lead to detrimental 
effects in the host. By inducing suppression of EBV lytic gene expression, TLR9 might 
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enhance the latent state of the virus and consequently the probability of tumor formation. 
Chronic stimulation of TLR9 – e.g., by the malaria pathogen Plasmodium falciparum in 
endemic BL regions – might therefore be one of the key factors of BL development and 
reflect a situation to which EBV has not had time to adapt, yet. 
The regulatory mechanisms of how TLR affects gene expression are only beginning to 
reveal. It is known that TLR stimulation leads to activation of transcription factors like NF-
κB, AP1 or IRFs and thus regulates gene expression. Recently it was found that TLR 
engagement also affects the histone architecture of host cytokine promoters and thereby 
modulates expression of specific genes to avoid extensive inflammation. We show for the 
first time that TLR9 also modulates viral promoters, reflecting presumably an evolutionary 
mechanism of gamma herpesvirus to avoid clearance from the immune system. How the 
modulation of histones on some but not all promoters is achieved is currently not known. The 
next milestones, that need to be further investigated, are the unidentified components 
participating in the TLR9-induced signaling pathway leading to modifications in the histone 
structure. As no study identified the mechanism by which the TLR9-induced nucleosome 
remodeling on host promoters occurred, it can only be speculated how TLR9 induces changes 
in the histone architecture. TLR engagement strongly induces distinct sets of MAP kinase 
kinases (MKKs/MEKs) as well as MAPK phosphatases, e.g. DUSP1 (MAPK phosphatase 1) 
(114). These enzymes in turn are able to differentially regulate the activity of the AGC kinase 
family members, e.g., MSK1/2 and RSK2, which are known to affect phosphorylation of 
histone H3 at Ser10 (114, 115). This specific histone modification was demonstrated to occur 
at the BZLF1 promoter (see manuscript 1). When it comes to acetylation of histones, TLR9 
might affect the recruitment of co-activators which have histone deacetylase (HDAC) or 
histone acetyl-transferase (HAT) activities (like p300/CBP), leading to chromatin remodeling 
on host and viral promoters and subsequent changes in gene expression.  
Revealing the signaling components responsible for the TLR9-induced histone 
modifications on the EBV BZLF1 promoter might lead to new therapeutic approaches to 
counteract the TLR9-induced suppression of lytic EBV. Thus, by blocking these signaling 
components during chronic malaria infection, one reduces the risk of endemic BL 
development. This approach might also be beneficial for oncolytic-aimed therapies in already 
established EBV-associated malignancies. Interfering with the TLR9-induced suppression of 
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EBV lytic gene expression might lower the threshold for inducing EBV reactivation and thus 
the death of EBV-positive tumor cells. 
 
Literature 
39 
Literature 
1. Cohen, J. I. 2000. Epstein-Barr virus infection. N Engl J Med 343:481-492. 
2. Thorley-Lawson, D. A. 2001. Epstein-Barr virus: exploiting the immune system. Nat 
Rev Immunol 1:75-82. 
3. Tsurumi, T., M. Fujita, and A. Kudoh. 2005. Latent and lytic Epstein-Barr virus 
replication strategies. Rev Med Virol 15:3-15. 
4. Thorley-Lawson, D. A. 2005. EBV the prototypical human tumor virus--just how bad 
is it? J Allergy Clin Immunol 116:251-261; quiz 262. 
5. Takada, K. 1984. Cross-linking of cell surface immunoglobulins induces Epstein-Barr 
virus in Burkitt lymphoma lines. Int J Cancer 33:27-32. 
6. Fahmi, H., C. Cochet, Z. Hmama, P. Opolon, and I. Joab. 2000. Transforming growth 
factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early 
gene product ZEBRA by an indirect mechanism which requires the MAPK kinase 
pathway. J Virol 74:5810-5818. 
7. Flamand, L., I. Stefanescu, D. V. Ablashi, and J. Menezes. 1993. Activation of the 
Epstein-Barr virus replicative cycle by human herpesvirus 6. J Virol 67:6768-6777. 
8. Gao, X., K. Ikuta, M. Tajima, and T. Sairenji. 2001. 12-O-tetradecanoylphorbol-13-
acetate induces Epstein-Barr virus reactivation via NF-kappaB and AP-1 as regulated 
by protein kinase C and mitogen-activated protein kinase. Virology 286:91-99. 
9. Faggioni, A., C. Zompetta, S. Grimaldi, G. Barile, L. Frati, and J. Lazdins. 1986. 
Calcium modulation activates Epstein-Barr virus genome in latently infected cells. 
Science 232:1554-1556. 
10. Baumann, M., H. Mischak, S. Dammeier, W. Kolch, O. Gires, D. Pich, R. Zeidler, H. 
J. Delecluse, and W. Hammerschmidt. 1998. Activation of the Epstein-Barr virus 
transcription factor BZLF1 by 12-O-tetradecanoylphorbol-13-acetate-induced 
phosphorylation. J Virol 72:8105-8114. 
11. Countryman, J., L. Gradoville, S. Bhaduri-McIntosh, J. Ye, L. Heston, S. 
Himmelfarb, D. Shedd, and G. Miller. 2009. Stimulus Duration and Response Time 
Independently Influence the Kinetics of Lytic Cycle Reactivation of Epstein-Barr 
Virus. J Virol. 
12. Amon, W., and P. J. Farrell. 2005. Reactivation of Epstein-Barr virus from latency. 
Rev Med Virol 15:149-156. 
13. Countryman, J., and G. Miller. 1985. Activation of expression of latent Epstein-Barr 
herpesvirus after gene transfer with a small cloned subfragment of heterogeneous 
viral DNA. Proc Natl Acad Sci U S A 82:4085-4089. 
14. Rooney, C. M., D. T. Rowe, T. Ragot, and P. J. Farrell. 1989. The spliced BZLF1 
gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces 
the virus productive cycle. J Virol 63:3109-3116. 
15. Gruffat, H., E. Manet, and A. Sergeant. 2002. MEF2-mediated recruitment of class II 
HDAC at the EBV immediate early gene BZLF1 links latency and chromatin 
remodeling. EMBO Rep 3:141-146. 
16. Bryant, H., and P. J. Farrell. 2002. Signal Transduction and Transcription Factor 
Modification during Reactivation of Epstein-Barr Virus from Latency. J Virol 
76:10290-10298. 
17. Speck, S. H., T. Chatila, and E. Flemington. 1997. Reactivation of Epstein-Barr virus: 
regulation and function of the BZLF1 gene. Trends Microbiol 5:399-405. 
Literature 
40 
18. Yin, Q., K. Jupiter, and E. K. Flemington. 2004. The Epstein-Barr virus transactivator 
Zta binds to its own promoter and is required for full promoter activity during anti-Ig 
and TGF-beta1 mediated reactivation. Virology 327:134-143. 
19. Montalvo, E. A., M. Cottam, S. Hill, and Y. J. Wang. 1995. YY1 binds to and 
regulates cis-acting negative elements in the Epstein-Barr virus BZLF1 promoter. J 
Virol 69:4158-4165. 
20. Thomas, C., A. Dankesreiter, H. Wolf, and F. Schwarzmann. 2003. The BZLF1 
promoter of Epstein-Barr virus is controlled by E box-/HI-motif-binding factors 
during virus latency. J Gen Virol 84:959-964. 
21. Segouffin-Cariou, C., G. Farjot, A. Sergeant, and H. Gruffat. 2000. Characterization 
of the epstein-barr virus BRRF1 gene, located between early genes BZLF1 and 
BRLF1. J Gen Virol 81:1791-1799. 
22. Yu, X., Z. Wang, and J. E. Mertz. 2007. ZEB1 regulates the latent-lytic switch in 
infection by Epstein-Barr virus. PLoS Pathog 3:e194. 
23. Burkitt, D. 1958. A sarcoma involving the jaws in African children. Br J Surg 46:218-
223. 
24. Burkitt, D. 1962. Determining the climatic limitations of a children's cancer common 
in Africa. Br Med J 2:1019-1023. 
25. Burkitt, D. 1962. A children's cancer dependent on climatic factors. Nature 194:232-
234. 
26. Epstein, M. A., B. G. Achong, and Y. M. Barr. 1964. Virus Particles in Cultured 
Lymphoblasts from Burkitt's Lymphoma. Lancet 1:702-703. 
27. Henle, W., V. Diehl, G. Kohn, H. Zur Hausen, and G. Henle. 1967. Herpes-type virus 
and chromosome marker in normal leukocytes after growth with irradiated Burkitt 
cells. Science 157:1064-1065. 
28. Pope, J. H., M. K. Horne, and W. Scott. 1968. Transformation of foetal human 
keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like 
virus. Int J Cancer 3:857-866. 
29. Miller, G. 1974. The oncogenicity of Epstein-Barr virus. J Infect Dis 130:187-205. 
30. Young, L. S., and P. G. Murray. 2003. Epstein-Barr virus and oncogenesis: from 
latent genes to tumours. Oncogene 22:5108-5121. 
31. Weiss, L. M., L. A. Movahed, R. A. Warnke, and J. Sklar. 1989. Detection of Epstein-
Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 
320:502-506. 
32. Thomas, J. A., N. A. Hotchin, M. J. Allday, P. Amlot, M. Rose, M. Yacoub, and D. 
H. Crawford. 1990. Immunohistology of Epstein-Barr virus-associated antigens in B 
cell disorders from immunocompromised individuals. Transplantation 49:944-953. 
33. Andersson-Anvret, M., N. Forsby, G. Klein, W. Henle, and A. Biorklund. 1979. 
Relationship between the Epstein-Barr virus genome and nasopharyngeal carcinoma 
in Caucasian patients. Int J Cancer 23:762-767. 
34. Pattle, S. B., and P. J. Farrell. 2006. The role of Epstein-Barr virus in cancer. Expert 
Opin Biol Ther 6:1193-1205. 
35. Magrath, I., V. Jain, and K. Bhatia. 1992. Epstein-Barr virus and Burkitt's lymphoma. 
Semin Cancer Biol 3:285-295. 
36. Lombardi, L., E. W. Newcomb, and R. Dalla-Favera. 1987. Pathogenesis of Burkitt 
lymphoma: expression of an activated c-myc oncogene causes the tumorigenic 
conversion of EBV-infected human B lymphoblasts. Cell 49:161-170. 
37. van den Bosch, C. A. 2004. Is endemic Burkitt's lymphoma an alliance between three 
infections and a tumour promoter? Lancet Oncol 5:738-746. 
Literature 
41 
38. Thorley-Lawson, D. A., and M. J. Allday. 2008. The curious case of the tumour virus: 
50 years of Burkitt's lymphoma. Nat Rev Microbiol 6:913-924. 
39. Takada, K., K. Horinouchi, Y. Ono, T. Aya, T. Osato, M. Takahashi, and S. 
Hayasaka. 1991. An Epstein-Barr virus-producer line Akata: establishment of the cell 
line and analysis of viral DNA. Virus Genes 5:147-156. 
40. Drotar, M. E., S. Silva, E. Barone, D. Campbell, P. Tsimbouri, J. Jurvansu, P. Bhatia, 
G. Klein, and J. B. Wilson. 2003. Epstein-Barr virus nuclear antigen-1 and Myc 
cooperate in lymphomagenesis. Int J Cancer 106:388-395. 
41. Ruf, I. K., P. W. Rhyne, H. Yang, C. M. Borza, L. M. Hutt-Fletcher, J. L. Cleveland, 
and J. T. Sample. 1999. Epstein-barr virus regulates c-MYC, apoptosis, and 
tumorigenicity in Burkitt lymphoma. Mol Cell Biol 19:1651-1660. 
42. Neri, A., F. Barriga, G. Inghirami, D. M. Knowles, J. Neequaye, I. T. Magrath, and R. 
Dalla-Favera. 1991. Epstein-Barr virus infection precedes clonal expansion in 
Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood 
77:1092-1095. 
43. Rowe, M., D. T. Rowe, C. D. Gregory, L. S. Young, P. J. Farrell, H. Rupani, and A. 
B. Rickinson. 1987. Differences in B cell growth phenotype reflect novel patterns of 
Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. Embo J 
6:2743-2751. 
44. Pierce, S. K. 2009. Understanding B cell activation: from single molecule tracking, 
through Tolls, to stalking memory in malaria. Immunol Res 43:85-97. 
45. Rochford, R., M. J. Cannon, and A. M. Moormann. 2005. Endemic Burkitt's 
lymphoma: a polymicrobial disease? Nat Rev Microbiol 3:182-187. 
46. Parroche, P., F. N. Lauw, N. Goutagny, E. Latz, B. G. Monks, A. Visintin, K. A. 
Halmen, M. Lamphier, M. Olivier, D. C. Bartholomeu, R. T. Gazzinelli, and D. T. 
Golenbock. 2007. From the Cover: Malaria hemozoin is immunologically inert but 
radically enhances innate responses by presenting malaria DNA to Toll-like receptor 
9. Proc Natl Acad Sci U S A 104:1919-1924. 
47. Traggiai, E., S. Becker, K. Subbarao, L. Kolesnikova, Y. Uematsu, M. R. Gismondo, 
B. R. Murphy, R. Rappuoli, and A. Lanzavecchia. 2004. An efficient method to make 
human monoclonal antibodies from memory B cells: potent neutralization of SARS 
coronavirus. Nat Med 10:871-875. 
48. Kataaha, P. K., C. A. Facer, and E. J. Holborow. 1984. Plasmodium falciparum 
products enhance human lymphocyte transformation by Epstein-Barr virus. Clin Exp 
Immunol 56:371-376. 
49. Chene, A., D. Donati, A. O. Guerreiro-Cacais, V. Levitsky, Q. Chen, K. I. Falk, J. 
Orem, F. Kironde, M. Wahlgren, and M. T. Bejarano. 2007. A Molecular Link 
between Malaria and Epstein-Barr Virus Reactivation. PLoS Pathog 3:e80. 
50. Lemaitre, B., E. Nicolas, L. Michaut, J. M. Reichhart, and J. A. Hoffmann. 1996. The 
dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal 
response in Drosophila adults. Cell 86:973-983. 
51. Wagner, H. 2004. The immunobiology of the TLR9 subfamily. Trends Immunol 
25:381-386. 
52. Medzhitov, R., P. Preston-Hurlburt, and C. A. Janeway, Jr. 1997. A human 
homologue of the Drosophila Toll protein signals activation of adaptive immunity. 
Nature 388:394-397. 
53. Bourke, E., D. Bosisio, J. Golay, N. Polentarutti, and A. Mantovani. 2003. The toll-
like receptor repertoire of human B lymphocytes: inducible and selective expression 
of TLR9 and TLR10 in normal and transformed cells. Blood 102:956-963. 
Literature 
42 
54. Bernasconi, N. L., N. Onai, and A. Lanzavecchia. 2003. A role for Toll-like receptors 
in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and 
constitutive expression in memory B cells. Blood 101:4500-4504. 
55. Hornung, V., S. Rothenfusser, S. Britsch, A. Krug, B. Jahrsdorfer, T. Giese, S. 
Endres, and G. Hartmann. 2002. Quantitative expression of toll-like receptor 1-10 
mRNA in cellular subsets of human peripheral blood mononuclear cells and 
sensitivity to CpG oligodeoxynucleotides. J Immunol 168:4531-4537. 
56. Chiron, D., I. Bekeredjian-Ding, C. Pellat-Deceunynck, R. Bataille, and G. Jego. 
2008. Toll-like receptors: lessons to learn from normal and malignant human B cells. 
Blood 112:2205-2213. 
57. Mansson, A., M. Adner, U. Hockerfelt, and L. O. Cardell. 2006. A distinct Toll-like 
receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 
and CpG-2006 stimulation. Immunology 118:539-548. 
58. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive 
immune responses. Nat Immunol 5:987-995. 
59. Liu, Y. J. 2005. IPC: professional type 1 interferon-producing cells and plasmacytoid 
dendritic cell precursors. Annu Rev Immunol 23:275-306. 
60. Krieg, A. M. 2007. Development of TLR9 agonists for cancer therapy. J Clin Invest 
117:1184-1194. 
61. Aderem, A., and R. J. Ulevitch. 2000. Toll-like receptors in the induction of the innate 
immune response. Nature 406:782-787. 
62. Medzhitov, R. 2001. Toll-like receptors and innate immunity. Nat Rev Immunol 
1:135-145. 
63. Kumagai, Y., O. Takeuchi, and S. Akira. 2008. TLR9 as a key receptor for the 
recognition of DNA. Adv Drug Deliv Rev 60:795-804. 
64. Barton, G. M., and J. C. Kagan. 2009. A cell biological view of Toll-like receptor 
function: regulation through compartmentalization. Nat Rev Immunol 9:535-542. 
65. Verthelyi, D., and R. A. Zeuner. 2003. Differential signaling by CpG DNA in DCs 
and B cells: not just TLR9. Trends Immunol 24:519-522. 
66. Coban, C., K. J. Ishii, T. Kawai, H. Hemmi, S. Sato, S. Uematsu, M. Yamamoto, O. 
Takeuchi, S. Itagaki, N. Kumar, T. Horii, and S. Akira. 2005. Toll-like receptor 9 
mediates innate immune activation by the malaria pigment hemozoin. J Exp Med 
201:19-25. 
67. Latz, E., A. Schoenemeyer, A. Visintin, K. A. Fitzgerald, B. G. Monks, C. F. Knetter, 
E. Lien, N. J. Nilsen, T. Espevik, and D. T. Golenbock. 2004. TLR9 signals after 
translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5:190-198. 
68. Rutz, M., J. Metzger, T. Gellert, P. Luppa, G. B. Lipford, H. Wagner, and S. Bauer. 
2004. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-
dependent manner. Eur J Immunol 34:2541-2550. 
69. Stunz, L. L., P. Lenert, D. Peckham, A. K. Yi, S. Haxhinasto, M. Chang, A. M. Krieg, 
and R. F. Ashman. 2002. Inhibitory oligonucleotides specifically block effects of 
stimulatory CpG oligonucleotides in B cells. Eur J Immunol 32:1212-1222. 
70. Yamada, H., I. Gursel, F. Takeshita, J. Conover, K. J. Ishii, M. Gursel, S. Takeshita, 
and D. M. Klinman. 2002. Effect of suppressive DNA on CpG-induced immune 
activation. J Immunol 169:5590-5594. 
71. Latz, E., A. Verma, A. Visintin, M. Gong, C. M. Sirois, D. C. Klein, B. G. Monks, C. 
J. McKnight, M. S. Lamphier, W. P. Duprex, T. Espevik, and D. T. Golenbock. 2007. 
Ligand-induced conformational changes allosterically activate Toll-like receptor 9. 
Nat Immunol 8:772-779. 
Literature 
43 
72. Ewald, S. E., B. L. Lee, L. Lau, K. E. Wickliffe, G. P. Shi, H. A. Chapman, and G. M. 
Barton. 2008. The ectodomain of Toll-like receptor 9 is cleaved to generate a 
functional receptor. Nature 456:658-662. 
73. Hacker, H., R. M. Vabulas, O. Takeuchi, K. Hoshino, S. Akira, and H. Wagner. 2000. 
Immune cell activation by bacterial CpG-DNA through myeloid differentiation 
marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med 
192:595-600. 
74. Baldari, C. T. 2008. DNA methylation and TLR9 ligands: not only a matter of 
semantics. Immunol Lett 121:84-85. 
75. Barton, G. M., J. C. Kagan, and R. Medzhitov. 2006. Intracellular localization of Toll-
like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. 
Nat Immunol 7:49-56. 
76. Ishii, K. J., F. Takeshita, I. Gursel, M. Gursel, J. Conover, A. Nussenzweig, and D. M. 
Klinman. 2002. Potential role of phosphatidylinositol 3 kinase, rather than DNA-
dependent protein kinase, in CpG DNA-induced immune activation. J Exp Med 
196:269-274. 
77. Dil, N., and A. J. Marshall. 2009. Role of phosphoinositide 3-kinase p110 delta in 
TLR4- and TLR9-mediated B cell cytokine production and differentiation. Mol 
Immunol 46:1970-1978. 
78. Peng, S. L. 2005. Signaling in B cells via Toll-like receptors. Curr Opin Immunol 
17:230-236. 
79. Takeshita, F., I. Gursel, K. J. Ishii, K. Suzuki, M. Gursel, and D. M. Klinman. 2004. 
Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like 
receptor 9. Semin Immunol 16:17-22. 
80. Prakash, A., E. Smith, C. K. Lee, and D. E. Levy. 2005. Tissue-specific positive 
feedback requirements for production of type I interferon following virus infection. J 
Biol Chem 280:18651-18657. 
81. Guiducci, C., G. Ott, J. H. Chan, E. Damon, C. Calacsan, T. Matray, K. D. Lee, R. L. 
Coffman, and F. J. Barrat. 2006. Properties regulating the nature of the plasmacytoid 
dendritic cell response to Toll-like receptor 9 activation. J Exp Med 203:1999-2008. 
82. Niiro, H., and E. A. Clark. 2002. Regulation of B-cell fate by antigen-receptor signals. 
Nat Rev Immunol 2:945-956. 
83. King, L. B., and J. G. Monroe. 2000. Immunobiology of the immature B cell: 
plasticity in the B-cell antigen receptor-induced response fine tunes negative 
selection. Immunol Rev 176:86-104. 
84. Hoffmann, R., T. Seidl, M. Neeb, A. Rolink, and F. Melchers. 2002. Changes in gene 
expression profiles in developing B cells of murine bone marrow. Genome Res 12:98-
111. 
85. Chung, J. B., M. A. Baumeister, and J. G. Monroe. 2001. Cutting edge: differential 
sequestration of plasma membrane-associated B cell antigen receptor in mature and 
immature B cells into glycosphingolipid-enriched domains. J Immunol 166:736-740. 
86. Sproul, T. W., S. Malapati, J. Kim, and S. K. Pierce. 2000. Cutting edge: B cell 
antigen receptor signaling occurs outside lipid rafts in immature B cells. J Immunol 
165:6020-6023. 
87. Allman, D., R. C. Lindsley, W. DeMuth, K. Rudd, S. A. Shinton, and R. R. Hardy. 
2001. Resolution of three nonproliferative immature splenic B cell subsets reveals 
multiple selection points during peripheral B cell maturation. J Immunol 167:6834-
6840. 
Literature 
44 
88. Norvell, A., L. Mandik, and J. G. Monroe. 1995. Engagement of the antigen-receptor 
on immature murine B lymphocytes results in death by apoptosis. J Immunol 
154:4404-4413. 
89. Yellen, A. J., W. Glenn, V. P. Sukhatme, X. M. Cao, and J. G. Monroe. 1991. 
Signaling through surface IgM in tolerance-susceptible immature murine B 
lymphocytes. Developmentally regulated differences in transmembrane signaling in 
splenic B cells from adult and neonatal mice. J Immunol 146:1446-1454. 
90. Dal Porto, J. M., S. B. Gauld, K. T. Merrell, D. Mills, A. E. Pugh-Bernard, and J. 
Cambier. 2004. B cell antigen receptor signaling 101. Mol Immunol 41:599-613. 
91. Harwood, N. E., and F. D. Batista. 2008. New insights into the early molecular events 
underlying B cell activation. Immunity 28:609-619. 
92. Campbell, K. S. 1999. Signal transduction from the B cell antigen-receptor. Curr 
Opin Immunol 11:256-264. 
93. Kurosaki, T. 1999. Genetic analysis of B cell antigen receptor signaling. Annu Rev 
Immunol 17:555-592. 
94. Lanzavecchia, A. 1990. Receptor-mediated antigen uptake and its effect on antigen 
presentation to class II-restricted T lymphocytes. Annu Rev Immunol 8:773-793. 
95. Viglianti, G. A., C. M. Lau, T. M. Hanley, B. A. Miko, M. J. Shlomchik, and A. 
Marshak-Rothstein. 2003. Activation of autoreactive B cells by CpG dsDNA. 
Immunity 19:837-847. 
96. Christensen, S. R., M. Kashgarian, L. Alexopoulou, R. A. Flavell, S. Akira, and M. J. 
Shlomchik. 2005. Toll-like receptor 9 controls anti-DNA autoantibody production in 
murine lupus. J Exp Med 202:321-331. 
97. Yi, A. K., J. G. Yoon, and A. M. Krieg. 2003. Convergence of CpG DNA- and BCR-
mediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: 
regulation by mitogen-activated protein kinases. Int Immunol 15:577-591. 
98. Yi, A. K., and A. M. Krieg. 1998. CpG DNA rescue from anti-IgM-induced WEHI-
231 B lymphoma apoptosis via modulation of I kappa B alpha and I kappa B beta and 
sustained activation of nuclear factor-kappa B/c-Rel. J Immunol 160:1240-1245. 
99. Yi, A. K., P. Hornbeck, D. E. Lafrenz, and A. M. Krieg. 1996. CpG DNA rescue of 
murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell 
death is associated with increased expression of c-myc and bcl-xL. J Immunol 
157:4918-4925. 
100. Han, S. S., S. T. Chung, D. A. Robertson, R. L. Chelvarajan, and S. Bondada. 1999. 
CpG oligodeoxynucleotides rescue BKS-2 immature B cell lymphoma from anti-IgM-
mediated growth inhibition by up-regulation of egr-1. Int Immunol 11:871-879. 
101. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. 
A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct 
B-cell activation. Nature 374:546-549. 
102. Leadbetter, E. A., I. R. Rifkin, A. M. Hohlbaum, B. C. Beaudette, M. J. Shlomchik, 
and A. Marshak-Rothstein. 2002. Chromatin-IgG complexes activate B cells by dual 
engagement of IgM and Toll-like receptors. Nature 416:603-607. 
103. Yi, A. K., D. W. Peckham, R. F. Ashman, and A. M. Krieg. 1999. CpG DNA rescues 
B cells from apoptosis by activating NFkappaB and preventing mitochondrial 
membrane potential disruption via a chloroquine-sensitive pathway. Int Immunol 
11:2015-2024. 
104. Krieg, A. M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu Rev 
Immunol 20:709-760. 
Literature 
45 
105. Chaturvedi, A., D. Dorward, and S. K. Pierce. 2008. The B cell receptor governs the 
subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-
containing antigens. Immunity 28:799-809. 
106. Eckl-Dorna, J., and F. D. Batista. 2009. BCR-mediated uptake of antigen linked to 
TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell 
formation. Blood 113:3969-3977. 
107. Minguet, S., E. P. Dopfer, C. Pollmer, M. A. Freudenberg, C. Galanos, M. Reth, M. 
Huber, and W. W. Schamel. 2008. Enhanced B-cell activation mediated by TLR4 and 
BCR crosstalk. Eur J Immunol 38:2475-2487. 
108. Broad, A., D. E. Jones, and J. A. Kirby. 2006. Toll-like receptor (TLR) response 
tolerance: a key physiological "damage limitation" effect and an important potential 
opportunity for therapy. Curr Med Chem 13:2487-2502. 
109. Poovassery, J. S., T. J. Vanden Bush, and G. A. Bishop. 2009. Antigen Receptor 
Signals Rescue B Cells from TLR Tolerance. J Immunol. 
110. Foster, S. L., D. C. Hargreaves, and R. Medzhitov. 2007. Gene-specific control of 
inflammation by TLR-induced chromatin modifications. Nature 447:972-978. 
111. Espino, P. S., B. Drobic, K. L. Dunn, and J. R. Davie. 2005. Histone modifications as 
a platform for cancer therapy. J Cell Biochem 94:1088-1102. 
112. Albrecht, I., T. Tapmeier, S. Zimmermann, M. Frey, K. Heeg, and A. Dalpke. 2004. 
Toll-like receptors differentially induce nucleosome remodelling at the IL-12p40 
promoter. EMBO Rep 5:172-177. 
113. Weinmann, A. S., D. M. Mitchell, S. Sanjabi, M. N. Bradley, A. Hoffmann, H. C. 
Liou, and S. T. Smale. 2001. Nucleosome remodeling at the IL-12 p40 promoter is a 
TLR-dependent, Rel-independent event. Nat Immunol 2:51-57. 
114. Vermeulen, L., W. V. Berghe, I. M. Beck, K. De Bosscher, and G. Haegeman. 2009. 
The versatile role of MSKs in transcriptional regulation. Trends Biochem Sci 34:311-
318. 
115. Ananieva, O., J. Darragh, C. Johansen, J. M. Carr, J. McIlrath, J. M. Park, A. 
Wingate, C. E. Monk, R. Toth, S. G. Santos, L. Iversen, and J. S. Arthur. 2008. The 
kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. 
Nat Immunol 9:1028-1036. 
116. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420:860-867. 
117. Balkwill, F., and L. M. Coussens. 2004. Cancer: an inflammatory link. Nature 
431:405-406. 
118. Beachy, P. A., S. S. Karhadkar, and D. M. Berman. 2004. Mending and malignancy. 
Nature 431:402. 
119. Chen, R., A. B. Alvero, D. A. Silasi, K. D. Steffensen, and G. Mor. 2008. Cancers 
take their Toll--the function and regulation of Toll-like receptors in cancer cells. 
Oncogene 27:225-233. 
120. Kreuz, S., D. Siegmund, J. J. Rumpf, D. Samel, M. Leverkus, O. Janssen, G. Hacker, 
O. Dittrich-Breiholz, M. Kracht, P. Scheurich, and H. Wajant. 2004. NFkappaB 
activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by 
FLIP. J Cell Biol 166:369-380. 
121. Wolffe, A. P. 2001. Chromatin remodeling: why it is important in cancer. Oncogene 
20:2988-2990. 
122. Martin, H. J., J. M. Lee, D. Walls, and S. D. Hayward. 2007. Manipulation of the toll-
like receptor 7 signaling pathway by epstein-barr virus. J Virol 81:9748-9758. 
123. Bekeredjian-Ding, I., Jego, G., Toll-like receptors – sentries in the B-cell response, 
Immunology, DOI: 10.1111/j.1365-2567.2009.03173.x 
 
Curriculum Vitae 
46 
Curriculum Vitae 
Name:    Ludwig Sebastian ZAUNER 
Date of birth:  April 2nd, 1978 
Place of birth:  Munich, Germany 
Nationality:   German 
Education: 
 
08/2008 – 07/2009 University of Zurich 
  Recipient of the “Forschungskredit” (scholarship) 
 
since 09/2006 University of Zurich,  
  Participant in the Microbiology and Immunology PhD program 
 
since 01/2006 University of Zurich / Kinderspital Zurich (PhD thesis) 
 
04/2005 Technical University of Munich (TUM) 
  finished study of biology with the overall grade 1,4 (very good) 
 
11/2003 – 11/2004 Technical University of Munich (TUM) 
  Diploma thesis in the group of Prof. E. Grill (Botany)  
”Investigations of the transport of EC- und ECG-conjugates on 
vacuoles of Hordeum vulgare L.” (grade 1,3) 
 
09/2003 Technical University of Munich (TUM):  
  Final university exams in: 
  - Botany/Molecular Plants Biology (Prof. E. Grill, grade 1,3) 
  - Microbiology (Prof. K.H. Schleifer, grade 1,3) 
  - Limnology (Prof. A. Melzer, grade 2,0) 
 
01/2003 – 04/2003 S*BIO, Singapore 
Internship at a cancer research company for drug; Functional 
Genomics Group, Group Leader: Dr. W. Stuenkel 
 
06/2002 – 01/2003 National University of Singapore (NUS) 
Exchange semester in the “LAOTSE” program of the TUM 
exams in Medical Microbiology, Mycology, and Chinese 
  
11/1998 – 11/2004 Technical University of Munich (TUM) 
  study of biology (“Diplom“) 
 
09/1997 – 10/1998 Blindeninstitutsstiftung München (social service) 
 
09/1988 – 06/1997 Gymnasium Gröbenzell (mathematisch-naturwissenschaftlich) 
 
09/1984 – 07/1988 Elementary school, Munich 
 
Curriculum Vitae 
47 
 
Publication list 
 
1) K. Ladell*, M. Dorner*, L. Zauner, C. Berger, F. Zucol, M. Bernasconi, F.K. Niggli, R.F. 
Speck, and D. Nadal. 2007. Immune activation suppresses initiation of lytic Epstein-Barr 
virus infection. Cell Microbiol 9:2055-2069; * contributed equally 
 
2) Rechsteiner, M.P., C. Berger, L. Zauner, J.A. Sigrist, M. Weber, R. Longnecker, M. 
Bernasconi, and D. Nadal. 2008. Latent Membrane Protein 2B Regulates Susceptibility to 
Induction of Lytic Epstein-Barr Virus Infection. J Virol 82:1739-1747 
 
3) M. Dorner, S. Brandt, M. Tinguely, F. Zucol, JP. Bourquin, L. Zauner, C. Berger, M. 
Bernasconi, RF. Speck, and D. Nadal. 2009. Plasma cell Toll-like receptor (TLR) expression 
differs from that of B-cells and plasma cell TLR triggering enhances immunoglobulin 
production. Immunulogy Accepted Article; doi: 10.1111/j.1365-2567.2009.03143.x 
 
 
Selected Poster Presentations, Talks and Awards 
 
1) Toll-like receptor 9 triggering inhibits Epstein-Barr virus lytic gene expression (Poster) 
XIX. Meeting of the Swiss immunology PhD students, Switzerland, March 26 – 28, 2007 
 
2) Suppression of Epstein-Barr virus (EBV) lytic gene expression in Burkitt’s lymphoma 
(BL) following CpG ODN treatment is dependent on Toll-like receptor-(TLR) 9 yet 
independent of NF-κB activation and cytokine signaling (Poster) 
Innate Immunity: Signaling Mechanisms, Keystone, Colorado, USA, February 24 - 29, 2008 
 
3) Suppression of Epstein-Barr virus (EBV) lytic gene expression in Burkitt’s lymphoma 
(BL) following CpG ODN treatment is dependent on Toll-like receptor-(TLR) 9 yet 
independent of NF-κB activation and cytokine signaling (Poster) 
7th Day of Clinical Research, University Hospital Zurich, Switzerland, March 27, 2008  
 
4) Toll-like receptor-9 signaling in the EBV-positive Burkitt’s lymphoma cell line Akata 
(Talk, 1st Prize for the best student talk). 
Microbiology and Immunology Student Retreat, Fiescheralp, Wallis, Switzerland, September 
07 – 09, 2008 
 
5) The Toll-like receptor 9 (TLR9)-induced suppression of Epstein-Barr virus (EBV) lytic 
gene expression is MyD88 dependent yet independent of NF-κB activation (Poster) 
1st Swiss Workshop in Fundamental Virology, Fribourg, Switzerland, January 26 – 27, 2009 
 
5) The Toll-like receptor 9 (TLR9)-induced suppression of Epstein-Barr virus (EBV) lytic 
gene expression is MyD88 dependent yet independent of NF-κB activation (Poster) 
9th Charles Rodolphe Brupbacher Symposium, Targets for Cancer Prevention and Therapy, 
Zurich, Switzerland, February 11 – 13, 2009 
 
6) The Toll-like receptor 9 (TLR9)-induced suppression of Epstein-Barr virus (EBV) lytic 
gene expression is MyD88 dependent yet independent of NF-κB activation (Poster) 
Pattern Recognition Molecules and Immune Sensors of Pathogens, Banff, Alberta, Canada, 
March 29 – April 3, 2009 
Acknowledgements 
48 
Acknowledgements 
I would like to thank and extend my gratitude to all who have supported and guided me in 
completing my Ph.D. thesis, in particular: 
• Prof. Dr. David Nadal, who was instrumental in supervising and guiding me 
throughout the entire process of working on this thesis. I am truly grateful to him in 
helping me design my project. He mustered the encouragement and support that I 
needed, in particular during challenging times, to make this happen.  
• Prof. Dr. Michael Hengartner and Prof. Dr. Urs Greber, my doctoral committees, who 
invested their time, their patience and gave crucial important advice. 
• PD Dr. Christoph Berger, PD Dr. Roberto Speck and Dr. Michele Bernasconi who 
helped me to outline important parts of my project and for the most helpful 
discussions. 
• Kathya Prêtre for being the most wonderful friend; for her enthusiasm, support and 
understanding, and for showing me every day how to become a better person. 
• Dagmar Walter, whose cheerful way always puts a smile on my face, and for the 
uplifting helpful discussions. 
• Regina Miller for walking together during this “thesis-hiking marathon”. Her honesty 
and way of dealing with people and issues was truly inspiring. 
• Dr. Margreth Ebauer, who moved ahead and showed me that there is life after a Ph.D. 
thesis. 
• Dr. Marcus Dorner, Jürg Sigrist and Dr. Franziska Zucoll who helped me in any way 
possible. 
• Martina Arnold, Natascha Wuillemin, Marta Wehrmüller. I have learned extremely a 
lot during my time as supervisor, confirming the fact that a teacher also learns from 
his/her students. 
• Dr. Gregory Melroe, a fantastic post-doc, whom I have learned tremendously from. 
• Valentina Alessandro for showing me how beautiful the German language can be, and 
more importantly, for being a truly amazing person. 
• All the people at August-Forel Strasse who helped and encouraged me, especially Dr. 
Kazuma Yamauchi, Dr. Beat Bornhauser, Dr. Marco Wachtel, Dr. Susanne Oesch, 
Acknowledgements 
49 
Dr. Markus Rechsteiner, Dr. Katarina Hajdin, Florian Haas, Elena Groppa, Julia 
Noack, Davide Alessi, Alexandar Boro, Regina Hecker. 
• My friends, who are scattered around the globe, but who were very near every time I 
needed their help or advice; Roger, Viradeth, Martin, Shahril, Claire, Elena, Andi S, 
Peter, Andi L, Ernst. 
• Finally, thank you to my parents and my brother for their unconditional love, wisdom 
and understanding. Their encouragement, support and guidance with the way I live 
my life are of immeasurable value to me. They have showed me how to fulfill my 
dreams and reminding me that life should be an incredible journey. No words can 
ever express the feelings of gratitude I have for you, and for being part of your life. 
Manuscripts 
50 
Manuscripts 
1) TLR9 triggering induces suppression of EBV lytic gene expression via histone 
modification  
Ludwig Zauner, Gregory T. Melroe, Markus P. Rechsteiner, Marcus Dorner, Martina Arnold, 
Christoph Berger, Michele Bernasconi, Beat W. Schaefer, Roberto F. Speck, David Nadal 
Manuscript submitted for publication. 
2) Immune activation suppresses initiation of lytic Epstein-Barr virus infection 
Kristin Ladell, Marcus Dorner, Ludwig Zauner, Christoph Berger, Franziska Zucol, Michele 
Bernasconi, Felix K. Niggli, Roberto F. Speck and David Nadal1 (2007) Cell Microbiol., 
Aug;9(8):2055-69. 
3) Plasma cell Toll-like receptor (TLR) expression differs from that of B-cells and 
plasma cell TLR triggering enhances immunoglobulin production 
Marcus Dorner, Simone Brandt, Marianne Tinguely, Franziska Zucol, Jean-Pierre Bourquin, 
Ludwig Zauner, Christoph Berger, Michele Bernasconi, Roberto F. Speck, and David Nadal; 
Accepted Article; doi: 10.1111/j.1365-2567.2009.03143.x 
4) Latent Membrane Protein 2B Regulates Susceptibility to Induction of Lytic Epstein-
Barr Virus Infection 
Markus P. Rechsteiner, Christoph Berger, Ludwig Zauner, Jürg A. Sigrist, Matthias Weber, 
Richard Longnecker, Michele Bernasconi, and David Nadal (2008) J. Virol., Feb;82(4):1739-
47. 
 
 1 
TLR9 triggering induces suppression of EBV lytic gene expression 
via histone modification 1 
 
 
Ludwig Zauner*, Gregory T. Melroe*2, Markus P. Rechsteiner*3, Marcus Dorner*, Martina 
Arnold*, Christoph Berger*, Michele Bernasconi*, Beat W. Schaefer*, Roberto F. Speck†, 
David Nadal*4 
 
* Laboratory for Experimental Infectious Diseases and Cancer Research of the Division of 
Infectious Diseases and Hospital Epidemiology and the Division of Oncology, University 
Children’s Hospital of Zurich, University of Zurich, 8032 Zurich, Switzerland. 
† Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, 
University of Zurich, 8091 Zurich, Switzerland. 
 
Correspondence: Prof. David Nadal 
eMail: david.nadal@kispi.uzh.ch 
Tel: +41 44 266 72 50 
Fax: +41 44 266 80 72 
 
Running title: Inhibition of EBV lytic gene expression via TLR9 
Keywords: EBV, TLR9, Burkitt’s lymphoma, histone modification 
 2 
Abstract 
By recognizing numerous pathogen-associated DNA sequences, Toll-like receptor 9 
(TLR9) causes a strong innate immune response resulting in cytokine secretion and 
costimulatory molecule expression. Immune activation with a TLR9 ligand was shown to 
suppress the initiation of EBV lytic replication in primary human B-cells. Here, we show that 
the suppression of EBV lytic gene expression is dependent on functional TLR9 and MyD88 
signaling in the Akata cell line. Furthermore, TLR9 activation suppresses not only human but 
also murine gamma herpesvirus lytic gene expression, independently of the pathway involved 
in reactivating the virus. Finally, suppression of EBV lytic gene expression due to TLR9 
activation in Akata cells involves histone modifications impacting on the activation of a viral 
lytic gene promoter. The suppression of EBV lytic gene expression, thus EBV hiding in 
latency, via histone modifications may have evolved to protect the virus against a TLR9-
induced immune response. 
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Introduction 
Epstein-Barr virus is a gamma herpesvirus infecting over 90% of the human 
population. Subsequent to primary infection, which largely takes place during childhood 
or adolescence, the virus persists in infected individuals as an asymptomatic latent 
infection of B-cells. Occasionally, EBV will reactivate from latency, ultimately resulting 
in the production of progeny viral particles, death of the host cell, and infection of new 
cells (1, 2). Upon initiation of lytic replication, the EBV immediate-early genes BZLF1 
(encoding the protein Zta) and BRLF1 (encoding the protein Rta) are the first viral genes 
expressed. They encode transcription factors that, when expressed in sufficient quantities, 
lead to reactivation from latency by inducing an ordered cascade of early and late lytic 
EBV genes expressions (3). Notably, in cell lines infected with latent EBV, the virus can 
be induced to lytic infection by various stimuli like anti-human Ig, TGFβ or TPA5 (4-7).  
Toll-like receptors are key components of the innate immune system and have 
been implicated in the recognition of structural motifs of a number of distinct microbes 
that cause human diseases. The endosomal TLR9 can be triggered by synthetic ODN6 
containing unmethylated CpG, a motif found in bacterial and viral DNA (8). Signaling of 
TLR9 in B-cells proceeds through MyD88, which then culminates in the activation of 
MAPKs, NF-κB and AP-1 complexes (9). Thus, NF-κB and AP-1 complexes are enabled 
to translocate into the cell nucleus where they promote the expression of genes involved 
in B-cell activation, proliferation, and in the production of inflammatory cytokines as a 
part of the innate immune response against pathogens (10). Moreover, it has been shown 
that TLRs regulate the shape and extent of the inflammatory response through chromatin 
modifications at the level of individual cellular promoters (11). 
EBV latent genes expression may lead to growth transformation of B-cells in vitro 
(12), and latent EBV infection is strongly associated with the development of Burkitt’s 
lymphoma (BL), the most common cancer of childhood in equatorial Africa (13). Cell 
lines derived from EBV-positive BL, such as the Akata cell line or the Mutu I cell line, 
are instrumental to elucidate the factors that regulate the balance between EBV latency 
and lytic reactivation. Recently, we have shown that triggering TLR9, but not TLR1/2 or 
TLR7/8, results in the suppression of EBV lytic gene expression and thus reinforcement 
of EBV latent gene expression (14).  
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Here, we investigated the impact of TLR9 stimulation and its downstream 
signaling pathways on gamma herpesviruses. Importantly, we provide strong evidence 
that TLR9 suppresses EBV lytic gene expression by histone modification on a viral gene 
promoter. We used EBV-positive Akata and Mutu I BL cells as model systems for human 
gamma herpesvirus and S11 lymphoma cells for murine gamma herpesvirus.  
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Material and Methods 
 
Cell culture and induction of lytic gamma herpesvirus infection 
Akata (EBV-positive cell line from a Japanese BL), Mutu I (EBV-positive cell line 
from an African BL) and S11 (cell line from murine gamma herpesvirus-68 infected mouse 
lymphoma) cells were cultured in RPMI 1640 medium supplemented with L-glutamine, 10 % 
heat-inactivated fetal calf serum, 100 U ml-1 penicillin and 100 µg ml-1 streptomycin sulphate 
(medium and supplements from Gibco, Invitrogen Life Sciences, Basel, Switzerland) at 37 ºC 
in a humidified atmosphere of 5 % CO2 in air. 
For induction of gamma herpesvirus lytic gene expression, cells were seeded at 1 x 106 
ml-1. Akata cells were treated with 100 µg ml-1 anti-IgG (Dako A0423, DakoCytomation, Zug, 
Switzerland) or with 50 ng ml-1 of TPA (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland), 
whereas Mutu I cells with 10 µg ml-1 anti-IgM (Dako A0426), or with 5 ng ml-1 human TGFβ 
(100-B-001, R&D Systems, Wiesbaden-Nordenstadt, Germany) and S11 cells with 50 ng ml-1 
of TPA (Sigma-Aldrich). 
 
Treatment of cells with ligands for TLR9 and inhibitors of its signaling 
CpG2006 for EBV and CpG1826 for MHV-68 (both final concentration 0.5 µM) 
treatment preceded virus induction with anti-IgG, anti-IgM, TGFβ, or TPA for 2 h. The TLR9 
inhibitor ODN IRS869 (final concentration 5.0 µM) was added very shortly, the TLR9 
inhibitor chloroquine (Sigma-Aldrich) (final concentration 10 µM) was added 15 min before 
CpG2006 treatments. Sequences of oligodeoxynucleotide (Eurogentec, Seraing, Belgium): 
CpG2006 (class B): 5`-T*C*G* T*C*G* T*T*T* T*G*T* C*G*T* T*T*T* G*T*C* 
G*T*T*-3´ (*bases are phosphorothioate); IRS869: 5`-T*C*C* T*G*G* A*G*G* G*G*T* 
T*G*T*-3´ (*bases are phosphorothioate); CpG1826: 5´-
T*C*C*A*T*G*A*C*G*T*T*C*C*T*G*A*C*G*T*T*-3´ (*bases are phosphorothioate). 
Used signaling inhibitors were applied 1 hour before CpG2006 treatment: The 
InSolutionTM NF-κB activation inhibitor (Calbiochem, San Diego, CA, USA) with final 
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concentration of 1.5 µM; the PI3K-inhibitor Ly294002 (Sigma-Aldrich) with final 
concentration of 20 µM; the MAPK/ERK-kinase-inhibitor PD98059 (LabForce-InvivoGen, 
Nunningen, Switzerland) with final concentration of 50 µM, the JNK inhibitor SP600125 
(Calbiochem) with a final concentration of 20 µM, and the p38 inhibitor SB203580 (upstate, 
Lake Placid, USA) with a final concentration of 20 µM. Trichostatin A (Sigma-Aldrich) was 
applied 12h before CpG2006 treatment at a final concentration of 50 ng ml-1. 
 
RNA preparation, reverse transcription and qPCR (TaqMan) 
Total RNA was isolated with RNeasy mini kit (Qiagen, Basel, Switzerland) according 
to the manufacturer’s instructions. RNA was treated with DNase (DNAfree; Ambion Europe, 
Huntington, Cambridgeshire, UK) for removal of residual DNA. RNA values were measured 
with Nanodrop-1000 (Nanodrop Technologies, Wilmington, DE, USA). RNA (1 µg) was 
reverse transcribed in a total volume of 20 µl with oligo dT15 (Microsynth, Balgach, 
Switzerland) and Omniscript Reverse Transcription kit (Quiagen). RNase inhibitor (10 units) 
(RNasin plus, Promega, Catalys AG, Wallisellen, Switzerland) was added to each 20 µl 
reaction volume. Quantitative real-time PCR (TaqMan) was performed with the ABI PRISM 
7900HT (Applied Biosystems, Foster City, CA, USA) in a reaction volume of 10 µl. Each 
reaction contained a mix of the 2x ABI-TaqMan Master Mix (Applied Biosystems), primers 
(Microsynth) at 300 nm each, the probe (Biosearch Technologies, Novato, CA, USA) at 200 
nm, and 0.67 µl of cDNA template. The assays were cDNA specific: either the forward or 
reverse primer or the probe was designed to span exon-exon junctions. Specificity 
(DNA/cDNA) was tested using RNA before and after DNase treatment and cDNA with or 
without prior DNase treatment. All reactions were performed in duplicate. TaqMan data were 
analyzed using SDS 2.2 (Applied Biosystems). BZLF1, BXLF1, BXLF2, BCRF1, MyD88wt, 
MyD88mutant, hIL10, IFNγ, TNFα, ORF50 mRNA expression was normalized to the 
housekeeping genes mRNA of HMBS, GAPDH or 18sRNA, resulting in ∆ threshold cycle 
(∆CT) values. ∆CT values were further normalized as stated in the figures. In some cases, 
SYBR-Green was used instead of probes according to the manufacturer’s instructions 
(Applied Biosystems).  
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Calcium-flux measurements and flow cytometry 
Akata cells (1 x 107 ml-1) were treated with CpG2006 two hours before, Fluo-3 and 
Fura-Red Dyes (Invitrogen) (final concentrations of 6 µM and 15 µM, respectively) were 
given 45 min before, and anti-IgG was given immediately before calcium-flux measurement 
with a FC-500 (Beckmann-Coulter, Fullerton, CA, USA). Incubation of dyes was performed 
in the dark at 37 °C with occasional shaking, followed by a PBS washing step. Excitation was 
performed at 488 nm and emission with Fluo-3 at 515-535 (FL1) and Fura Red at 665-685 
(Fl3). Calcium flux was measured over 5 min as a ratio of Fluo-3 / Fura Red as previously 
described (15). 
 
Immunoprecipitation and western blot analyses 
Cells were harvested by centrifugation. After two washes in cold PBS, cells (5 x 106) 
from each sample were incubated on ice for 20 min in 0.5 ml of immunoprecipitation (16) 
lysis buffer (20 mM Tris-HCl [pH 7.5], 50 mM NaCl, 0.1 % NP-40, 10 mM b-
glycerophosphate, 5 mM NaF, 1 mM PMSF, 2.5 % glycerol, and 1 complete mini protease 
inhibitor cocktail tablet [Roche Applied Science, Indianapolis, Ind.] per 10 ml). Cell lysates 
were clarified by centrifugation at 8,000 x g at 4 ºC for 10 min. Immunoprecipitation was 
carried out with the monoclonal BZLF1 antibody (1:20 dilution; M7005, Dako) and protein 
G-sepharose beads (Sigma-Aldrich, product no. P3296) at 4ºC for 24 h. After four washes in 
washing buffer (20 mM Tris-HCl pH 7.5, 50 mM NaCl, 0.1 % NP-40, and 1 mM PMSF), the 
immunoprecipitates were dissolved in Laemmli buffer for separation by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in a 4-12 % bis-cross-linked 
polyacrylamide gel (Invitrogen).  
After electrophoresis, the proteins were transferred onto a nitrocellulose membrane 
(Protran; Schleicher & Schuell Bioscience, Keene, NH) by electroblotting at 20V for 2 h. The 
membranes were blocked in 5 % milk in Tris-buffered saline (TBS), probed for the 
appropriate antibody in TBS containing 0.1 % Tween 20, and stained with enhanced 
chemiluminescence western blotting detection reagents (PerkinElmer, Boston, MA) in 
accordance with the manufacturer’s protocol.  
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Immunofluorescence 
For indirect immunofluorescence, Akata cells (5 x 105) were spun down onto pre-
coated Shandon Double Cytoslides (Thermo Electron Corporation, Waltham, MA) using a 
cytospin apparatus (Shandon Cytospin3, Frankfurt am Main, Germany). After drying for 30 
min, the cells were fixed for 15 min in PBS with 3.7 % formaldehyde and permeabilized for 2 
min with ice-cold methanol. The anti-BZLF1 (Zta) primary antibody (Argene Biosoft, North 
Massapequa, NY) was used at a 1:100 dilution. Alexa Fluor 488- or Alexa Fluor 594-
conjugated goat anti-rabbit or goat anti-mouse secondary antibodies (Invitrogen) were used at 
a 1:1.000 dilution. Coverslips were mounted on glass slides in Vectashield Mounting Medium 
(Vector Laboratories, Burlingame, CA). Images were obtained with a Zeiss Axioskop 2 mot 
plus microscope using a Zeiss digital camera (AxioCam MRm) and AxioVision software 
version 4.4 (Carl Zeiss, Göttingen, Germany). 
 
Chromatin immunoprecipitation (CHIP) analysis 
CHIP was preformed according to the manufacture’s instructions (ChIP-IT Express, 
Active Motif, Rixensart, Belgium). Briefly, 10 x 106 cells were incubated with CpG2006 2h 
prior to incubation with anti-IgG, anti-IgM, TGFβ or TPA for 3-5 hours. Cells were harvested 
and fixed by formaldehyde treatment for 10 min on a shaking platform. Fixation was stopped 
and cells were lysed and homogenized using an ice-cold douncer. Enzymatic shearing was 
performed for 12.5 min. The supernatant containing the sheared chromatin was then incubated 
over night on a rotating wheel with the antibody of interest and the protein G magnetic beads. 
Washing steps and elution of the chromatin was followed by proteinase treatment. PCR 
analysis at 30 to 40 cycles was done in a 2 % agarose gel. Antibodies used for CHIP: 
Phospho-Histone H3 (ser-10) (sc 8656-R, Santa Cruz), anti-acetyl H3 (06-599 Upstate), anti-
acetyl H4 (06-598 Upstate). PCR primers for CHIP: BZLF1 Rev (+8) 5’-CTC GAG GTG 
CAA TGT TTA GTG AGT TAC-3’, BZLF1 For (-222) 5’-GCT AGC GCC ATG CAT ATT 
TCA ACT GGG C-3’, BdRF1 and BKRF4 (17), Cp (C1) (18), human GAPDH primers (ChIP-
IT control kit, Active Motif, Belgium), Actin For 5’-TGC ACT GTG CGG CGA AGC-3’, 
Actin Rev 5’-TCG AGC CAT AAA AGG CAA-3’, ORF50 and mouse GAPDH primers for 
S11 cells (19). 
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Statistical Methods 
Level of significance was evaluated by an unpaired Student’s t test if two data groups 
were compared. When three to five data groups were compared, Bonferroni’s multiple 
comparison test (ANOVA) was used for selected pairs of columns. 
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Results 
 
TLR9 triggering inhibits BCR-induced EBV lytic gene expression in Akata cells 
In order to characterize the effect of TLR9 triggering on EBV gene expression in more 
detail, we stimulated Akata cells with CpG2006 prior to cross-linking of the B-cell receptor 
(BCR) with anti-human IgG and subsequently measured the mRNA expression of BZLF1 at 
various time points by quantitative real-time PCR (qPCR). Following cross-linking of the 
BCR, we detected a rapid increase of BZLF1 mRNA expression with maximal levels at 4h 
followed by a decrease in BZLF1 mRNA expression over the next 20 hours (Fig. 1A), which 
conforms with previous reports (6, 20). After TLR9 triggering with CpG2006, a reproducible 
significant reduction of the induced BZLF1 mRNA expression was observed (Fig. 1A), 
whereas treatment with CpG2006 alone did not result in any measurable BZLF1 mRNA 
expression. 
Next, we wanted to determine if the inhibitory effect of TLR9 triggering on EBV gene 
expression also acts on EBV late lytic genes such as BXLF2 (gp85 protein). The mRNA 
expression of BXLF2 after BCR cross-linking was strongly reduced following TLR9 
triggering with a more pronounced reduction at the end of the 24h observation period (Fig. 
1B). Similar observations were made with the early lytic gene BXLF-1 (thymidine kinase TK) 
and the late lytic gene BCRF1 (viral IL10) in accordance with their appearance in the lytic 
cascade (data not shown). 
To confirm the mRNA data, we performed western blot analyses of Zta (protein of the BZLF1 
gene). To enhance the detection of Zta we performed immunoprecipitation of Zta. Triggering 
TLR9 reduced the BCR-induced Zta expression to undetectable levels (Fig. 1C). To see 
whether TLR9 triggering reduces the number of cells switching to EBV lytic gene expression 
or if TLR9 activation reduces Zta expression to a lower level in all BCR-induced cells, we 
performed immunofluorescence microscopy for the Zta protein. After cross-linking the BCR 
we observed 10% of Akata cells expressing detectable levels of Zta after 6 hours (Fig. 1D). 
Treatment with CpG2006 before BCR cross-linking led to a significant reduction in the 
number of cells producing observable Zta (Fig. 1D). This confirmed that Zta expression is 
efficiently inhibited following the triggering of TLR9. 
 11 
 
Triggering of TLR9 in Akata cells results in an up-regulation of human cytokines, 
primarily IL10 
Further, we tested the cytokine response by treating Akata cells with the TLR9 ligand 
CpG2006. After 12 hours, the mRNA levels of hIL10, IFNγ and TNFα were increased 
compared to mock treatment, whereby the anti-inflammatory cytokine hIL10 showed the 
highest (20 fold) increase (Fig. 2A). Measurements of those cytokines at the protein level in 
the cellular supernatant confirmed that the most abundant cytokine was hIL10 (Fig. 2B). 
Levels of TNFα were increased to a detectable level and IFNγ was not detected. The lack of 
IFNγ protein might be explained by either (i) the high levels of hIL10, since IL10 is known to 
inhibit cytokine production at transcriptional and posttranscriptional level (21-24), or (ii) 
insufficient translation of the IFNγ transcripts at this time point.  
 
TLR9-induced suppression of EBV lytic gene expression is not due to interference with 
BCR signaling  
To characterize the effect of CpG2006 on EBV gene expression, we addressed the 
possibility that TLR9 triggering might interfere with the first steps in BCR signaling. BCR 
cross-linking leads to binding and activation of tyrosine kinases Lyn and Syk, followed by a 
distinct release of intracellular Ca2+ (25-29). Therefore, CpG ODN treatment could possibly 
affect cellular levels of Lyn (30), leading to an inhibition of the Ca2+ flux, and thus reduce 
BZLF1 mRNA expression.  
We investigated this possibility by examining the effects of CpG2006 on Ca2+ flux 
using flow cytometry with the fluorescent dyes Fluo-3 and Fura Red as previously described 
(15, 29). As expected, we detected a strong release of intracellular Ca2+ immediately after 
BCR cross-linking with anti-IgG; CpG2006 alone had no affect on Ca2+ release (Fig. 3 A). 
When TLR9 triggering preceded BCR cross-linking, the signal for Ca2+ release was at least as 
strong as following BCR cross-linking alone. Thus, TLR9 triggering does not interfere with 
the initial BCR cross-linking nor the first steps in the BCR signaling pathway leading Lyn 
activation and Ca2+ release. 
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 To corroborate the conclusion above, we used 12-O-tetradecanoylphorbol 13-acetate 
(TPA) treatment as an alternative means of promoting EBV lytic gene expression in Akata 
cells. TPA is known to transiently activate the Ras-MAPK pathway through Protein Kinase C 
(PKC) activation (31). In Akata cells, TPA treatment leads to activation of Zta in the absence 
of BCR cross-linking. Indeed, triggering of TLR9 significantly inhibited TPA-induced BZLF1 
mRNA expression (Fig. 3 B). This finding supports our hypothesis that TLR9-induced 
inhibition of EBV lytic gene expression is not due to general interference with BCR cross-
linking nor with the first steps in BCR signaling.  
 
CpG-induced inhibition of EBV lytic gene expression requires signaling through TLR9 
and MyD88 
To formally prove that the CpG2006’s inhibitory effects on EBV replication acts 
through the TLR9 pathway, we investigated the effect of two TLR9 inhibitors on BZLF1 
expression, namely IRS869 which competes with binding to TLR9 (32, 33), and chloroquine, 
which blocks the acidification of endosomes (34). We incubated Akata cells with IRS869 or 
chloroquine and CpG2006, followed by BCR cross-linking. Both TLR9 inhibitors were able 
to reverse the inhibitory effect of CpG2006 on BZLF1 and BXLF2 mRNA expression (Fig. 
4A). Moreover, both TLR9 inhibitors reduced hIL10 mRNA expression (Fig. 4A), confirming 
the inhibitory effects of chloroquine and IRS869 on TLR9-induced signaling.  
 To test if the TLR9-induced inhibition of EBV lytic gene expression requires signaling 
through MyD88, the only known adaptor protein for TLR9 signaling in B cells (35, 36), we 
stably overexpressed a dominant negative mutant form of MyD88 (a gift from J. Tschopp) in 
Akata cells. Overexpression was confirmed by measuring MyD88 mutant and MyD88 wild 
type (WT) mRNA expression (Fig. 4B). Moreover, we investigated if the MyD88 mutant 
form acts indeed as a dominant negative protein in Akata cells. TLR9 triggering induces 
translocation of NF-κB into the nucleus in a MyD88-dependent manner. As expected, we did 
not observe translocation of NF-κB into the nucleus in Akata cells stably expressing the 
MyD88 mutant in response to the TLR9 ligand (Fig. 4C). Moreover, TLR9 triggering did not 
increase cytokine transcripts of hIL10 (Fig. 4D) and TNFa (data not shown) in the MyD88 
mutant Akata cells. Thus, the MyD88 mutant Akata cells can be used to examine whether 
CpG2006-induced suppression of EBV lytic gene expression is MyD88 dependent. Indeed, in 
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Akata cells stably expressing the MyD88 mutant, the TLR9 ligand CpG did not inhibit EBV 
lytic gene expression of BZLF1, which was in clear contrast to the effects observed in Akata 
wild-type cells (Fig. 4D).  
Taken together, TLR9-induced suppression of EBV lytic gene expression is 
unequivocally dependent on the TLR9-MyD88 signaling axis. 
 
NF-κB is not fully responsible for the TLR9-mediated inhibition of EBV lytic gene 
expression 
Triggering of TLR9 activates a number of transcription factors, including NF-κB [Fig. 
4C and (10)]. Notably, NF-κB has a key regulatory role in EBV replication, i.e. activation of 
NF-κB inhibits gamma herpesvirus lytic replication while blocking of NF-κB leads to EBV 
reactivation in latently infected lymphocytes (37). Consequently, we investigated if the 
inhibitory effect of TLR9 triggering on EBV lytic infection is mediated by NF-κB. The 
BZLF1 mRNA expression induced by BCR cross-linking was increased by co-treatment with 
the NF-κB inhibitor (Fig. 5A). Nevertheless, TLR9 triggering still reduced BZLF1 mRNA 
expression when NF-κB activation was inhibited (Fig. 5A), indicating that NF-κB is not the 
main mediator of TLR9’s inhibitory effect on EBV reactivation. In contrast, hIL10 transcripts 
were reduced due to the NF-κB inhibitor (Fig. 5A), which speaks in favor that hIL10 
expression is indeed NF-κB dependent. Thus, although NF-κB is involved in hIL10 and 
BZLF1 mRNA expression, the inhibitory effect of TLR9 triggering on BZLF1 mRNA 
expression is independent of NF-κB.  
Next, we investigated if other signaling pathways activated upon TLR9 triggering 
might be involved in the inhibition of BZLF1 mRNA expression, in particular the 
Phosphatidylinositol-3 kinases (PI3K) and the MAPK ERK pathway. Using the PI3-Kinase 
inhibitor Ly-294002, we could show that expression of BCR-induced BZLF1 and hIL10 
mRNA is very strongly inhibited (Fig. 5B). Further, TLR9-induced hIL10 mRNA expression 
was significantly suppressed after PI3K inhibition (Fig. 5B). PI3K is therefore important for 
both BCR and TLR9 signaling pathways; therefore the use of Ly294002 was not able to 
identify the contribution of a specific signaling molecule key in the effects observed with 
TLR9 on EBV.  
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Similar to Ly294002, treatment with the MAPK ERK inhibitor PD98059 resulted in a 
strong reduction of anti-IgG-induced BZLF1 mRNA expression in Akata cells. In contrast, 
hIL10 mRNA expression induced via TLR9 or BCR was not suppressed by this inhibitor (Fig. 
5C). Therefore, this kinase is an important component in the anti-IgG-mediated BZLF1 
mRNA expression, yet is not involved in the CpG-induced expression of hIL10, and thus is 
very unlikely to be involved in the TLR9-mediated inhibitory effects on BZLF1.  
Moreover, inhibition of JNK completely blocked BCR-mediated BZLF1 expression 
(Fig. 5E), in contrast to inhibition of p38 (Fig. 5D). However, both components of the TLR9 
signaling pathway could not be solely identified for being responsible for the TLR9-induced 
suppression of BZLF1.  
In conclusion, we could demonstrate that the known signaling components of TLR9 
are not solely responsible for the suppression of EBV lytic gene expression. 
 
The histone deacetylase agent Trichostatin A rescues TLR9-induced suppression of EBV 
lytic gene expression 
We investigated the possibility that TLR9 triggering might regulate EBV gene 
expression by other means than affecting transcription factor activity. We found that BZLF1 
mRNA is very stable over time (see Supplementary Figure 1), and therefore is not the 
mechanism of how TLR9 affects EBV gene expression. 
TLRs can regulate their own inflammatory response through chromatin modifications 
at the level of individual host promoters (11). Importantly, the promoter region of the EBV 
lytic gene BZLF1 undergoes modifications, i.e. acetylation and phosphorylation of histones 
upon BCR cross-linking (17, 38). These histone modifications seem to be necessary, but not 
exclusively responsible for inducing EBV lytic gene expression (17). Therefore, we 
hypothesized that TLR9’s inhibitory effect on EBV activation may act by blocking 
acetylation and phosphorylation of histones. Using Trichostatin A, an inhibitor of histone 
deacetylases (HDAC) (39, 40), we investigated whether the effect of TLR9 triggering on 
suppression of EBV lytic gene expression can be abolished. Treating Akata cells with TSA 
prior to TLR9 triggering rescued expression of BZLF1 almost completely (Fig 6A). 
Moreover, TSA inhibited hIL10 mRNA expression in Akata cells (Fig. 6A). Thus, histone 
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modifications play a role in TLR9-induced suppression of BZLF1 expression as well as in 
TLR9- and BCR-induced hIL10 expression. 
As TSA blocks the effect of TLR9 in the BL cell line Akata, we investigated if this 
mechanism is operative in other gamma herpesvirus-infected cell lines. Therefore, we tested 
the EBV-positive BL cell line Mutu I and a murine gamma herpesvirus-68 (MHV-68)-
positive cell line S11. In Mutu I cells, EBV enters its lytic pathway following cross-linking of 
surface IgM or upon treatment with TGFβ. Notably, triggering of TLR9 significantly 
inhibited EBV lytic gene mRNA expression (BZLF1) induced by either treatment (Fig. 6B). 
As observed in Akata cells (Fig. 6A), TSA alone was not able to induce expression of BZLF1 
(Fig. 6B). However, TSA in combination with anti-IgM or TGFβ lead to a significant increase 
in BZLF1 mRNA levels in comparison to anti-IgM or TGFβ alone (Fig. 6B). In contrast to 
Akata cells, triggering of TLR9 in combination with TSA and the lytic EBV-inducing agents 
lead to a suppression of BZLF1 mRNA expression (Fig. 6B). 
S11 lymphoma cells, infected with MHV-68, are known to enter the lytic cycle 
following treatment with TPA (16, 41). The MHV-68 gene ORF50 (protein name RTA) is a 
homologue to the EBV immediate-early lytic gene BRLF1 and responsible in S11 cells for 
initiation of the viral lytic gene expression (42, 43). When we triggered mouse TLR9 with the 
mouse-specific CpG1826, we detected a significant reduction in the TPA-induced ORF50 
mRNA expression (Fig. 6C), similar as for EBV. In contrast to Akata and Mutu I BL cells, 
TSA alone induces the lytic gene expression of ORF50 in S11 cells (Fig. 6C) confirming 
published data (19). Combining TSA and TPA treatments did not show an additional increase 
in ORF50 expression, probably due to full activation of lytic infection upon TSA treatment 
alone. However, triggering TLR9 still reduced TSA/TPA-induced lytic gene expression (Fig. 
6C). Thus, in mouse S11 lymphoma cells as in human Mutu I BL cells, TLR9 is able to 
suppress gamma herpesvirus lytic gene expression with or without prior TSA treatment.  
 
TLR9 signaling induces modifications in histone structure of the EBV lytic promoter 
BZLF1  
To verify that TLR9 affects histone modifications on the BZLF1 promoter and thus 
interferes with viral gene expression in Akata cells, we preformed chromatin 
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immunoprecipitation (CHIP) analyses. We confirmed that cross-linking the BCR leads to an 
increased amount of phosphorylated histone H3 (Ser10) and acetylated histones H4 and H3 
bound to the BZLF1 promoter in Akata cells (Fig. 7). Moreover, triggering of TLR9 prior to 
BCR cross-linking decreased levels of phosphorylated and acetylated histones bound to the 
BZLF1 promoter (Fig. 7). This, together with the TSA experiments (Fig. 6A), strongly 
suggests that the TLR9-induced histone modification on the viral BZLF1 promoter is 
responsible for suppression of EBV gene expression in Akata cells. In contrast, upon 
treatment with anti-IgM, TGFβ, or TPA alone, there was no consistent change in the amount 
of acetylated or phosphorylated histones bound to the BZLF1 promoter or the ORF50 
promoter in Mutu I cells or S11 cells respectively (data not shown). Moreover, consistent and 
significant modifications of the chromatin structure in Mutu I cells or S11 cells on their lytic 
promoter sites upon TLR9 triggering could not be observed (data not shown). 
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Discussion 
The aim of the current study was to determine the mechanism of the TLR9-mediated 
suppression of gamma herpesvirus lytic gene expression in Burkitt lymphoma (BL) and 
murine lymphoma cells. As EBV-associated lymphomas express EBV latency genes in vivo 
and EBV latency genes induce and maintain cell transformation in vitro, elucidating the 
factors that promote EBV latency will contribute to the understanding of EBV-associated 
lymphoma formation. Here, we demonstrate that: (i) suppression of EBV lytic gene 
expression following treatment with CpG2006 is mediated through TLR9 and its adaptor 
protein MyD88 in Akata cells, (ii) TLR9 activation suppresses not only human but also 
murine gamma herpesvirus lytic gene expression, independently of the pathway involved in 
activating lytic virus, (iii) suppression of EBV lytic gene expression due to TLR9 activation 
in Akata cells is independent of TLR9-elicited NF-κB activity, but involves histone 
modifications. Our findings argue that engagement of TLR9 and subsequent signal 
transduction via MyD88 may result in histone modification directly inhibiting activation of 
viral gene promoters. This in turn suggests that evolutionary gamma herpesviruses selection 
by, or adaptation to, TLR9-mediated histone modification may have contributed to the 
increased survival of the virus in its latent state in the host cell.  
A most remarkable observation is that TLR9-mediated suppression of lytic gamma 
herpesvirus is maintained across species, i.e. EBV and MHV-68, in lymphoma cells harboring 
latent virus, suggesting a general role of innate immunity receptor signaling in controlling 
virus gene expression. This suppression may have fundamental consequences towards tumor 
formation and maintenance considering the different properties of EBV and MHV-68, as EBV 
has strong cell transformation capacity (12) not matched by MHV-68 (44). In recent work, we 
showed that TLR9-mediated suppression of EBV lytic gene expression is not restricted to 
latently infected lymphoma cells but can also be observed in ex-vivo acutely infected primary 
cells (14). This, together with our observation made here that the TLR9-mediated suppression 
takes place independently of the pathway inducing lytic virus, may indicate that TLR9-
mediated suppression of gamma herpesvirus lytic gene expression is likely due to a general 
mechanism.  
A finding of considerable relevance for the understanding of innate immune responses 
to pathogens is our demonstration that histone modifications on an EBV promoter in response 
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to TLR9 triggering is involved in the suppression of EBV lytic gene expression in Akata cells. 
As TLR9 and BCR triggering activates partly the same signaling components like MAPK, it 
is reasonable that the signaling inhibitors used here did not result in elucidating the important 
factors for EBV regulation. However, this implies that TLR9-mediated regulatory 
mechanisms are not restricted to activation of host transcription factors such as NF-κB or 
IRFs (interferon regulatory factors) and subsequent regulation of host genes for host defense 
(45), but may target viral chromatin structure and thus influence viral gene expression. 
Admittedly, we could show histone modifications in Akata cells, but not in Mutu I cells or 
murine S11 lymphoma cells. However, histone modifications in Mutu I cells or murine S11 
lymphoma cells may have escaped detection due to lower efficiencies of lytic virus induction 
when compared to Akata cells (46). Furthermore, a recent study by Miller’s lab (38) suggests 
that in Mutu I cells, acetylation and phosphorylation of histones on the BZLF1 promoter upon 
anti-IgM/TGFβ or TPA treatment, respectively, cannot be detected because (i) too few cells 
are induced into the lytic cycle, and (ii) multiple copies of EBV genomes are found in the cell, 
but not all of them become hyperacetylated in a responsive cell. Thus, the large background of 
hypoacetylated histones may have blurred the assays performed here. Consequently, 
triggering of TLR9 might as well lead to reduction of acetylation and phosphorylation of the 
histones on the viral promoters in Mutu I cells and murine S11 lymphoma cells, but this 
escapes detection when the cells are examined as whole population. Moreover, other histone 
modifications than the ones investigated here could be of importance in Mutu I and S11 cells. 
Based on our findings and on the findings by Foster et al. (11), who showed that TLR 
signaling induces chromatin modification in order to differentially regulate host cytokine gene 
expression, the effect of TLR triggering on chromatin structure might be a general mechanism 
by which TLRs modulate host and viral gene expression in response to a danger signal. Foster 
et al. (11) suggested that TLR-induced histone modifications on host promoters regulate 
cytokine expression to avoid excessive inflammation while fighting an invading pathogen. 
Similarly, TLR9-induced histone modifications on viral promoters, as shown here, may be 
beneficial for the host cells and the virus, as well. Histone modifications leading to 
suppression of viral lytic gene expression prevent viral replication and subsequent cell death. 
Nevertheless, this is beneficial for the virus as well, since survival of the host cell also ensures 
survival of latent gamma herpesviruses. Thus, gamma herpesviruses may have taken 
advantage of host innate immune mechanisms during evolution to secure their latency in 
danger situations for the host cell. Histone modifications leading to enforcement of the viral 
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latent state in the case of EBV with its unique transforming potential, however, may establish 
a prerequisite for the development and maintenance of EBV-associated B-cell lymphomas. 
This must be taken into consideration when using novel cancer treatment regimens, including 
TLR9 triggering (47, 48), for EBV-associated B-cell lymphomas as histone modification may 
interfere with antineoplastic effects, but it may also represent a therapeutic target (49).  
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Figure Legends 
 
Fig. 1. TLR9 triggering with CpG2006 suppresses BCR cross-linking-induced EBV lytic 
gene expression in Akata cells.  
A–B. TLR9 triggering reduces anti-IgG induced BZLF1 (A) and BXLF2 (B) mRNA 
expression in Akata cells. Akata cells were treated with CpG2006. After 2 hours anti-IgG was 
added. Cells were harvested at indicated times, followed by lysis of the cells, RNA extraction, 
reverse transcription and qPCR. Results show mRNA transcripts of (A) BZLF1 and (B) 
BXLF2 normalized to the mRNA levels of the housekeeping gene HMBS and over 
unstimulated cells. One representative experiment in TaqMan duplicates is shown out of three 
independent experiments.  
C. TLR9 triggering reduces anti-IgG induced Zta production. Results show Western blot for 
Zta protein with immunoprecipitation. Cells were treated with CpG2006 for 2h, followed by 
anti-IgG for 6 hours.  
D. TLR9 triggering leads to less cells producing Zta. Cells were treated with CpG2006, 
followed by anti-IgG for 6h. Zta positive cells were detected by immunofluorescence. N = 3 
independent experiments. Data are represented as mean +/- SEM. *** Level of significance 
was P<0.001 by an unpaired Student’s t test. n.d. denotes not detectable. 
 
Fig. 2. TLR9 triggering with CpG2006 in Akata cells leads to an increase in cytokine 
expression, primarily hIL10. 
Cells were treated with CpG2006 for 12 hours. Results in (A) show mRNA expression of 
hIL10, IFNγ and TNFα normalized to the mRNA levels of the housekeeping gene HMBS. N = 
at least 4 independent experiments each in TaqMan duplicates. Results in (B) show protein 
levels of the investigated cytokines in pg ml-1. N = 3 independent experiments. Data are 
represented as mean +/- SEM. *** Significance relative to the mock treated control was 
P<0.001 by an unpaired Student’s t test. ** Significance relative to the mock treated control 
was P<0.01 by an unpaired Student’s t test. n.d. denotes not detectable. 
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Fig. 3. TLR9 triggering does not interfere with the first steps of BCR signaling. 
A. Triggering of TLR9 does not inhibit the anti-IgG induced Ca2+ flux. Akata cells were 
treated with CpG2006 for 2 hours and anti-IgG immediately before FACS measurements. Top 
left shows baseline measurement with mock treated cells. Top right shows cells stimulated 
with CpG2006. Bottom left shows stimulation with anti-IgG. Bottom right shows stimulation 
with CpG2006 and anti-IgG. 
B. TLR9 triggering with CpG2006 reduces TPA-induced BZLF1 mRNA expression. Akata 
cells were treated with CpG2006 for 2 hours before TPA treatment. Cells were harvested 24 
hours after TPA treatment. Results show mRNA transcripts of BZLF1 normalized each to the 
mRNA levels of the housekeeping gene HMBS and over mock treated cells. N = 3 
independent experiments. Data are represented as mean +/- SEM. *Level of significance was 
P=0.0163 by an unpaired Student’s t test. 
 
Fig. 4. CpG2006-induced suppression of EBV lytic gene expression is TLR9 and MyD88 
dependent. 
A. TLR9 inhibitors IRS869 and chloroquine rescue the TLR9-induced decrease of BZLF1 and 
BXLF2 mRNA expression. Akata cells were treated with chloroquine, CpG2006 or IRS869, 
followed by anti-IgG. Harvesting of the cells was done 4 hours after anti-IgG treatment for 
BZLF1 and hIL10 and 24 hours after anti-IgG treatment for BXLF2. Results show mRNA 
transcripts of BZLF1, BXLF2 or hIL10 normalized each to the mRNA levels of the 
housekeeping gene HMBS and to the highest value (without TLR inhibitors). Results show at 
least 3 independent biological experiments each in TaqMan duplicates. Data are represented 
as mean +/- SEM. Bonferroni’s multiple comparison test (ANOVA) was used for selected 
samples. Level of significance was *** P<0.001. 
B-D. TLR9 ligand CpG2006 suppresses EBV lytic gene expression in a MyD88-dependent 
way. B) Overexpression of a MyD88 dominant negative mutant in Akata cells. Results show 
mRNA expression of MyD88 wildtype (WT) and MyD88 dominant negative mutant and in 
transfected and not transfected Akata cells. At least 3 independent biological experiments 
each in TaqMan duplicates are shown. Data are represented as mean +/- SEM. Level of 
significance was *** P<0.001 by an unpaired Student’s t test. C) Akata cells transfected with 
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MyD88 dominant negative mutant do not show translocation of NF-κB (p65) after TLR9 
triggering. Western blot of nuclear NF-κB (p65) in transfected and non transfected Akata 
cells after mock treatment (lane 1), after 30 min (lane 2) and 90 min (lane 3) of CpG2006 
treatment. One representative experiment is shown out of three independent experiments. D) 
TLR9 ligand CpG2006 does not suppress EBV lytic gene expression in the MyD88 dominant 
negative mutant transfected Akata cells. Cells were treated with CpG2006 and anti-IgG. 
Transcripts of BZLF1, hIL10 were normalized each to the mRNA levels of the housekeeping 
gene HMBS and over mock treated samples (mock=1). Results show at least 3 independent 
biological experiments each in TaqMan duplicates. Data are represented as mean +/- SEM. 
Bonferroni’s multiple comparison test (ANOVA) was used for selected samples. Level of 
significance was *** P<0.001 and ** P<0.01. 
 
Fig. 5. TLR9-induced inhibition of BZLF1 expression is not mediated by NF-κB. 
Akata cells were treated with CpG2006 and anti-IgG as described before. (A) NF-κB-
activation inhibitor, (B) PI3K-inhibitor (Ly294002), (C) MAPK/ERK-kinase-inhibitor 
(PD98059), (D) p38 inhibitor (SB203580), or (E) JNK inhibitor (SP600125) were added 1 
hour before CpG2006 treatment. Harvesting of the cells was done 4 hours after anti-IgG 
treatment. Results show mRNA expression levels of BZLF1 and hIL10 normalized each to the 
mRNA levels of the housekeeping gene HMBS. For BZLF1 transcripts, samples with anti-IgG 
treatment alone were set to 1. For hIL10 transcripts, samples with anti-IgG plus CpG 
treatment were set to 1. Results show at least 3 independent biological experiments each in 
TaqMan duplicates. Data are represented as mean +/- SEM. Bonferroni’s multiple comparison 
test (ANOVA) performed for BZLF1 transcripts only. Level of significance was *** P<0.001 
or ** P<0.01. 
 
Fig. 6. TLR9 triggering suppresses human and murine gamma herpesvirus lytic gene 
expression, whereas Trichostatin A shows a different effect the TLR9-induced viral 
suppression. 
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Cells were treated with Trichostatin A, CpG2006, anti-IgG, anti-IgM and TPA, followed by 
harvest of cells. 
A. Trichostatin A reverses the TLR9-induced suppression of BZLF1 expression in Akata 
cells. Results show mRNA expression levels of BZLF1 and hIL10 normalized each to the 
mRNA levels of the housekeeping gene 18sRNA (as HMBS levels vary due to TSA 
treatment). For BZLF1 transcripts, samples with anti-IgG treatment alone were set to 1. For 
hIL10 samples with anti-IgG plus CpG2006 treatment were set to 1. 
B. TLR9 triggering in Mutu cells suppresses EBV lytic gene BZLF1 induced by anti-IgM or 
TGFβ, but Trichostatin A does not reverse the effect of TLR9. Results show mRNA 
expression levels of BZLF1 normalized each to the mRNA levels of the housekeeping gene 
18sRNA. Samples with anti-IgM or TGFβ treatment alone were set to 1. 
C. TLR9 triggering in S11 murine lymphoma cells with CpG1826 suppresses MHV-68 lytic 
gene ORF50, but Trichostatin A (50) does not reverse the effect of TLR9. Results show 
mRNA expression levels of the immediate-early ORF50 normalized each to the mRNA levels 
of the housekeeping gene mouse GAPDH. Samples with TPA treatment alone were set to 1. 
Results show at least 3 independent biological experiments each in TaqMan duplicates. Data 
are represented as mean +/- SEM. Statistical test used for selected samples: Bonferroni’s 
multiple comparison test (ANOVA). *** P<0.001. ** P<0.01. * P<0.05. 
 
Fig. 7. TLR9 triggering leads to decreased levels of phosphorylated and acetylated 
histones bound to the BZLF1 promoter in Akata cells. 
Akata cells were treated with CpG2006 and anti-IgG. Harvest of the cells and performance of 
CHIP assay was followed by PCR for the BZLF1 promoter region. As controls, PCRs for 
various host and viral promoters regions (Actin, GAPDH, Cp, BdRF1, BKRF4) were 
performed, as well as PCR of BZLF1 from the input DNA and a CHIP assay using a control 
antibody (IgG). One representative experiment is shown out of at least two independent 
experiments. Annotations: Lanes 1: mock treated; 2: CpG2006 treated; 3: anti-IgG treated; 4: 
CpG2006 and anti-IgG treated. 
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Supplemental Data 
 
Supplementary Fig. 1: Transcripts of BZLF1 are stable over time. 
Akata cells were treated with CpG2006 and anti-IgG as described before. Actinomycin D 
(final 2µg ml-1) was added after 1h after anti-IgG treatment. Transcripts of BZLF1, hIL10 and 
TNFα were normalized over the housekeeping gene HMBS and over the starting value (t=0). 
Results show at least 3 independent biological experiments each in TaqMan duplicates. Data 
are represented as mean. 
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TNFα mRNA half life 
anti-IgG t1/2 =  20.54 ± 4.28 
CpG + anti-IgG t1/2 =  39.71 ± 6.89  
 
hIL10 mRNA half life: 
anti-IgG t1/2  =  43.45 ± 16.25 
CpG + anti-IgG t1/2 =  22.17 ± 4.723 
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Summary
Primary infection with Epstein-Barr virus (EBV) is
asymptomatic in children with immature immune
systems but may manifest as infectious mononucleo-
sis, a vigorous immune activation, in adolescents
or adults with mature immune systems. Infectious
mononucleosis and chronic immune activation
are linked to increased risk for EBV-associated
lymphoma. Here we show that EBV initiates progres-
sive lytic infection by expression of BZLF-1 and the
late lytic genes gp85 and gp350/220 in cord blood
mononuclear cells (CBMC) but not in peripheral blood
mononuclear cells (PBMC) from EBV-naive adults
after EBV infection ex vivo. Lower levels of proinflam-
matory cytokines in CBMC, used to model a state of
minimal immune activation and immature immunity,
than in PBMC were associated with lytic EBV
infection. Triggering the innate immunity specifically
via Toll-like receptor-9 of B cells substantially sup-
pressed BZLF-1 mRNA expression in acute EBV
infection ex vivo and in anti-IgG-stimulated chroni-
cally latently EBV-infected Akata Burkitt lymphoma
cells. This was mediated in part by IL-12 and IFN-g.
These results identify immune activation as critical
factor for the suppression of initiation of lytic EBV
infection. We hypothesize that immune activation
contributes to EBV-associated lymphomagenesis by
suppressing lytic EBV and in turn promotes latent
EBV with transformation potential.
Introduction
Epstein-Barr virus (EBV), a human B lymphotropic gam-
maherpesvirus, infects at least 90% of the world’s human
population. Different EBV latency gene programs allow
EBV to persist in the host in latently infected B cells.
Proliferation of the latently infected cells propagates EBV
to the daughter cells. Latent EBV may switch to its lytic
gene expression program, leading to EBV replication and
subsequent lysis of the infected cell (Cohen, 2000; Rick-
inson and Kieff, 2001; Thorley-Lawson, 2001; Thorley-
Lawson and Gross, 2004).
The vast majority of primary EBV infections occur in
infants and toddlers and are usually asymptomatic
(Biggar et al., 1978; Chan et al., 2001). By contrast,
primary EBV infection in adolescence or adulthood may
manifest as infectious mononucleosis (IM) (Biggar et al.,
1978), with fever and enlargement of tonsils, lymph
nodes, liver and spleen. This clinical presentation results
from the vigorous immune activation involving proinflam-
matory cytokines (Foss et al., 1994; Chan et al., 2001;
Rickinson and Kieff, 2001).
Epstein-Barr virus is also associated with B cell lym-
phoproliferative disorders, including Burkitt lymphoma,
Hodgkin lymphoma, and post-transplant lymphoprolifera-
tive disease harbouring latent EBV. Infection of B cells
with EBV in vitro in the absence of immune control is
associated with B cell proliferation and transformation,
indicating the oncogenic potential of EBV (Rickinson and
Kieff, 2001). Immunosuppression subsequent to organ
transplantation or secondary to infection with the human
immunodeficiency virus increases the risk of EBV-
associated lymphoproliferation (Cohen, 2000; Rickinson
and Kieff, 2001; Thorley-Lawson, 2001). Also immuno-
competent patients may develop Burkitt lymphomas and
Hodgkin lymphomas harbouring EBV.
Burkitt lymphoma harbouring EBV is mainly seen in
areas that are endemic for malaria leading to the specu-
lation that repeated immune activation by chronic malaria
or other infections is an important pathogenic factor for
this tumour (Rochford et al., 2005). Strikingly, young
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adults, experiencing IM and its vigorous immune activa-
tion to primary EBV infection, are at increased risk for
EBV-positive Hodgkin lymphoma (Hjalgrim et al., 2003).
Thus, immune activation seems to be a critical pathogenic
factor in EBV-associated lymphomagenesis. The impact
of activation via the innate immunity in this process is
largely unknown.
Toll-like receptors (TLRs) are key players in the innate
immunity. TLRs are transmembrane receptors related to
the TOLL protein of Drosophila (Hashimoto et al., 1988).
They are involved in the recognition of pathogens and
microbial products and activate antimicrobial effector path-
ways (Medzhitov, 2001). Among other TLRs, B cells
express TLR-9 (Hornung et al., 2002). TLR-9 sensors
unmethylated CpG (cytosine-guanosin) dinucleotides
within particular oligodeoxynucleotide sequences of micro-
organisms as well as the malaria pigment hemozoin
(Coban et al., 2005). While triggering TLR-9 increases
transformation rates of ex vivo EBV-infected B cells (Trag-
giai et al., 2004), its effect on the EBV gene expression
pattern is unknown.
Based on above-mentioned epidemiological and in vitro
Fig. 1. Epstein-Barr virus (EBV) expresses
lytic EBV mRNAs and proteins in cord blood
mononuclear cells (CBMC) but not in
EBV-seronegative peripheral blood
mononuclear cells (PBMC) infected ex vivo
with EBV.
A and B. mRNA expression of latent EBV
genes EBNA-1, EBNA-2, LMP-1 and LMP-2
in CBMC (A) and in PBMC (B).
C and D. mRNA expression of the
immediate-early lytic EBV gene BZLF-1 and
the late lytic EBV gene gp85 in CBMC (C)
and in PBMC (D).
E. Immunofluorescence of BZLF-1 protein
(green) in CBMC at 240 h post inoculation
with EBV.
F and G. Latent EBV infection rates in CBMC
(F) and PBMC (G).
H and I. Fraction of CD5+(H) and CD5– (I) B
cells in CBMC showing lytic EBV at 144 h
post inoculation with EBV.
mRNA expression was measured by real-time
PCR and normalized to the housekeeping
gene hydroxymethylbilane synthase (HMBS).
Values are expressed as means  SD
induction of mRNA expression (fold) over
baseline mRNA expression. No transcription
was set to a value of 0.005 log10 as
normalization to the expression of HMBS with
a cycle threshold value of 40 (i.e. no
transcription at cycle 40 of amplification) was
always below 0.01 log10. The dashed lines
indicate the lower limit of detection. Detection
of BZLF-1 was done by indirect
immunofluorescence staining in the nucleus
(blue) of approximately 1 in 106 mononuclear
cells in CBMC infected ex vivo with EBV.
Nuclear staining with DAPI. Scale bar: 15 mm.
The EBV infection rates were monitored by
flowcytometry using B95.8EBfaV-GFP, a
recombinant EBV encoding enhanced green
fluorescent protein, and a PE-labelled
anti-human CD19 antibody. Flow cytometry
detection of the late lytic EBV glycoprotein
gp350/220 after inoculation with B95.8 was
performed using a FITC-labelled anti-EBV
gp350/220 antibody, a PE-labelled anti-human
CD19 antibody and a Cy5-labelled anti-human
CD5 antibody to assess the susceptibility of B
cell subpopulations to lytic EBV infection.
2056 K. Ladell et al.
© 2007 The Authors
Journal compilation © 2007 Blackwell Publishing Ltd, Cellular Microbiology, 9, 2055–2069
observations, we hypothesized that immune activation
affects EBV gene expression. We tested our hypothesis
by activating cord blood mononuclear cells (CBMC) and
peripheral blood mononuclear cells (PBMC) from adults
acutely infected ex vivo with EBV, and chronically EBV-
infected Akata Burkitt lymphoma cells. The rationale to
use CBMC was its minimal immune activation and matu-
rity status compared with PBMC from adults (Bradley and
Cairo, 2005). We avoided bias from pre-existing EBV-
specific T-cell immunity by using primary cells only from
EBV-naive donors.
Results
Epstein-Barr virus expresses BZLF-1 and gp85 in
CBMC, but not in PBMC, after EBV infection ex vivo
We hypothesized that CBMC and adult PBMC, given
their different degrees of immune activation and matu-
ration, display distinct EBV gene expression patterns
after EBV infection. Using flow cytometry, we first veri-
fied that CBMC show a lower degree of immune activa-
tion than adult PBMC by assessing the proportion of
CD4+ and CD8+ cells expressing HLA-DR. Indeed, in
CBMC (n = 10 donors), the percentages of CD4+/HLA-
DR+ and CD8+/HLA-DR+ cells were 0.8  0.5 and
0.8  0.2, respectively, and in PBMC (n = 4 donors),
they were 11.5  0.4 and 20.5  3.6 respectively. Next,
to test our hypothesis, we quantified latent (EBNA-1,
EBNA-2, LMP-1 and LMP-2) and lytic (BZLF-1, the ini-
tiator of EBV lytic infection, and gp85, a late lytic gene)
EBV gene mRNA expression in CBMC and adult PBMC
after infection with EBV ex vivo. We used CBMC to
model a state of immature and less vigorous immune
responses than in adolescents or adults, and we used
PBMC from EBV-naive individuals to prevent potential
influences on EBV gene mRNA expression by pre-
existing EBV-specific immunity. We measured EBV gene
mRNA expression levels by real-time polymerase chain
reaction (PCR) and normalized to levels of the house-
keeping gene hydroxymethylbilane synthase (HMBS) at
0, 2, 24, 48, 72, 144 and 168 h after in vitro EBV inocu-
lation of CBMC or PBMC. Similar levels of the latent
genes EBNA-1, EBNA-2, LMP-1 and LMP-2 were
detected 24 h after EBV inoculation of CBMC or PBMC
(Fig. 1A and B), documenting successful infection with
EBV. Levels of EBNA-2 mRNA tended to be higher than
those of EBNA-1, and mRNA levels of these two genes
were higher than those of LMP-1, and LMP-2 both in
CBMC and PBMC. By contrast, significant mRNA
expression of the lytic genes BZLF-1 and gp85 was con-
sistently observed in CBMC (Fig. 1C) at and after 72 h
post inoculation of EBV, but was never seen in adult
PBMC (Fig. 1D). Accordingly, BZLF-1 protein was
detected by immunofluorescence in CBMC (Fig. 1E), but
not in PBMC (not shown). It is known that EBV lytic
cycle coincides with host shutoff mediated through
Fig. 1. cont.
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mRNA degradation (Glaunsinger and Ganem, 2006). If
that concerns the housekeeping gene HMBS, we used
to normalize our data, this could lead to an overestima-
tion of the lytic EBV genes. We found that the cycle
threshold (Ct) values for HMBS mRNA expression in
CBMC (n = 6) following ex vivo infection with EBV were
rather constant in the first 72 h and showed a slight
decrease thereafter (not shown), indicating that the
abundance of HMBS mRNA expression is not diminish-
ing but rather increasing.
The fractions of B cells latently infected with EBV in
CBMC and PBMC following ex vivo infection are similar,
and CD5+ and CD5– B cell subsets in CBMC are equally
susceptible to lytic EBV
We asked whether the difference in lytic EBV gene
expression between CBMC and PBMC was due to dif-
ferent EBV infection rates. Thus, we estimated the frac-
tions of latently EBV-infected B cells following ex vivo
infection using an enhanced green fluorescent protein
expressing B95.8 EBV, EBfaV-GFP (Speck and Long-
necker, 1999). In separate experiments we documented
that ex vivo infection with EBfaV-GFP resulted in quali-
tative and quantitative latent EBV gene expression pat-
terns in CBMC and PBMC similar to those observed
following ex vivo infection with B95.8 (M. Dorner et al.,
manuscript in preparation), suggesting that EBfaV-GFP
is a valid substitute of B95.8. The fraction of CD19+
B cells in CBMC (n = 3) and PBMC (n = 3) at baseline
was 11.6  2.4% and 7.3  2.3% respectively. The
overall EBV infection rates were similar in CBMC and
PBMC in the first 144 h after EBV inoculation ex vivo
when they reached around 1% in relation to all cells and
around 4–5% of CD19+ B cells (Fig. 1F and G). To
assess the fractions of lytically infected cells we stained
the cells for the late lytic glycoprotein gp350/220 which
is expressed on the plasma membrane (Gong and Kieff,
1990) following ex vivo infection with 95.8 EBV. Using
flow cytometry we documented that the proportion of B
cells exhibiting lytic EBV infection peaked between 2
and 3% at 144 h post EBV inoculation in CBMC while no
cells expressing lytic EBV were found in PBMC (not
shown). The vast majority of B cells in CBMC (n = 3)
belonged to the CD5+ B cell subset (74.17  8.15%),
whereas in adult PBMC the minority of B cells were
CD5+ (28.81  11.16%). To evaluate whether the sus-
ceptibility of these B cell subsets in CBMC to lytic EBV
is different, we determined the numbers of CD5+ and
CD5– B cells staining for gp350/220. Flow cytometry
showed that the numbers of CD5+ B cells in CBMC
(n = 3) were 78  5% and that the proportions of CD5+
and CD5– B cells expressing gp 350/220 in CBMC
(n = 3) were similar (11.5  3.2% vs. 12.8  3.8%) at
144 h following ex vivo infection (Fig. 1H and I), indicat-
ing comparable susceptibility to EBV lytic infection.
Thus, although the fractions of B cells infected with EBV
in CBMC and PBMC following ex vivo infection were
similar, CBMC exhibited lytic EBV infection whereas
PBMC did not. The expression of gp350/220 clearly indi-
cates that the lytic infection is not only initiated (Laichalk
and Thorley-Lawson, 2005) but is also fully executed in
CBMC. Furthermore, the difference between CBMC and
PBMC in lytic EBV gene expression cannot be attributed
to the higher content of CD5+ cells in CBMC than in
PBMC, because CD5+ and CD5– cells were equally sus-
ceptible to lytic EBV infection.
Cord blood mononuclear cells express lower levels of
IL-12 p35, IFN-g and IL-2 mRNA than PBMC at baseline
and in response to EBV
Because CBMC and adult PBMC represent immune cells
with dissimilar states of immune maturation with different
abilities to express cytokines, we asked whether the dis-
tinct EBV gene expression in CBMC and PBMC was
associated with differing cytokine gene expression. We
compared mRNA levels of proinflammatory cytokines in
CBMC and PBMC before and after EBV infection in vitro.
CBMC displayed lower mRNA levels of IL-12 p35
(P = 0.0001), IFN-g (P < 0.0075) and IL-2 (P < 0.001) than
PBMC at baseline (Fig. 2). mRNA levels of TNF-a, IL-1b,
IL-6 and IL-8 did not significantly differ between CBMC
and PBMC at baseline (not shown).
Inoculation with EBV led to increased mRNA levels of
IL-12 p35, IFN-g and IL-2 in CBMC and adult PBMC.
However, mRNA levels in CBMC never reached the
levels observed in adult PBMC, and significant differences
between CBMC and adult PBMC were also found after
inoculation with EBV (Fig. 3). Because host shutoff medi-
ated through mRNA degradation during EBV lytic gene
expression may result in false high positive cytokine mRNA
levels, we also measured IL-12, IFN-g and IL-2 at the
protein level. At 96 h after inoculation with EBV, protein
levels of IL-12 p40, IFN-g and IL-2 were 11.4  1.5 pg ml-1,
6.5  2.1 pg ml-1 and 0.8  0.6 pg ml-1, respectively, in
CBMC supernatants (n = 4) versus 22.5  2.3 pg ml-1,
34.5  7.8 pg ml-1 and 7.6  1.7 pg ml-1, respectively, in
PBMC supernatants (n = 4). Overall, mRNA levels of IL-12
p35, IFN-g and IL-2 were lower in CBMC than adult PBMC
before EBV infection ex vivo and both mRNA and protein
levels of these cytokines were also lower in CBMC than
adult PBMC after EBV infection ex vivo, suggesting that
differences in expression levels of these proinflammatory
cytokines may be due to maturational differences in cytok-
ine responses and the degree of immune activation
or maturation may influence the initiation of lytic EBV
infection.
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The lower levels of IL-12, IFN-g and IL-2 in CBMC than
in PBMC in response to EBV are not associated with
higher levels of TGF-b or IL-10 mRNA
To explore whether lower levels of proinflammatory cytok-
ines in CBMC than PBMC after infection with EBV were
associated with higher mRNA levels of anti-inflammatory
cytokines in CBMC than in PBMC, we measured mRNA
expression of the anti-inflammatory cytokine genes TGF-b
and IL-10. Importantly, the assay we used to detect
human IL-10 is highly host specific and does not detect
EBV-encoded viral IL-10. At baseline, mRNA levels of
TGF-b were lower whereas levels of IL-10 were higher in
CBMC than in PBMC (Fig. 4). Following infection with
EBV, levels of TGF-b remained lower in CBMC compared
with in PBMC. By contrast, levels of IL-10 became signifi-
cantly lower in CBMC than in PBMC after EBV inoculation
in vitro (Fig. 4). These findings strongly indicate that the
lower levels of induction of IL-12, IFN-g and IL-2 in CBMC
than in PBMC after inoculation with EBV are not due to
higher expression of TGF-b or IL-10 mRNA in CBMC than
in PBMC.
To investigate the effects of IL-10 on lytic EBV infection,
we treated CBMC (n = 3) with recombinant human IL-10
at 1, 10, or 100 pg ml-1. Adding IL-10 did not result in
significant changes in BZLF-1 mRNA expression following
EBV infection ex vivo (not shown). Similarly, neutralizing
IL-10 in PBMC from EBV-seronegative adults (n = 3) with
anti-human IL-10 antibody at 1.0 U ml-1 did not result in
BZLF-1 mRNA expression following EBV infection ex vivo
(not shown). Thus, IL-10 levels appear to have no effect
on EBV lytic gene expression patterns.
rIL-12 and rIFN-g decrease BZLF-1 mRNA expression in
CBMC during EBV infection in vitro
Next, we asked whether IL-12 or IFN-g have an effect on
BZLF-1 expression in CBMC after infection with EBV.
We infected CBMC with EBV ex vivo, treated with rIL-
12, rIFN-g or both, and measured mRNA expression
96 h after infection when BZLF-1 is detectable in all of
the EBV-infected untreated CBMC cultures (Fig. 5). In
CBMC treated with rIL-12 simultaneously with EBV
inoculation and then every 24 h, IL-12 p35 mRNA
expression was unchanged, whereas IFN-g mRNA
expression increased about 6.5-fold at 96 h, and BZLF-1
mRNA expression level was reduced by 50%, compared
with untreated CBMC (Fig. 5). As expected, treatment of
CBMC with rIL-12 also increased the IFN-g protein con-
centration in the cell-free supernatant of CBMC com-
pared with no treatment (1368 vs. 37 pg ml-1). This
higher increase in protein concentration compared with
the increase in mRNA expression may be explained by
either accumulation of transcribed protein in the super-
Fig. 2. CBMC express significantly lower mRNA levels of
proinflammatory cytokine genes than PBMC at baseline.
A. IL-12 p35.
B. IFN-g.
C. IL-2.
CBMC (n = 19) and PBMC (n = 20) were isolated by
density-gradient centrifugation. RNA was extracted from cell pellets
and treated with DNase to remove residual genomic DNA. The
mRNA was reverse transcribed into cDNA using an oligo-d(T)15
primer. mRNA expression was measured by real-time PCR and
normalized to the housekeeping gene HMBS. Median values (solid
black line) of fold mRNA expression in relation to HMBS are shown
as box plots with whiskers that extend to the highest and lowest
values above and below the box. The dashed lines indicate the
lower limit of detection. * refers to CBMC versus PBMC.
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natant or expressed mRNA being transcribed to protein
at higher rates, or both. Treatment of CBMC with rIFN-g,
simultaneously with EBV inoculation and then every
24 h, did not change IFN-g mRNA expression and did
not influence IL-12 p35 mRNA expression, but reduced
BZLF-1 mRNA expression by 50% compared with
untreated CBMC (Fig. 5). Finally, treatment with both
rIL-12 and rIFN-g simultaneously with EBV inoculation
and then every 24 h, did not change IL-12 p35 mRNA
expression, increased IFN-g mRNA expression around
17-fold, and resulted in a stronger suppression (sixfold)
of BZLF-1 mRNA expression than when treatment
included only one of both cytokines (Fig. 5). Conversely,
we treated adult PBMC infected with EBV ex vivo with
antibodies to IL-12 and IFN-g and could not provoke
BZLF-1 mRNA expression (not shown). Thus, substitu-
tion of the proinflammatory cytokines IL-12 and IFN-g
partially suppressed BZLF-1 mRNA expression in CBMC
infected with EBV ex vivo, indicating that the weaker
proinflammatory immune response in CBMC contributes
to the initiation of lytic EBV infection seen in CBMC. The
failure to provoke BZLF1 mRNA expression in acutely
infected PBMC with antibodies to IL-12 and IFN-g
together with their incomplete suppression of BZLF-1
mRNA expression suggests that these two cytokines are
Fig. 3. CBMC express significantly lower mRNA levels of
proinflammatory cytokine genes than PBMC from EBV-seronegative
adults following infection with EBV ex vivo.
A. IL-12 p35.
B. IFN-g.
C. IL-2.
mRNA expression was measured by real-time PCR and normalized
to the housekeeping gene HMBS. Results are means  SD of
mRNA expression normalized to HMBS (fold) during 7 days of
culture. The dashed lines indicate the lower limit of detection. * or
** refers to CBMC (n = 3–8) versus PBMC (n = 3).
Fig. 4. CBMC express lower mRNA levels of anti-inflammatory
cytokine genes than PBMC from EBV-seronegative adults in
response ex vivo infection with EBV.
A. TGF-b.
B. IL-10.
mRNA expression was measured by real-time PCR and normalized
to the housekeeping gene HMBS. Results are means  SD of
mRNA expression normalized to HMBS (fold) during 7 days of
culture. * refers to CBMC (n = 3–8) versus PBMC (n = 3).
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not the only players suppressing the initiation of lytic
EBV infection.
CpG ODN 2006 suppress BZLF-1 mRNA expression in
CBMC infected with EBV in vitro
We next sought to test whether other means of immune
stimulation would lead to suppression of BZLF-1 expres-
sion in CBMC. To stimulate CBMC we used the unm-
ethylated CpG-containing ODN 2006 that triggers the
innate pathogen-associated molecular pattern recogni-
tion receptor TLR-9 which is also expressed in B cells
(Hornung et al., 2002) and exerts a proinflammatory
effect (Peng, 2005). We asked if stimulating CBMC with
CpG ODN 2006 alters EBV gene expression. Thus, we
cultured CBMC with or without CpG ODN 2006 and with
or without EBV for 96 h respectively. Treatment of
uninfected CBMC with CpG ODN 2006 resulted in a 2.6-
fold increase of TLR-9 mRNA expression versus no
treatment (Fig. 6A). EBV infection by itself led to 3.7-fold
increase in levels of TLR-9 mRNA expression in CBMC
over uninfected CBMC (Fig. 6B). The large number of
CpG motifs in the EBV DNA genome or a CpG-motif-
independent mechanism may explain the upregulation of
TLR-9 by EBV. Treatment of EBV-inoculated CBMC with
CpG ODN 2006 resulted in a further but not significant
increase of TLR-9 mRNA expression (Fig. 6B). As
expected, inoculation of CBMC with EBV resulted in
marked expression of BZLF-1 mRNA. By contrast, EBV-
infected CBMC cultures treated with CpG ODN 2006
exhibited a 5.8-fold lower BZLF-1 mRNA expression
(Fig. 6C). Although EBV itself induced TLR-9 mRNA
expression in CBMC, the induction did not suppress
BZLF-1 mRNA expression. Therefore, the reduction of
BZLF-1 mRNA expression in EBV-infected CBMC after
CpG ODN 2006 treatment did not seem to depend on
induction of TLR-9, but rather on the additional stimula-
tion by CpG ODN 2006 (e.g. increased TLR-9 signalling
mediated by CpG binding). Expression levels of latent
EBV gene mRNAs were not significantly different in
untreated or CpG ODN 2006-treated EBV-infected
CBMC (not shown).
Next, we asked whether triggering of other TLRs
present on B cells also results in suppression of lytic EBV.
Triggering of TLR-1/2, TLR-4, or TLR-7/8 on EBV-infected
CBMC did not result in significant suppression of BZLF-1
and gp85 mRNA expression and gp350/220 expression
compared with controls (Fig. 6D–F). These data suggest
that CpG ODN 2006 stimulation of TLR-9 on EBV-infected
CBMC is rather specific in inhibiting the mRNA and
protein expression of EBV genes involved in lytic infection
but has no effect on latent EBV gene mRNA expression.
This suppression of the initiation and completion of lytic
EBV infection in turn may support maintenance of EBV
latency.
Antibodies to IL-12 and IFN-g partially restore BZLF-1
mRNA expression in EBV-infected CBMC treated with
CpG ODN 2006
We next explored whether IL-12 and IFN-g contribute to
the suppression of BZLF-1 mRNA expression induced
after TLR-9 triggering by CpG ODN 2006. We added
antibodies to IL-12 and IFN-g to cultures of CBMC inocu-
lated with EBV and treated with CpG ODN 2006.
Indeed, treatment with anti-IL-12 and anti-IFN-g partially
restored expression of BZLF-1 mRNA in these CBMC
Fig. 5. rIL-12, rIFN-g, or both suppress the transcription of BZLF-1
in CBMC infected with EBV ex vivo. rIL-12, rIFN-g, or both were
added together with EBV and then every 24 h over 96 h to the
cultures. mRNA was measured by real-time PCR. Results shown
are from one representative experiment of six from CBMC from
different donors. RNA was extracted and analysed from four
different cell pellets per condition, except for the treatments with
rIFN-g (two cell pellets per condition). Means  SD represent the
differences of mRNA expression between treated and untreated
samples after normalization to the housekeeping gene HMBS.
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(Fig. 7A). Even though these antibodies exhibited little
effect on CpG ODN 2006-induced enhanced IL-12 p35
and IFN-g mRNA expression (Fig. 7B and D), the protein
levels of both cytokines were below the lower limit of
detection (Fig. 7C and E). These data at the protein
level excluded potentially misleading results due to host
shutoff mediated through mRNA degradation during EBV
lytic gene expression. Thus, our observations provide
evidence that part of the negative impact on the initiation
of lytic EBV infection in CBMC exhibited by CpG ODN
2006 through TLR-9 triggering is mediated by IL-12 and
IFN-g.
A key question is which cells are implicated in the
effects observed. Thus, we infected highly purified B cells
from CBMC and PBMC with EBV. Indeed, BZLF-1 was
expressed in B cells from CBMC but not from PBMC.
mRNA and protein levels for IL-12 and IFN-g were strik-
ingly lower in B cells from CBMC than from PBMC
(Fig. 7F–O). Moreover, we could reproduce the inhibitory
effects on BZFL-1 expression when triggering TLR-9
Fig. 6. CpG ODN 2006 specifically suppresses initiation and execution of lytic EBV in CBMC following ex vivo infection.
A. mRNA expression of TLR-9 in CBMC (n = 3) treated or not with CpG ODN 2006.
B. mRNA expression of TLR-9 in CBMC (n = 3) infected ex vivo with EBV and treated or not with CpG ODN 2006.
C. mRNA expression of BZLF-1 in CBMC (n = 3) infected ex vivo with EBV and treated or not with CpG ODN 2006.
D and E. mRNA expression of BZLF-1 (D) and EBV glycoprotein (gp) 85 (E) in CBMC (n = 3) that were stimulated with ligands of TLRs
present in B cells and infected ex vivo.
F. Expression of the lytic EBV glycoprotein gp350/220 in CBMC treated with ligands of TLRs present in B cells and infected ex vivo.
TLR ligands were added at 0 h and 90 h to 2 ¥ 106 CBMC (n = 3) infected ex vivo with EBV. Cells were collected at 96 h. Concentrations of
TLR ligands were 10 mg ml-1 for peptidoglycan (TLR-1/2), 3 mM for R-848 (TLR-7/8) and 1 mM for CpG ODN 2006 (TLR-9). RNA was extracted
from two cell pellets per condition, treated with DNase, and reverse-transcribed into cDNA with an oligo-dT15 primer. mRNA expression was
measured in duplicate by real-time PCR. Means  SD of fold induction over resting normalized to the housekeeping gene HMBS.
Flowcytometry was performed using a FITC-anti-EBV gp350/220 antibody. Events shown are gated for CD19+ B cells. One representative
experiment of three is shown.
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similar as outlined above. TLR-9 triggering was associ-
ated with an increase in IL-12 and IFN-g at the mRNA as
well as protein level. Thus, the effects we observed when
triggering TLR-9 are rather direct than indirect.
CpG ODN 2006 suppresses induction of BZLF-1 mRNA
expression in Akata Burkitt lymphoma cells
The above experiments addressed the effect of immune
stimulation triggered by cytokines and TLR-9 on the
initiation of lytic EBV infection in cells exposed to acute
infection with EBV, but not in cells with chronic latent EBV
infection. Switching from latent to lytic EBV infection may
occur spontaneously or be provoked in EBV-transformed
cells by several agents in vitro (Kieff and Rickinson,
2001). Cells from the Burkitt lymphoma cell line Akata can
readily be provoked to switch from latent to lytic EBV
infection within hours by cross-linking their surface IgG
using anti-IgG antibodies. Thus, we asked whether trig-
gering of TLR-9 exhibits an effect on the induction of lytic
EBV infection in Akata cells, used as a surrogate for
Burkitt lymphoma cells. We first determined whether
Akata cells express TLR-9. Using quantitative PCR, we
demonstrated that Akata cells constitutively express
TLR-9 mRNA. Stimulation of Akata cells with CpG ODN
2006 did not increase TLR-9 mRNA expression (Fig. 8A).
This suggested that TLR-9 expression in the fully differ-
entiated Akata cells was maximal before treatment with
CpG ODN 2006 as opposed to CBMC which contain
naive B cells and showed an increase in TLR-9 mRNA
expression upon stimulation with CpG ODN 2006
(Fig. 6A). As expected, cross-linking of surface IgG after
treatment with anti-IgG provoked the expression of
BZLF-1 mRNA and thus the initiation of lytic EBV infection
(Fig. 8B). Treatment of Akata cells with CpG ODN 2006
before treatment with anti-IgG reduced BZLF-1 mRNA
expression provoked by surface IgG cross-linking by 50%
(Fig. 8B). By contrast, treatment with CpG ODN 2006
simultaneously or deferred to anti-IgG treatment had no
significant effect on the initiation of lytic EBV infection (not
shown); indicating that the signalling cascade initiated by
anti-IgG appears to be dominant to the intracellular
changes subsequent to triggering TLR-9. These data
suggest that triggering innate immunity via TLR-9 sup-
presses the initiation of lytic EBV infection in transformed
B cells with established EBV latency and that this sup-
pression is independent from other immune cells express-
ing TLR-9.
Discussion
Immune activation may be a critical factor in EBV-
associated lymphomagenesis. In this work, we examined
the effect of immune activation on EBV gene expression.
We found that (i) EBV expresses BZLF-1, the initiator of
lytic EBV infection, and the late lytic genes gp85 and
gp350/220 in CBMC, but not in adult PBMC infected ex
vivo with EBV, (ii) lower levels of proinflammatory cytok-
ines in CBMC than in adult PBMC are associated with
expression of lytic EBV genes and (iii) triggering of TLR-9
suppresses lytic gene expression in CBMC acutely
infected ex vivo with EBV and in anti-IgG-stimulated
chronically infected Akata Burkitt lymphoma cells. Our
findings, indeed, identify immune activation as critical
factor for the suppression of lytic EBV infection.
We used CBMC to model a state of minimal immune
activation compared with PBMC from adults. Importantly,
by using primary cells only from EBV-naive individuals,
we avoided bias from pre-existing EBV-specific T-cell
responses, which may be triggered by ex vivo EBV
infection. In CBMC, BZLF-1 and gp85 mRNA expression
and gp350/220 protein expression showed a sharp rise
after ex vivo EBV infection that persisted over the entire
observation time. In adult PBMC, no BZLF-1, gp85 or
gp350/220 expression was seen at all, although the frac-
tions of B cells infected with EBV following ex vivo infec-
tion were similar in CBMC and PBMC. The difference in
lytic EBV gene expression cannot be attributed to the
higher content of CD5+ cells in CBMC than in PBMC,
because CD5+ and CD5– cells exhibited lytic EBV equally.
By contrast, mRNA expression patterns of latent EBV
genes were similar in CBMC and PBMC. Extending data
published by Hunt et al. (1994) the proinflammatory cytok-
ines IL-12, IFN-g and IL-2 were lower in CBMC than in
PBMC before EBV infection. Furthermore, levels of these
cytokines in CBMC did not increase to the levels seen in
PBMC in response to EBV. Based on these data, we
hypothesized that the higher levels of proinflammatory
cytokines in PBMC may result in the suppression of
BZLF-1 expression (i.e. that differences in the status of
immune activation/maturation are responsible for the pro-
found difference in EBV gene expression between CBMC
and PBMC).
The main sources of IL-12 are monocytes and dendritic
cells (DCs) (Trinchieri, 2003). As mentioned above,
CBMC produce less IL-12 than PBMC (Hunt et al., 1994),
and DC derived from neonatal monocytes transcribe
much less IL-12 p35 than adult monocytes (Goriely et al.,
2001). IFN-g produced by natural killer (NK) cells (Biron
et al., 1999) may, in part, be responsible for the IFN-g
production in CBMC upon EBV encounter in vitro (Wilson
and Morgan, 2002). The frequency of NK cells in CBMC
and PBMC is similar, but NK cells in CBMC have an
immature function compared with NK cells in PBMC
(Nomura et al., 2001). To determine if the immune
activation/maturation deficiencies in IL-12 and IFN-g
production indeed enable BZLF-1 mRNA expression in
CBMC cultures, we added rIL-12 and rIFN-g to the CBMC
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cultures infected ex vivo with EBV. Indeed, BZLF-1 mRNA
expression in CBMC decreased significantly, albeit not
completely, with rIL-12 and rIFN-g. The incomplete sup-
pression of BZLF-1 mRNA expression may be explained
by immature cytokine receptor signalling pathways in
CBMC (Marodi, 2002) or the need of additional stimuli
operative in the innate immune responses (Medzhitov,
2001). Thus, activation of the immune system results in
efficient suppression of the initiation of lytic EBV infection.
The anti-inflammatory cytokine TGF-b induces lytic
infection in EBV-transformed CBMC-derived cell lines
(Liang et al., 2002). Thus, we explored the possibility that
Fig. 7. BZLF-1 mRNA expression in CpG ODN 2006-treated CBMC infected ex vivo with EBV is dependent on IL-12 and IFN-g expressed in
B lymphocytes.
A. mRNA expression of BZLF-1 in CBMC infected ex vivo with EBV and treated or not with CpG ODN 2006 and with or without anti-IL12 plus
anti-IFN-g blocking antibodies.
B. mRNA expression of IL-12p35 in CBMC infected ex vivo with EBV and treated or not with CpG ODN 2006 and with or without anti-IL12
plus anti-IFN-g antibodies.
C. IL-12p40 in supernatants of CBMC infected ex vivo with EBV and treated or not with CpG ODN 2006 and with or without anti-IL12 plus
anti-IFN-g antibodies.
D. mRNA expression of IFN-g in CBMC infected ex vivo with EBV and treated or not with CpG ODN 2006 and with or without anti-IL12 plus
anti-IFN-g antibodies.
E. IFN-g in supernatants of CBMC infected ex vivo with EBV and treated or not with CpG ODN 2006 and with or without anti-IL12 plus
anti-IFN-g antibodies.
F. mRNA expression of BZLF-1 in CD19+ B cells isolated from cord blood infected ex vivo with EBV.
G. mRNA expression of IL-12p35 in CD19+ B cells isolated from cord blood infected ex vivo with EBV and treated or not with CpG ODN 2006.
H. IL-12p40 in supernatants of CD19+ B cells isolated from cord blood infected ex vivo with EBV and treated or not with CpG ODN 2006.
I. mRNA expression of IFN-g in CD19+ B cells isolated from cord blood infected ex vivo with EBV and treated or not with CpG ODN 2006.
J. IFN-g in supernatants of CD19+ B cells isolated from cord blood infected ex vivo with EBV and treated or not with CpG ODN 2006.
K. mRNA expression of BZLF-1 in CD19+ B cells isolated from peripheral blood infected ex vivo with EBV.
L. mRNA expression of IL-12p35 in CD19+ B cells isolated from peripheral blood infected ex vivo with EBV and treated or not with CpG ODN
2006.
M. IL-12p40 in supernatants of CD19+ B cells isolated from peripheral blood infected ex vivo with EBV and treated or not with CpG ODN
2006.
N. mRNA expression of IFN-g in CD19+ B cells isolated from peripheral blood infected ex vivo with EBV and treated or not with CpG ODN
2006.
O. IFN-g in supernatants of CD19+ B cells isolated from peripheral blood infected ex vivo with EBV and treated or not with CpG ODN 2006.
CpG ODN 2006 (1 mM) was added at 0 and 90 h to the EBV-containing culture medium of 2 ¥ 106 CBMC. Anti-IL-12 and anti-IFN-g antibodies
were given to the cultures 1 h before stimulation with CpG ODN 2006. Cells were collected at 96 h. RNA was extracted from two cell pellets
per condition, treated with DNase, and reverse-transcribed into cDNA with an oligo-dT15 primer. mRNA expression was measured in duplicate
by real-time PCR. Results are means  SD of fold induction over resting normalized to the housekeeping gene HMBS. The dashed lines
indicate the lower limit of detection. One representative experiment of two is shown.
Fig. 8. CpG ODN 2006 suppresses induction of BZLF-1 mRNA expression in Akata Burkitt lymphoma cells provoked to switch to lytic EBV
infection.
A. Expression of TLR-9 mRNA before and after stimulation with CpG ODN 2006, anti-IgG, or both.
B. Expression of BZLF-1 mRNA before and after stimulation with CpG ODN 2006, anti-IgG, or both.
Akata cells (1.0 ¥ 106 each) were seeded and treated with or without CpG ODN 2006 (0.5 mM) After 6 h 0.1 mg ml-1 polyclonal rabbit
anti-human IgG was added to the cultures. Cells were collected at 6 h after anti-IgG treatment. RNA was extracted from one cell pellet per
condition, treated with DNase, and reverse-transcribed into cDNA with an oligo-dT15 primer. mRNA expression was measured in duplicate by
real-time PCR. Results are means  SD of fold induction over resting normalized to the housekeeping gene HMBS from three independent
experiments.
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the lower levels of IL-12, IFN-g and IL-2 in CBMC than in
PBMC were coupled to higher mRNA levels of TGF-b.
However, TGF-b mRNA expression was lower in CBMC
than in PBMC irrespective of ex vivo EBV infection,
making a contribution of TGF-b to BZLF-1 expression in
CBMC highly unlikely. Another possible reason for the
lower IL-12, IFN-g and IL-2 levels in CBMC than in PBMC
could have been increased levels of the anti-inflammatory
cytokine IL-10 (Wang et al., 1994). The lower mRNA
levels of IL-10 in CBMC in response to EBV infection
compared with in PBMC, however, argued against IL-10
being responsible for the lower levels of proinflammatory
cytokines in CBMC. Notably, adding or blocking IL-10 had
no effect on lytic EBV gene expression patterns.
We wanted to verify our observation that activation of
the immune system results in suppression of BZLF-1 by
activating the innate immune response triggering TLR-9.
Indeed, triggering of innate immunity via TLR-9 with CpG
ODN 2006 resulted in suppression of BZLF-1 but not
latent EBV gene mRNA expression in acutely ex vivo
EBV-infected CBMC. Notably, triggering TLR-9 resulted in
higher transformation rates of B cells infected ex vivo with
EBV (Traggiai et al., 2004), but the effect of stimulating
TLR-9 of B cells on EBV gene expression was not
investigated. Thus, the molecular mechanism(s) resulting
in the more efficient transformation rate of B cells when
triggering TLR9 may be due to reduction of initiation of
lytic EBV infection and thereby reinforce maintenance of
EBV latency.
Our results seem to be in conflict with the findings of Liu
et al. (2005) and Lim et al. (2007). Liu et al. (2005)
reported that truncated thioredoxin (Trx80) inhibits B cell
growth in EBV infected CBMC through T cells activated by
monocyte derived IL-12. They assessed B cell transfor-
mation by EBV by measuring the thymidine incorporation
on the 12th day. Patterns of EBV latent and lytic gene
expression were not investigated. In contrast, our experi-
ments focusing on acute ex vivo EBV infection were
limited to 7 days. Through the use of isolated B cells in
selected experiments we showed that IL-12 derived from
B cells mediated suppression of lytic EBV. We did not
assess B cell transformation. Thus, the results of these
two studies cannot be directly compared due to the differ-
ent experimental settings used; they are not mutually
contradictory. Future experiments may resolve this
enigma. Furthermore, Lim et al. (2007), reported that
human plasmacytoid DCs regulated immune responses
to EBV in humanized NOD-SCID mice resulting in
delayed EBV-related mortality. From indirect proof using
an inhibitor for triggering TLR-9 they concluded that
TLR-9 in part mediated activation of plasmacytoid DCs
resulting in anti-EBV-active CD3+ T cells. In this study,
PBMC from EBV-seropositive donors were used; thus, the
protective effect observed is most likely due to the boost-
ing effect of an adaptive EBV-specific cellular immune
response.
Next, we addressed the question whether TLR-9 trig-
gering affects on EBV in chronically infected cells. Chroni-
cally EBV-infected cells express latent EBV genes and
only very rarely lytic EBV genes. To assess the effects of
triggering of TLR-9 on lytic EBV in chronically EBV-
infected cells, we used Akata Burkitt lymphoma cells,
which undergo lytic EBV infection upon anti-IgG stimula-
tion (Kieff and Rickinson, 2001). Similarly to ex vivo
acutely infected B cells, TLR-9 triggering suppresses anti-
IgG-induced BZLF-1 expression in Akata cells. This result
also indicates that triggering TLR-9 directly affects the
EBV gene expression pattern and is not a consequence of
indirect effects due to stimulation of other cellular subsets.
Of note in this context, Plasmodium falciparum malaria
pigment hemozoin also stimulates TLR-9 (Coban et al.,
2005). Children in areas endemic for both EBV-positive
Burkitt lymphoma and malaria are dually infected with
EBV and malaria very early in life (Rochford et al., 2005).
We show that suppression of lytic EBV via TLRs on and in
B cells is specifically linked to triggering of TLR-9 and that
suppression of lytic EBV occurs following direct triggering
of TLR-9 in B cells. Thus, repeated activation of the innate
immunity via TLR-9 (e.g. due to chronic malaria infection)
may foster the propagation of latently EBV-infected cells
by suppressing lytic EBV infection and thus development
of Burkitt lymphoma.
We and others have documented increased plasma
EBV DNA levels in patients with IM or EBV-associated
lymphoproliferative diseases in immunocompetent and
immunodeficient patients (Berger et al., 2001; Ryan et al.,
2004) as well as in individuals with malaria (Moormann
et al., 2005; Donati et al., 2006). Plasma EBV DNA is
sensitive to DNase; this indicates that it is not encapsi-
dated and does not originate from lytic infection but rather
from dying latently infected cells (Ryan et al., 2004;
Donati et al., 2006). Moorman et al. also found elevated
EBV DNA blood levels in children with malaria and sug-
gested as likely reasons an increased frequency of
latently EBV-infected cells, indirectly due to polyclonal B
cell activation or due to suppression of EBV-specific
immunity, and that recurrent malaria infections affect
either the establishment or maintenance of EBV latency
(Moormann et al., 2005). Notably, no BZLF-1 transcription
is found in PBMC from IM patients (Tierney et al., 1994)
with high serum levels of IL-12, IFN-g and IL-2 (Corsi
et al., 2004). This is in line with our findings showing
IL-12- and IFN-g-mediated suppression of BZLF-1
expression. Our findings are further supported by the
observations that IFN-g blocks gammaherpesvirus reacti-
vation from latency (Steed et al., 2006) and nuclear factor
kB, activated downstream of TLR-9, inhibits gammaherp-
esvirus lytic replication (Brown et al., 2003). Thus, we
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hypothesize that in states of increased immune activation
propagation of EBV is due to promotion of latent rather
than of lytic EBV infection. Because control of EBV infec-
tion may substantially differ between tissue compartments
(Hislop et al., 2005; Donati et al., 2006), in states of
immune activation or cellular immune compromise lytic
EBV infection may be confined to tissues at mucosal
surfaces with excretion of EBV particles.
Experimental procedures
Isolation of mononuclear cells and cell culture
Cord blood mononuclear cells and PBMC from healthy adult
EBV-seronegative donors were obtained from heparinized blood
by Ficoll-Hypaque (Amersham Biosciences Europe GmbH,
Otelfingen, Switzerland) gradient centrifugation. Cells were
washed with phosphate-buffered saline (Gibco, Invitrogen Life
Sciences, Basel, Switzerland). The EBV-producing cell lines
B95.8 (Miller and Lipman, 1973) and B95.8EBfaV-GFP (Speck
and Longnecker, 1999), CBMC, PBMC and Akata (Takada, 1984)
cells were cultured in RPMI 1640 supplemented with Hepes
buffer, L-glutamine, 10% fetal bovine serum, 1 mM sodium pyru-
vate, 1 mM non-essential amino acids, 100 U ml-1 penicillin and
100 mg ml-1 streptomycin sulphate (medium and supplements
from Gibco). Informed consent was obtained from subjects or
parents before the study. The institutional ethics committee
approved the collection and use of clinical material.
Isolation of B cells from CBMC and PBMC
B cells were isolated from CBMC or PBMC by the use of mag-
netic beads (Miltenyi Biotech, Bergisch-Gladbach, Germany)
according to the manufacturer’s instructions. Purity of isolated B
cells was determined by flow cytometry using anti-human CD19,
and anti-human CD3 antibodies for the detection of B cells and
eventually remaining T cells. The purity of each separation was
above 97%.
Epstein-Barr virus infections ex vivo
After resting overnight, CBMC or PBMC (1 ¥ 107 cells) were
infected with supernatants from B95.8 cells or B95.8EBfaV-GFP
(1 ¥ 106 ml-1) harvested on day 4 after splitting and filtered using
a 0.45 mm sterile filter (Millipore, Cork, Ireland). The cell-free
supernatants contained approximately 7 log10 EBV copies ml-1,
as evaluated by real-time PCR for EBV DNA (Berger et al., 2001).
Infections were performed as described (Tosato, 1991). Briefly,
cells were centrifuged, resuspended in 2.5 ml of RPMI and 2.5 ml
of B95.8 supernatant, and incubated in 50 ml conical Falcon
tubes (BD Biosciences, Basel, Switzerland) at 37°C in a water
bath for 2 h. Subsequently, 5 ml of RPMI 1640 were added, and
1 ml aliquots (1 ¥ 106 cells ml-1) were seeded into 24-well plates
(BD Biosciences). Cell pellets were centrifuged at 300 g, frozen
on dry ice, and stored at -80°C.
Assessment of EBV and cytokine gene transcription
RNA extractions were performed with the RNA Easy Extraction
kit (Qiagen, Basel, Switzerland), according to the supplier’s
instructions. RNA was treated with DNase [DNAfree; Ambion
(Europe), Huntington, Cambridgeshire, UK] for removal of
residual DNA. RNA (1 mg) was reverse transcribed in a total
volume of 20 ml with oligo-dT15 primer (Microsynth, Balgach,
Switzerland) using Omniscript Reverse Transcription kit
(Qiagen). RNase inhibitor (10 units) (RNasin plus, Promega,
Catalys AG, Wallisellen, Switzerland) was added to each 20 ml
reaction. Real-time PCR (TaqMan) for human IL-2, IL-12 p35,
IFN-g, IL-1b, IL-6, IL-8, IL-10, TGF-b, TNF-a genes, EBV nuclear
antigen (EBNA)-1, EBNA-2, latent membrane protein (LMP)-1,
LMP-2, BamHI Z fragment (BZLF)-1, glycoprotein (gp) 85
(C. Berger, et al. submitted), and the housekeeping gene,
hydroxymethylbilane synthase (HMBS), were performed accord-
ing to the supplier’s instructions (Applied Biosystems, Foster City,
CA, USA) and as described (Bonanomi et al., 2003). The assays
were cDNA specific: either the forward or reverse primer or the
probe was designed to span exon-exon junctions. Specificity
(DNA/cDNA) was tested using RNA before and after DNase
treatment and cDNA with or without prior DNase treatment. The
assay for human IL-10 is highly specific and does not detect viral
IL-10 (data not shown). All reactions were performed in duplicate.
Each 15 ml reaction contained a mix of the 2¥ ABI-TaqMan
Master Mix (Applied Biosystems), primers (Microsynth) at
300 nM each, the probe (Biosearch Technologies, Novato, CA,
USA) at 200 nM, and 1 ml of cDNA template. Ct values obtained
for HMBS were used for normalization. Both positive (amplified
cDNA sequences of the selected cytokines or EBV genes tested)
and negative controls (no template) were included on every plate.
Immunofluorescence
Cord blood mononuclear cells were washed in PBS, transferred
to coated slides in a Cytospin 3 centrifuge (Shandon, Histocom,
Zug, Switzerland), air dried, fixed with acetone at 4°C, and stored
at -20°C. After thawing and before staining, the cells were
blocked with 5% goat serum in PBS, incubated with the anti-
BZLF-1 antibody (1:40; Clone BZ.1, DakoCytomation, Zug, Swit-
zerland), followed by the secondary goat anti-mouse IgG
antibody labelled with the green fluorescent Alexa Fluor 488 dye
(Molecular Probes-Invitrogen, Basel, Switzerland). Nuclei were
stained with 4,6 diamidino-2-phenylindole (DAPI; Vector Labora-
tories, Burlingame, CA, USA). Analysis was carried out with the
Zeiss AXIOSKOP 2 Mot Plus microscope, the Plan Neofluar
20 ¥/0.50 Ph2 objective, the Fluoarc Lamp, the AxioCam MR and
the AxioVision 3.1 software (all from Carl Zeiss AG, Oberkochen,
Germany). Adobe Photoshop 6.0 was used to magnify the region
of interest.
Flowcytometric analyses to determine T-cell activation
or fractions of EBV-infected B cells
The cell pellets were resuspended and washed in staining buffer
(PBS with 5% FBS and 0.1% sodium azide but without Ca+2 or
Mg+2). Cells were double stained with an FITC-labelled and a
PE-labelled mouse anti-human monoclonal antibody (all from
BD Biosciences, if not stated otherwise) at 4°C in the dark for
30 min. As isotype controls, FITC-conjugated anti-mouse IgG1
(FITC-IgG1) with PE-conjugated anti-mouse IgG1 (PE-IgG1) and
FITC-IgG1 with PE-HLA-ABC were used. Activated T cells were
evaluated with FITC-anti-HLA-DR and either PE-anti-CD4 or
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PE-anti-CD8. B cells were evaluated with PE-anti-CD19 and
Cy5-anti-CD5. Detection of the late lytic EBV glycoprotein gp350/
220 was performed using a FITC-labelled anti-EBV gp350/220
antibody (Milan Analytica, La Roche, Switzerland).The samples
were analysed using a FACSCalibur (BD Biosciences) equipped
with 488 nm and 635 nm lasers for double colour analysis.
Events (10 000 per lymphocyte gate) were recorded and analy-
sed with the Cell Quest software (BD Biosciences).
Assessment of cytokine levels
Samples were analysed using multiplex bead analysis that uses
microspheres as the solid support for immunoassays (Chen
et al., 1999). Cytokine levels were measured according to the
manufacturer’s instructions (Upstate Biotechnology UK, Bucking-
ham, UK).
Stimulation of CBMC with rIFN-g, rIL-12, or IL-10 and
inhibition of IL-12 or IFN-g by addition of anti-IL-12,
anti-IFN-g, or IL-10 antibodies
Cord blood mononuclear cells (1 ¥ 106 ml-1) were infected with
EBV as described above, but with or without addition of
20 ng ml-1 rIL-12, or 10 ng ml-1 rIFN-g, or both (both from R&D
Systems, Abingdon, UK), or 1, 10, or 100 pg ml-1 IL 10 (Pepro-
tech EC, London, UK). RIL-12, rIFN-g, or both, or IL-10 were
added in 24 h intervals to the cells. CBMC or PBMC (1 ¥ 106 ml-1)
were infected with EBV with or without 100 ng anti-IL-12, 1 mg
anti-IFN-g antibodies (both from R&D Systems), or anti-IL-10
antibodies (Biolegend, San Diego, USA).
Stimulation of CBMC, PBMC, or Akata cells with
ligands to TLRs
Cells (3 or 5 ¥ 106 cells ml-1) were left uninfected or infected with
EBV and were stimulated with TLR ligands added at 0 h and
90 h. Concentrations of TLR ligands were 10 mg ml-1 for pepti-
doglycan (TLR1/2), 20 mg ml-1 for lipopolysaccharide (TLR4),
3 mM for R-848 (TLR7/8) and 0.5 mM for CpG ODN 2006 (TLR9)
(InvivoGen, San Diego, CA, USA). The cells were kept in culture
for a total of 96 h.
Initiation of lytic EBV infection in Akata Burkitt
lymphoma cells
Akata cells were split to a concentration of 1 ¥ 106 cells ml-1 24 h
before stimulation. Cells (1 ¥ 106 ml-1) were stimulated with
0.1 mg ml-1 polyclonal rabbit anti-human IgG (Dako, Zug, Switzer-
land) and suspended in fresh RPMI 1640. After 6 h, stimulated
cells were collected for RNA isolation.
Statistical analyses
The Mann–Whitney U-test (two-tailed) was used for comparison
of differences between groups. The level of statistical signifi-
cance was set at P < 0.05.
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Plasma cell toll-like receptor (TLR) expression differs from that of
B cells, and plasma cell TLR triggering enhances immunoglobulin
production
Introduction
Toll-like receptors (TLRs) are key recognition structures
of the innate immunity.1 They trigger antimicrobial
responses by conserved pathogen-associated molecular
patterns. The signalling cascade culminates, among others,
in the activation of nuclear factor-jB (NF-jB), which
results in the expression of pro-inflammatory cytokines
that are critical for the innate as well as for the adaptive
immune responses.1 Furthermore, TLRs play a role in
autophagy,2 haematopoiesis3 and neutrophil activation.4
For each of the 10 known human TLRs (TLR1–TLR10),
at least one distinct ligand has been identified, except for
TLR10.1
Cell subpopulations exhibit specific TLR expression
patterns,5,6 indicating that TLR expression is tailored to
distinct cellular functions. Furthermore, the TLR expres-
sion pattern depends on the developmental stage, as
exemplified by the developmental-dependent degree of
TLR1–TLR5 expression in dendritic cells7 and of TLR9 in
B cells.8 Delineation of the expression of TLRs during
human B-cell development is so far incomplete.9 Data on
TLR expression in human B cells at their maturation
stages and in terminally differentiated plasma cells from
the same donors and from the same secondary lymphatic
organ where differentiation actually takes place (e.g. ton-
sils), have not yet been presented, and such data form the
basis for functional studies.
Here, we hypothesized that the expression and function
of TLRs are tailored to stages of B-cell development and
differentiation. Therefore, we investigated the quantitative
expression of TLR1–TLR10 in haematopoietic stem cells
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Summary
Toll-like receptors (TLRs) are key receptors of the innate immune system
and show cell subset-specific expression. We investigated the messenger
RNA (mRNA) expression of TLR genes in human haematopoietic stem
cells (HSC), in naı¨ve B cells, in memory B cells, in plasma cells from pala-
tine tonsils and in plasma cells from peripheral blood. HSC and plasma
cells showed unrestricted expression of TLR1–TLR9, in contrast to B cells
which lacked TLR3, TLR4 and TLR8 but expressed mRNA of all other
TLRs. We demonstrated, for the first time, that TLR triggering of termi-
nally differentiated plasma cells augments immunoglobulin production.
Thus, boosting the immediate antibody response by plasma cells upon
pathogen recognition may point to a novel role of TLRs.
Keywords: B-cell subpopulations; immunoglobulin production; mRNA
expression; plasma cells; toll-like receptors
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(HSC) as well as in naı¨ve B cells, memory B cells and
plasma cells from the same lymphoid tissue. Furthermore,
we addressed the as-yet uninvestigated issue of whether
TLR triggering affects plasma cell function, and we
showed that TLR triggering increases the production and
secretion of immunoglobulin from plasma cells.
Materials and methods
Cells and subpopulations
Cells were isolated from cord blood or tonsils, as
described previously.10–12 The study was approved by the
local ethics committee, and written informed consent was
obtained for all tissue obtained. Cord blood HSC, B cells
and plasma cells were isolated using CD34 microbeads,
the B-cell isolation kit II and CD138 microbeads, respec-
tively, according to the instructions of the manufacturer
(Miltenyi Biotech, Bergisch Gladbach, Germany). Further
separation of B cells into naı¨ve and memory B cells was
performed using the naı¨ve-B-cell isolation kit (Miltenyi
Biotech) or CD27 microbeads (Miltenyi Biotech).12 Iso-
lated cell populations used for experiments were always
> 95% pure, as determined by flow cytometry.
Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction (PCR)
was performed for TLR9 and the housekeeping gene
hydroxymethylbilane-synthase (HMBS), as described
previously.10,12 TLR10 was analyzed using primer/probe
on demand (Hs01935337_s1, Assay-on-demand gene
expression product; Applied Biosystems, Foster City, CA).
SYBR Green primers for HMBS and TLR1–TLR8 were as
described previously.13
Flow cytometry
Flow cytometry using fluorochrome-conjugated monoclo-
nal antibodies to human CD34, CD19, CD27, CD138,
IgM or IgG (BD Biosciences, Basel, Switzerland) was exe-
cuted on a Cytomics FC500 instrument (Beckman Coul-
ter, Nyon, Switzerland); data were analyzed using FLOWJO
software (Treestar, Ashland, OR).
Intracellular immunoglobulin staining and enzyme-
linked immunosorbent assay
Tonsillar plasma cells were either untreated or were stim-
ulated with 10 lg/ml of peptidoglycan (TLR1/2 ligand;
Fluka, Buchs, Switzerland), 1 lg/ml of poly(I:C) (TLR3
ligand; InvivoGen, San Diego, CA), 10 ng/ml of lipopoly-
saccharide (LPS) (TLR4 ligand; Sigma-Aldrich, Buchs,
Switzerland), 10 ng/ml of flagellin (TLR5 ligand; Invivo-
Gen), 3 lM R-848 (TLR7/8 ligand; InvivoGen), or 2 lM
cytosine–phosphate–guanosine (CpG) oligonucleotide
(ODN) 2006 (TLR9 ligand; Eurogentec, Ko¨ln, Germany).
Seventy-two hours after stimulation, cells were harvested,
fixed, permeabilized and stained. Intracellular staining of
IgM and IgG on plasma cells was performed using fluoro-
chrome-conjugated monoclonal antibodies and the BD
Cytofix/Cytoperm kit (both from BD Biosciences),
according to the manufacturer’s instructions.
The total amount of secreted immunoglobulin was
determined using an in-house enzyme-linked immunosor-
bent assay: briefly, 96-well microtitre plates were coated
with 10 lg/ml of Protein G (Calbiochem, Dietlikon,
Switzerland) diluted in a carbonate–bicarbonate buffer
(pH 96) and stored overnight at room temperature in a
humid chamber. The plates were washed four times with
phosphate-buffered saline (PBS) and incubated for 1 hr at
room temperature with 200 ll per well of 3% bovine
serum albumin in PBS. After discarding the blocking buf-
fer, 50 ll of supernatant of the plasma cell samples, or
serial dilutions of human immunoglobulin (NIBSC, Hert-
fordshire, UK) as a reference, were added to each well
and allowed to react for 30 min at 37. After three wash-
ing steps, peroxidase-labelled sheep anti-human immuno-
globulin (Millipore, Munich, Germany) was incubated for
30 min at 37. After three washing steps, 100 ll of
3,30,5,50-tetramethyl-benzidine substrate (Mabtech, Ham-
burg, Germany) was added and incubated for 30 min at
37 in the dark. The reactions were stopped by the addi-
tion of 50 ll of 1 M citrate. The absorbance was deter-
mined photometrically at 450 nm, with 620 nm as the
reference filter.
Results
Pattern of TLR mRNA expression changes during
B-cell development
We aimed to assess the TLR expression patterns of dis-
tinct human B-cell subpopulations, including HSC and
naı¨ve and memory B cells, as well as plasma cells
(Fig. S1). TLR protein levels may correlate with mRNA
expression for cell-surface TLRs14,15 but in our hands
commercially available TLR antibodies failed to reproduce
previously described results on the subcellular localization
of TLRs (data not shown). Thus, we quantified TLR
expression using real-time PCR to TLR mRNA. Indeed,
TLR expression patterns display notable changes during
B-cell development. HSC and tonsillar plasma cells
expressed all TLRs with the exception of TLR10 (Fig. 1).
In contrast to HSC and plasma cells, we found a com-
plete absence of TLR3, TLR4 and TLR8 expression in
naı¨ve and memory B cells, which is in agreement with
published data,5,6,16 while the other TLRs were expressed
to varying degrees (Fig. 1). Next, we investigated whether
circulating plasma cells differ in their TLR expression
2  2009 Blackwell Publishing Ltd, Immunology
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from their tonsillar counterparts to exclude the possibility
plasma cells exhibit distinct TLR expression patterns after
exiting secondary lymphoid organs. We found that
plasma cells from the peripheral blood exhibited the same
expression pattern as tonsillar plasma cells but that
expression of TLR9 was around 10-fold higher (Fig. 1).
The cell subset-specific TLR expression observed here sug-
gests that HSC and periphery terminally differentiated
plasma cells need the expression of TLR1–TLR9, whereas
B cells from secondary lymphoid organs need expression
of TLR1, TLR2, TLR5–TLR7, TLR9 and TLR10.
Engagement of TLRs on terminally differentiated
plasma cells increases immunoglobulin production
and secretion
Based on the constitutively high TLR1–TLR9 expression
by plasma cells (i.e. of the TLRs for which ligands are
known), we wondered whether TLR triggering affects the
function of these cells. Indeed, plasma cell TLR triggering
resulted in significantly increased production of intra-
cellular IgM following triggering of TLR1/2 (Fig. 2a,c)
and of IgG following triggering of TLR3 or TLR9
(Fig. 2b,d) as well as secretion of total immunoglobulin
following triggering of TLR1–TLR3 and TLR5 (Fig. 2e),
when compared with freshly ex vivo isolated plasma cells.
Next, we evaluated whether the increased TLR9 expres-
sion by plasma cells from peripheral blood compared
with that from tonsils influences immunoglobulin pro-
duction upon TLR triggering (Fig. 3). We observed a sig-
nificant increase of intracellular IgM production following
triggering of TLR1–TLR4 (Fig. 3a,c), and a significant
increase of intracellular IgG production following trigger-
ing of TLR7/8 (Fig. 3b,d), when compared with freshly
isolated plasma cells ex vivo.
This increased immunoglobulin production/secretion
suggests that terminally differentiated plasma cell TLRs
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Figure 1. Messenger RNA (mRNA) expression levels of toll-like
receptor (TLR)1–TLR10 show distinct regulation patterns during
B-cell development. mRNA expression profiling is shown of TLR1–
TLR10 in haematopoietic stem cells (HSC) isolated from cord blood,
in naı¨ve B cells, in memory B cells, in terminally differentiated
plasma cells from tonsils and in terminally differentiated plasma cells
from peripheral blood. HSC and plasma cells were isolated by posi-
tive selection using CD34 microbeads and CD138 microbeads,
respectively. Naı¨ve B cells and memory B cells were isolated using
the naı¨ve B-cell isolation kit and a combination of the B-cell isola-
tion kit II and CD27 microbeads, respectively. Expression of TLR1–
TLR10 and of the housekeeping gene hydroxymethylbilane-synthase
(HMBS) mRNA was monitored by quantitative real-time polymerase
chain reaction (PCR). Results shown are the means ± standard devi-
ation (SD) of three biological replicates of one out of three represen-
tative experiments. *Denotes not detectable.
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have functions beyond mere innate immunity pathogen
sensing and thus may be critical in regulating the strength
of adaptive antibody-mediated immune responses. The
omnipresent TLR1–TLR9 mRNA expression by plasma
cells seems to contrast the selective, strong responses to
TLR1–TLR3, TLR5, or TLR9 triggering in tonsillar plasma
cells and to TLR1–TLR4 and TLR7/8 triggering in periph-
eral blood plasma cells. One possible explanation for this
could be that different TLRs drive different classes of
antibodies. Nevertheless, the selective responses observed
may depend on the specific adaptive immunity repertoire
of the plasma cell donor, as indicated by the divergent
results obtained for TLR3 and TLR7/8 triggering of ton-
sillar versus peripheral blood plasma cells, which were
obtained from different donors.
Discussion
In the present study we aimed to assess the TLR expres-
sion patterns in human B cells (including HSC, naı¨ve
and memory B cells, as well as plasma cells) at distinct
developmental stages and to analyze the impact of plasma
cell TLR engagement. Indeed, we demonstrated that TLR
expression patterns display notable changes during
peripheral B-cell development, that plasma cells exhibit
TLR expression distinct from naı¨ve and memory B cells
but similar to HSC, and that engagement of plasma cell
TLRs results in augmented immunoglobulin production
and secretion by these cells. These results suggest that
TLR expression is tailored to cellular developmental stage
function.
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Figure 2. Triggering of toll-like receptors (TLRs) on plasma cells isolated from tonsils induces increased production of immunoglobulin. Intra-
cellular (a) IgM and (b) IgG expression in plasma cells, mean fluorescence intensity of (c) IgM and (d) IgG in plasma cells and (e) secretion of
immunoglobulin by plasma cells isolated from tonsils. Plasma cells were isolated from palatine tonsils by positive selection using CD138
microbeads. The viability of plasma cells after 72 hr in culture was always above 75%. Black histograms indicate isotype-control staining. The
results shown are the means ± standard deviation of three biological replicates of one out of three representative experiments. *P < 0001;
**P < 001; ***P < 005, by Kruskall–Wallis and Dunn’s multicomparison test. CpG ODN, cytosine–phosphate–guanosine oligonucleotide 2006;
LPS, lipopolysaccharide.
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In agreement with published data,5,6,16 we found a
complete absence of TLR3, TLR4 and TLR8 expression in
naı¨ve and memory B cells, while varying levels of the
other TLRs were expressed in those cells. We comple-
mented the characterization of the TLR profile in the
B-cell lineage by examining terminally differentiated
plasma cells: we found that plasma cells expressed all
TLRs, with the exception of TLR10 which is very weakly
expressed. By contrast, TLR10 was expressed very strongly
in naı¨ve and memory B cells. Strikingly, HSC expressed
virtually no TLR10. Lack of acceptable specificity of anti-
bodies to TLRs (data not shown) precluded analysis at
the protein level. Triggering TLRs resulted in increased
production of IgM and IgG as well as in the secretion of
soluble immunoglobulin by plasma cells, which also
speaks in favour of the functional integrity of TLRs and
their immunological significance. This increased immuno-
globulin production/secretion points to a novel role of
TLRs: TLRs are known for their role in the innate
immune response as well as for linking the innate and
adaptive immune responses by enhancing cellular activa-
tion, up-regulation of the major histocompatibility com-
plex (MHC) class molecules and release of cytokines; the
fact that TLR agonists directly engage in the generation
and strength of antibody production uncovers a novel
role that may have therapeutic application (e.g. boosting
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Figure 3. Triggering of toll-like receptors (TLRs) on plasma cells isolated from peripheral blood induces increased production of immunoglobu-
lin. Intracellular (a) IgM and (b) IgG expression, and mean fluorescence intensity of (c) IgM and (d) IgG, in plasma cells isolated from peri-
pheral blood. Plasma cells were isolated from peripheral blood by positive selection using CD138 microbeads. The viability of plasma cells after
72 hr in culture was always above 75%. Black histograms indicate isotype-control staining. The results shown are the means ± standard deviation
of three biological replicates of one out of three representative experiments. **P < 001, by Kruskall–Wallis and Dunn’s multicomparison test.
CpG ODN, cytosine–phosphate–guanosine oligonucleotide 2006; LPS, lipopolysaccharide.
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an antibody response). Noteworthy, we observed prefer-
ential production of IgM following triggering of TLR1/2
and of IgG following triggering of TLR3 or TLR9, as well
as a preferential secretion of immunoglobulin following
triggering of TLR1/2, TLR3, or TLR5 by terminally differ-
entiated plasma cells isolated from tonsils. By contrast, we
observed preferential production of IgM following trigger-
ing of TLR1–TLR4, and of IgG following triggering of
TLR7/8, by terminally differentiated plasma cells isolated
from peripheral blood. This may be a result either of
preferential recognition and specialized function of TLRs
in terminally differentiated plasma cells in response to
distinct conserved motifs or because of the preferential iso-
type immunoglobulin responses of the plasma cells we
purified. The latter is dependent on the donor’s immunity
repertoire. Previous analyses of TLR function in B-cell
lineages have shown that naı¨ve and memory B cells
respond to TLR agonists by sustaining or increasing their
TLR expression or by inducing the expression of pro-
inflammatory cytokines such as interleukin-8 (IL-8).5,6,16
Thus, the data we report outline a higher complexity of
TLR function in B-cell immunology when expanded to
terminal plasma cell differentiation.
Our observation of TLR expression by plasma cells from
tonsils or peripheral blood is in contrast to that reported
for plasma cells from the bone marrow, which shows lar-
gely the absence of TLR expression.17 It is generally agreed
that the bone marrow is the primary site of long-lived
plasma cells which are responsible for at least some persis-
tent antibodies, and that occur independently of memory
B cells and antigen.18 Thus, given their continuous anti-
body production, long-lived plasma cells in the bone mar-
row may not need to be boosted via TLR triggering and
therefore TLR expression by bone marrow plasma cells
may be dispensable. Intriguingly, we found that peripheral
blood plasma cells expressed TLR9 at approximately 10-
fold higher levels than their tonsillar counterparts. Never-
theless, triggering of TLR9 in peripheral blood plasma cells
did not result in increased intracellular IgG production, as
observed in tonsillar plasma cells. Thus, the level of TLR9
expression seems not to correlate to the level of augmented
immunoglobulin production upon triggering. A possible
explanation for this may be that only a small portion of
TLR9 is cleaved to the active form.19
The cell subset-specific TLR expression observed here
suggests that HSC and periphery plasma cells need the
expression of TLR1–TLR9, whereas B cells from secondary
lymphoid organs need the expression of TLR1, TLR2,
TLR5–TLR7, TLR9 and TLR10. We speculate that the dis-
tinct TLR profile of HSC is critical for their differentia-
tion towards a specific cell subset and dependent upon
the encountered pathogen recognition pattern to optimize
pathogen-driven immune responses. Indeed, recent work
in mice3 and humans20 has demonstrated that TLR sig-
nals bias HSC towards myelopoiesis directly by replacing
endogenous cytokines normally required for the survival,
proliferation and development of haematopoietic progeni-
tors. In naı¨ve and memory B cells, TLR triggering seems
to be restricted to sustaining or increasing their TLR
expression or inducing the expression of pro-inflamma-
tory cytokines such as IL-8.5,6,16 Finally, as we show,
peripheral plasma cell TLR engagement augments immuno-
globulin release. Nevertheless, other so far unidentified
TLR functions in these cell subsets may exist.
In conclusion, we report that TLR expression differs
according to the B-cell developmental stage. TLR1–TLR9
may promote augmentation of antibody production by
plasma cells, which may have therapeutic application. By
contrast, TLR10, for which no ligand has so far been rec-
ognized and which is virtually unexpressed in HSC or in
plasma cells, may functionally be linked to specific naı¨ve
and memory B-cell actions rather than simple pathogen
sensing. It is tempting to speculate that TLR10 mediates a
unique function (e.g. interaction with self-proteins and
thereby homing of naı¨ve and memory B cells to second-
ary lymphoid organs). This speculation is based on
TLR10 being expressed at the cell surface1 and not by cell
lineages other than B cells,5,6,9,16 B-cell differentiation to
plasma cells, requiring (among others) changes in cell-
surface proteins and homing,18 on findings of TLR4
recognizing host structures21 and of toll guiding dorsal-
ventral cell orientation in Drosophila.22
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The B-lymphotropic Epstein-Barr virus (EBV) encodes two isoforms of latent membrane protein 2 (LMP2),
LMP2A and LMP2B, which are expressed during latency in B cells. The function of LMP2B is largely unknown,
whereas LMP2A blocks B-cell receptor (BCR) signaling transduction and induction of lytic EBV infection,
thereby promoting B-cell survival. Transfection experiments on LMP2B in EBV-negative B cells and the
silencing of LMP2B in EBV-harboring Burkitt’s lymphoma-derived Akata cells suggest that LMP2B interferes
with the function of LMP2A, but the role of LMP2B in the presence of functional EBV has not been established.
Here, LMP2B, LMP2A, or both were overexpressed in EBV-harboring Akata cells to study the function of
LMP2B. The overexpression of LMP2B increased the magnitude of EBV switching from its latent to its lytic
form upon BCR cross-linking, as indicated by a more-enhanced upregulation and expression of EBV lytic genes
and significantly increased production of transforming EBV compared to Akata vector control cells or LMP2A-
overexpressing cells. Moreover, LMP2B lowered the degree of BCR cross-linking required to induce lytic EBV
infection. Finally, LMP2B colocalized with LMP2A as demonstrated by immunoprecipitation and immuno-
fluorescence and restored calcium mobilization upon BCR cross-linking, a signaling process inhibited by
LMP2A. Thus, our findings suggest that LMP2B negatively regulates the function of LMP2A in preventing the
switch from latent to lytic EBV replication.
Epstein-Barr virus (EBV) is a ubiquitous B-lymphotropic
gammaherpesvirus which persists after primary infection la-
tently in the host for life and may switch periodically to its lytic
form (28). In vitro, EBV undergoes very efficient growth trans-
formation and immortalizes infected B cells by latent infection,
resulting in lymphoblastoid cell lines (LCLs) expressing a lim-
ited number of viral genes, including six viral nuclear antigens
(EBNAs) and latent membrane protein 1 (LMP1) and LMP2
(30). The ability to transform B cells implicates EBV as the
culprit for a variety of malignancies, including Burkitt’s lym-
phoma, Hodgkin’s disease, and posttransplant lymphoprolif-
erative disease (8, 24, 38). In vivo, EBV persists in latently
infected memory B cells circulating in the peripheral blood
(30). These latently infected cells do not express EBNAs or
LMP1, but may express LMP2 (1, 2). Since LMP2 has no
transformation capacity (12), this may suggest a pivotal role of
LMP2 in the regulation of the balance between latent and lytic
EBV.
Transcription of LMP2 is controlled by two promoters sep-
arated in the viral DNA by 3 kb (31). Two mRNAs that have
different 5 exons followed by eight common exons encode two
distinct proteins, LMP2A and LMP2B, respectively. LMP2A
contains an N-terminal cytoplasmic domain of 119 amino acids
with eight tyrosines that are phosphorylated in LCLs, 12 trans-
membrane domains, and a C-terminal domain of 12 amino
acids. LMP2A blocks B-cell receptor (BCR) signal transduc-
tion through specific phosphotyrosine motifs in its N-terminal
domain and promotes B-cell survival. This function is depen-
dent on the expression level of LMP2A (1, 2, 5, 6, 15, 21, 35).
LMP2B lacks the entire N-terminal cytoplasmic domain. A
recent work using transfection of LMP2 into EBV-negative
cells has suggested possible roles for LMP2B. LMP2B colocal-
ized with LMP2A in the membrane where the C terminus of
both splice variants can interact and regulate the activity of
each other (17). Furthermore, LMP2B was shown to negatively
regulate LMP2A activity by interfering with its aggregation
(29). Another study revealed protein domains of LMP2B
which are required for intra- and extracellular localization and
self-aggregation (37), which raised the question of whether the
function of LMP2B in EBV is bound to its localization inde-
pendently of LMP2A. Nevertheless, whether and how LMP2B
is involved in the regulation of latent and lytic EBV infection
in B cells harboring the functional virus remains a largely
unresolved question.
Burkitt’s lymphoma-derived Akata cells provide an optimal
model to study the balance between latent and lytic EBV.
Specifically, lytic EBV infection can be initiated in Akata cells
by cross-linking their BCR using anti-immunoglobulin G (anti-
IgG) (36). Importantly, upon induction of lytic EBV infection,
the majority of viral genes are expressed (3, 39). Since these
EBV genes could have an impact on the function of LMP2B,
we used Akata cells to investigate the function of LMP2B in
cells harboring functional EBV. Recently, we found that the
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Hospital Epidemiology, University Children’s Hospital of Zurich, Zur-
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silencing of LMP2B reduces susceptibility to induction of lytic
EBV infection upon BCR cross-linking (27). This result indi-
cated a role of LMP2B distinct from that of LMP2A in the
regulation of EBV lytic activation. In this work, we further
pursue the hypothesis that LMP2B exhibits a negative-regula-
tory effect on LMP2A maintenance of EBV latency. Thus, we
compared the effects of overexpression of LMP2B and LMP2A
on the susceptibility to induction of lytic EBV infection and on
cellular signaling pathways in Akata cells.
MATERIALS AND METHODS
Cell lines and primary cells. The Burkitt’s lymphoma cell line Akata (36) was
grown in RPMI 1640 supplemented with 10% fetal calf serum, L-glutamine (2
mM), penicillin (100 U/ml), and streptomycin (100 g/ml). Akata cells were a
kind gift of A. Bell (Birmingham, United Kingdom). Akata cells transfected with
the plasmids pEneo (33), pEneo-LMP2A (27), and pEneo-FLAG-LMP2B,
named Akata-vector (27), Akata-LMP2A (27), and Akata-LMP2B pools 1 to 3,
respectively, were cultured in the same medium supplemented with 0.4 mg/ml
G418 (Promega, Mannheim, Germany). Akata-cre cells that stably overexpress
the regulatable creERT2 recombinase (9) integrated into the vector pcDNA3.1
were cultured in the same medium supplemented with 0.4 mg/ml G418 (Pro-
mega, Mannheim, Germany). Cord blood mononuclear cells (CBMC) were
obtained from heparinized blood by Ficoll-Hypaque gradient centrifugation
(Amersham Biosciences Europe GmbH, Otelfingen, Switzerland) and washed
with phosphate-buffered saline (Gibco, Invitrogen Life Sciences, Basel, Switzer-
land). Informed consent was obtained from parturient women. The Zurich in-
stitutional ethics committee approved the collection and use of clinical material.
B95.8 cells were cultured in Dulbecco’s minimal essential medium supplemented
with 10% fetal calf serum, L-glutamine (2 mM), penicillin (100 U/ml), and
streptomycin (100 g/ml) (23).
Plasmids. The sequence coding for LMP2B was PCR amplified from the
vector pSG5-LMP2 (15, 31) with following primers, including cloning adapters
and 3 FLAG for LMP2B tagging: FLAG-LMP2B-F (5-CGCGTTTAAACAT
GGACTACAAAGACCATGACGGTGATTATAAAGATCATGATATCGAT
TACAAGGATGACGATGACAAGAATCCAGTATGCCTGCCTG-3) and
LMP2-Rev (5-GCGCTCGAGTTATACAGTGTTGCGATATGGGGTC-3).
The PCR product was cloned via PmeI/XhoI into the Moloney murine leukemia
virus-derived pEneo bicistronic expression vector containing an internal ribo-
some entry site with a neomycin selection marker (33), resulting in the vectors
pEneo-FLAG-LMP2B and pEneo-LMP2A (27). Positive clones were verified by
sequencing. The parental pEneo plasmid was used as the control vector.
Transfection. Cells (1  106) were electroporated with 2 g of the pEneo,
pEneo-LMP2A, or pEneo-FLAG-LMP2B plasmid with Nucleofector II (Amaxa
GmbH, Cologne, Germany) with Buffer T and the program A-23. Electroporated
cells were allowed to recover for 2 days and were then selected with 0.8 mg/ml
G418 (Promega) for 2 to 3 weeks until resistant cells arose. These cells were
named Akata-vector, Akata-LMP2A, and Akata-LMP2B pools 1 to 3, respec-
tively. One month after selection, cells were supplemented with 0.4 mg/ml G418
and used for experiments. To generate double-transfected Akata cells, either
stable Akata-LMP2B cells were electroporated transiently (t) with the vector
pEneo-LMP2A (named 2B  At) or Akata-LMP2A cells were electroporated
transiently with the vector pEneo-FLAG-LMP2B (named 2A  Bt).
Immunoblot analysis. Total cellular protein extracts were prepared by disrup-
tion of cells in radioimmunoprecipitation assay lysis buffer (150 mM NaCl, 1%
NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate [SDS], and 50 mM Tris,
pH 7.5). After denaturation for 10 min in 4 loading LDS buffer (Invitrogen,
Basel, Switzerland), samples were separated on a 10% Bis-Tris gel (Invitrogen)
and transferred to a nitrocellulose membrane (Schweitzer & Schell Bioscience
GmbH, Dassel, Germany). Membranes were blocked with 5% low-fat milk in 1
phosphate-buffered saline (PBS)–0.1% Tween 20 and incubated with either
mouse anti-FLAG M2 (Sigma, St. Louis, MO), rat anti-LMP2A (clone 14B7) (5),
or anti-c-myc (A-14; Santa Cruz Biotech, Inc., Santa Cruz, CA) antibody over-
night at 4°C. Immunoreactive proteins were detected by the secondary antibodies
against mouse and rabbit, respectively (Cell Signaling Technology, Danvers,
MA) and an enhanced chemiluminescence detection kit (SuperSignal West
Femto; Perbio Science Switzerland S.A., Lausanne, Switzerland).
IP. Total cellular protein extracts were prepared by disruption of 5  106 cells
in Tris nondenaturing lysis buffer (150 mM NaCl, 1% Triton X-100, 1 mM
EDTA, and 50 mM Tris, pH 7.5), 2 mM NaF, and 2 mM Orthovanadate (all from
Sigma). Isolated proteins were immunoprecipitated with a Sigma immunopre-
cipitation (IP) kit according to the manufacturer’s instructions. IPs were per-
formed with the same antibodies used for immunoblotting or without an anti-
body.
Immunostaining. Cells (5  104) were centrifuged by Cytospin on double
Cytofunnel glass slides (Thermo, Waltham, MA) and fixed with methanol for 10
min at 20°C. Cells were permeabilized with 1% Triton X-100 in 1 PBS for 20
min at room temperature. Immunoreactive proteins were detected with a rat
anti-LMP2A antibody, 14B7 (1:100), and a secondary Alexa 488-labeled goat
anti-rat IgG antibody diluted 1:200 (Molecular Probes, Invitrogen). FLAG-
tagged LMP2B was detected with anti-FLAG M2 from Sigma (1:500) and a
secondary Alexa 594-labeled goat anti-mouse IgG antibody diluted 1:200 (Mo-
lecular Probes, Invitrogen). BZLF1 was detected with anti-BZLF1 (Argene,
North Massapequa, NY) diluted 1:100 and probed with the same secondary
antibody used for FLAG detection.
Flow cytometry. To evaluate the surface IgG (sIgG) content of transfected
cells for later stimulation experiments with BCR cross-linking, cells were fixed in
4% paraformaldehyde (Sigma) and stained with a phycoerythrin-labeled anti-
human IgG1, antibody (BD Biosciences, Basel, Switzerland). A phycoerythrin-
labeled anti-mouse IgG1, antibody (BD Biosciences) was used as an isotype
control. To determine the percentage of cells in which EBV was activated by
BCR cross-linking, 0.5 106 cross-linked and non-cross-linked cells were stained
with a fluorescein isothiocyanate (FITC)-labeled antiviral gp350/220 antibody
diluted 1:10 (Biodesign International, Saco, ME) and analyzed by flow cytometry
(FC-500; Beckmann-Coulter, Krefeld, Germany).
BCR cross-linking of Akata cells. Akata cells were split to 0.5  106 cells/ml
24 h before BCR cross-linking. Cells (0.5  106/ml) were then BCR cross-linked
with 0.1 g/l polyclonal rabbit anti-human-IgG (Dako, Zug, Switzerland) for
3 h and suspended afterwards in fresh RPMI 1640. Cross-linked and non-cross-
linked cells were collected for subsequent analyses.
qRT-PCR. Total RNA was extracted from 0.5  106 cells with an RNeasy kit
from Qiagen (Hombrechtikon, Switzerland). DNase [DNA-free; Ambion (Eu-
rope), Huntington, Cambridgeshire, United Kingdom] treatment was performed
before cDNA synthesis with an Omniscript RT kit (Qiagen). Quantitative real-
time PCR (qRT-PCR) was done with validated TaqMan systems for the house-
keeping gene HMBS and the lytic EBV genes BZLF1, BXLF1, and LMP2 (14) on
an ABI 7200 (Applied Biosystems). TaqMan data were analyzed using SDS 2.2
(Applied Biosystems), and mRNA expression was normalized to HMBS mRNA,
resulting in threshold cycle (CT) values. CT values were further normalized by
dividing “cross-linked” by “not cross-linked” values, resulting in CT values.
qRT-PCR data for control vector CT were set to 100% and LMP2B- or
LMP2A-overexpressing cells were compared to it.
Transformation assay. Fifty thousand freshly isolated CBMC per well were
seeded in a 96-well plate. Culture supernatants were filtered through a 0.45-m
polyvinylidene difluoride Millex-HV filter (Millipore Corporation, MA). Fifty
microliters of filtered culture supernatant of cells 24 h after anti-IgG cross-
linking or no cross-linking was added to a final volume of 100 l per well. A total
of 10 wells for each filtered culture supernatant was plated and inoculated.
Filtered supernatant from B95.8 served as the positive control, whereas the
negative control was CBMC cultured with medium only (23). The transformation
capacity was monitored by counting the wells after 6 weeks, when growth and
clustering of cells could be observed (34). The percentage of transformation was
calculated by setting 10 transformed wells to 100% and by normalization to the
transformation capacity of the supernatant of cells that were not cross-linked,
representing the spontaneous activation of EBV in Akata cells. Statistics were
done with Prism 4 (GraphPad Software, Inc.).
Calcium mobilization. Cells (5  106) were stained with Fluo-3 (6 M final
concentration) and Fura-Red (15 M final concentration; both from Invitrogen)
for 45 min in RPMI 1640 at 37°C. After a washing step with 1 PBS, cells were
stored at room temperature in the dark. Before measurement, cells were incu-
bated for 5 min at 37°C. Calcium mobilization was measured by adding ionomy-
cin (2 g/ml final concentration; Invitrogen) as the control and anti-IgG at the
same concentration as in stimulation experiments (100 g/ml) by using a FC-500
(Beckmann-Coulter) with an argon laser at 488 nm. Fluorescent emission was
recorded at 520 nm (Fluo-3) and 670 nm (Fura-Red), and the Fluo-3/Fura-Red
ratio was plotted against time. The baseline was recorded prior to anti-IgG
addition for 30 s and for 5 min after BCR cross-linking. The increase over the
baseline level was calculated for the time of peak of calcium mobilization (tp) by
using FlowJo 5.7.2 software. The percentage of responding cells was calculated
for the time slice from tp to tp  2 min. As an additional control, Akata-cre cells
were stimulated and the calcium mobilization was measured.
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RESULTS
Construction of LMP2B-overexpressing Akata cells. In or-
der to investigate the effects of LMP2B on LMP2A and the
switch from latent to lytic EBV replication, we first constructed
EBV-harboring Akata cells overexpressing either LMP2B or
LMP2A (27) and Akata cells with the vector control (27).
Given that no specific antibody against LMP2B exists, we
chose to tag LMP2B with a 3 FLAG sequence at the N
terminus. The tag was placed at the N terminus, since it has
been suggested that clustering of LMP2A and LMP2B occurs
over the common C termini and that LMP2B influences the
activity of its LMP2A isoform only when they colocalize (18,
29). As the transfection efficiency of B cells is low with com-
mon protocols, we decided to establish Akata cell pools stably
overexpressing LMP2B, LMP2A, or a control vector. Thus,
Akata cells were transfected independently with pEneo-
FLAG-LMP2B, pEneo-LMP2A, or the control vector pEneo
alone, as described in Materials and Methods. After neomycin
selection, stable overexpression of LMP2B was verified for all
three independently transfected Akata cell pools at the RNA
level by qRT-PCR and at the protein level by immunoblotting
and immunostaining. The three LMP2B-overexpressing cell
pools (Akata-LMP2B pools 1, 2, and 3) showed different levels
of overexpression of LMP2B after transfection (Fig. 1A). The
mRNA expression levels correlated with protein levels,
whereby Akata-LMP2B pool 1 showed a medium level, pool
2 a high level, and pool 3 the lowest level of LMP2B mRNA
and protein, respectively (Fig. 1B). Immunostaining was done
with Akata-LMP2B pool 2. Most overexpressed LMP2B local-
ized to cytosolic compartments, whereas smaller amounts were
detected in the plasma membrane (Fig. 1C). Furthermore, all
cell lines were stained for sIgG and were found to express sIgG
in similar percentages (Table 1). Thus, similar prerequisites for
susceptibility to stimulation by BCR cross-linking with anti-
IgG were ensured in the distinct cell lines.
LMP2B overexpression increases the magnitude of EBV
lytic activation after BCR cross-linking. To assess the distinct
effects of LMP2B and LMP2A on lytic activation of EBV in
FIG. 1. Generation of LMP2B-overexpressing Akata cells. (A) Overexpression of LMP2B pools 1 to 3 (2B-1, 2B-2, 2B-3) by qRT-PCR using
specific TaqMan systems targeting HMBS and LMP2 mRNA, respectively. (B) Immunoblot of FLAG-LMP2B pools 1 to 3 (2B-1, 2B-2, 2B-3).
(C) Immunostaining of FLAG-LMP2B in Akata-vector control cells and Akata-LMP2B pool 2 (2B-2).
TABLE 1. Characteristics of Akata cells useda
Cell line Vector construct % sIgG cells
% Cells activated by gp350/220 staining
0 h
24 h
Cross-linked Not cross-linked
Akatab None 96  1 ND ND ND
Akata-vectorb pEneo 92  2 0.30  0.11 4.62  0.06 0.58  0.09
Akata-LMP2Bc pEneo-FLAG-LMP2B 88  4 0.36  0.20 5.42  0.94 0.69  0.23
Akata-LMP2Ab pEneo-LMP2A 92  1 0.24  0.05 1.00  0.81 0.34  0.13
a ND, not detected.
b Values are presented as means  SD from three independent experiments.
c Values are presented as means  SD from pools 1 to 3.
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Akata cells, we stimulated Akata-LMP2B cells or Akata-
LMP2A cells and the corresponding Akata-vector control cells
by BCR cross-linking. After 24 h, cross-linked and non-cross-
linked cells were collected and examined by qRT-PCR for
expression of the immediate-early lytic gene BZLF1 and the
early lytic gene BXLF1 encoding the viral thymidine kinase.
The data were normalized to HMBS mRNA expression and
are presented as ratios of cross-linked to non-cross-linked cells
(Fig. 2). Akata-LMP2B cells showed mRNA expression levels
of BZLF1 and BXLF1 that increased 4-fold and 55-fold, re-
spectively (Fig. 2A). By contrast and as expected, transcription
levels of lytic EBV genes were reduced in Akata-LMP2A cells,
where expression of BZLF1 and BXLF1 mRNAs was reduced
by 97% and 99%, respectively (Fig. 2B). To confirm these
results at the protein level, we stained cells before and 24 h
after BCR cross-linking with a FITC-labeled antiviral gp350/
220 antibody in three independent stimulations. Indeed, as
determined by flow cytometry, Akata-LMP2B cell pools ex-
pressed up to 5.4-fold- and 4.6-fold-higher gp350/220 levels
than Akata-LMP2A cells and Akata-vector control cells, re-
spectively (Fig. 2C; Table 1).
LMP2B-overexpressing Akata cells produce more infectious
EBV than control cells upon BCR cross-linking. To verify the
complete activation of the EBV lytic cycle following BCR
cross-linking, the production of infectious EBV was monitored
by the transformation of primary human B cells (34). Follow-
ing BCR cross-linking of Akata-LMP2B, Akata-LMP2A, and
Akata-vector control cells, supernatants were prepared from
three independent experiments and added to freshly isolated
CBMC to determine the transformation capacity of the infec-
tious EBV produced. After normalization to non-cross-linked
cells, the transformation capacities of supernatants from
Akata-vector control cells were 67%, but those from Akata-
LMP2B-cell pools were up to 100% (P 	 0.0356), in contrast
to the 0% transformation capacity of supernatants from Akata-
LMP2A cells (P 	 0.0089; Fig. 3).
Overexpression of LMP2B decreases the degree of BCR
stimulation required to induce lytic EBV infection, in contrast
to overexpression of LMP2A. LMP2A blocks BCR signaling,
thereby impeding EBV lytic activation (6). It is not clear how
the expression level of LMP2A influences the degree of BCR
cross-linking (BCR activation) required to induce lytic EBV
infection and how this is affected by LMP2B overexpression.
Therefore, we assessed the magnitude of EBV lytic activation
as a function of the anti-IgG dose to engage BCR by cross-
linking Akata-vector, Akata-LMP2B, or Akata-LMP2A cells
with increasing concentrations of anti-IgG. To quantify the
activation of EBV lytic infection, mRNA expression of BZLF1
FIG. 2. LMP2B overexpression increases the magnitude of EBV lytic activation after BCR cross-linking, whereas LMP2A overexpression
results decreased magnitude. qRT-PCR with specific systems for HMBS, BZLF1, and BXLF1 mRNA, respectively, for Akata-vector control,
Akata-LMP2B (A), and Akata-LMP2A (B) 24 h after BCR cross-linking. Means and standard deviations (SD) of qRT-PCR results are from three
independent stimulation experiments on one representative polyclonal population. (C) Flow cytometry for gp350/220-FITC-labeled unstimulated
(gray line) or stimulated (black line) cells 24 h after BCR cross-linking. One representative measurement is shown for Akata-vector control,
Akata-LMP2B, and Akata-LMP2A cells with gp350/220-FITC-positive cells gated and indicated as percentages. Means and SD for three
independent experiments are summarized in Table 1.
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at 24 h after BCR cross-linking was measured (Fig. 4). Cross-
linked Akata-vector control cells compared to non-cross-
linked control cells showed an almost 100-fold increase of
BZLF1 mRNA expression with the lowest anti-IgG concentra-
tion of 5 g/ml and around 100-fold-higher peak BZLF1
mRNA expression levels with anti-IgG concentrations of 25
g/ml or higher. Akata-LMP2B cells showed a similar but
greater increase in BZLF1 mRNA expression and around five-
fold-higher peak levels than Akata-vector cells with anti-IgG
concentrations of 25 g/ml or higher. By contrast, Akata-
LMP2A cells required anti-IgG concentrations of at least 25
g/ml to show an increase in BZLF1 mRNA expression and an
anti-IgG concentration of 625 g/ml to show maximal BZLF1
mRNA expression levels, which were around 10-fold lower
than peak expression levels in Akata-vector cells. Thus, cells
with higher expression levels of LMP2A required higher doses
of anti-IgG to induce an EBV lytic activation, which was still of
a considerably lower magnitude than that for Akata-vector
control cells. These results suggest that the expression level of
LMP2A has an impact on the amount of BCR cross-linking
required to induce lytic EBV infection and that higher expres-
sion levels of LMP2A can be overridden, though only partially,
with a higher degree of BCR cross-linking. On the other hand,
higher LMP2B expression levels seemed to lower the degree of
BCR cross-linking required to induce EBV lytic activation and
to increase the magnitude of inducible EBV lytic activation.
LMP2B physically interacts with LMP2A before and after
BCR cross-linking in Akata cells. To investigate whether over-
expressed LMP2B physically interacts with endogenous
LMP2A, we isolated whole-cell protein extracts from Akata-
LMP2B pool 2 (2B-2) and Akata-vector control cells with a
subsequent pull-down IP of LMP2A. Subsequently, we per-
formed immunoblotting against FLAG tags and LMP2A (Fig.
5A). Indeed, coimmunoprecipitated LMP2B was detected by
anti-FLAG in Akata-LMP2B cells but not in Akata-vector
control cells, whereas endogenous LMP2A was detected in
both. Control IPs, with an anti-c-myc antibody or without an-
tibody and subsequent immunoblotting against c-myc or FLAG
(Fig. 5B and C) showed no unspecific pull-down, confirming
the specificity of the IPs, despite the overexpression of FLAG-
LMP2B.
Next, to elucidate in which compartment LMP2B and
LMP2A localize, we transfected Akata-LMP2A (2A) tran-
siently with FLAG-LMP2B (Bt) (indicated as 2A  Bt) and
immunostained LMP2A or FLAG-LMP2B for fluorescent mi-
croscopy. The images shown in Fig. 6B suggest partial colocal-
ization of both LMP2 isoforms in the same cellular compart-
ments (Fig. 6B). Additionally, we found an accumulation of
LMP2B in the cytosolic region, as seen in stable Akata-LMP2B
and described above (Fig. 1C). To determine if there is a
relocalization of LMP2A or LMP2B upon BCR cross-linking,
we double-stained Akata-LMP2A cells transiently transfected
with FLAG-LMP2B (2A  Bt) for FLAG-LMP2B and for
LMP2A (Fig. 6C), and for BZLF1 and LMP2A (Fig. 6D) after
BCR cross-linking. An immunofluorescence analysis indicated
a rather modest shift of LMP2A and LMP2B into the cytosol
after BCR cross-linking, but still-adequate amounts of both
LMP2s were located in the same compartments as before BCR
cross-linking.
LMP2B restores calcium mobilization in LMP2A-overex-
pressing Akata cells. It has been previously established that
LMP2A blocks calcium mobilization induced by BCR cross-
linking (20–22). To investigate the impact of LMP2B overex-
pression on calcium mobilization, we determined the calcium
levels before (baseline) and after BCR cross-linking, monitor-
ing the kinetics for 5 min in Akata-vector control, Akata-
LMP2B pool 2 (2B-2), and Akata-LMP2A (2A) cells, respec-
tively. Additionally, Akata-cre cells overexpressing creERT2
FIG. 3. More infectious EBV is produced in LMP2B-overexpress-
ing Akata cells than in the control. Isolated CBMC were infected with
supernatant from Akata-vector control, Akata-LMP2A, or Akata-
LMP2B pools 1 to 3 collected 24 h after stimulation by BCR cross-
linking. The transformation capacity was monitored by counting the
wells after 6 weeks, at which time growth and clustering of cells indi-
cated transformation. The percentage of transformation was calcu-
lated by setting 10 wells showing signs of transformation to 100% and
by normalization to the transformation capacity of the supernatant of
the corresponding BCR non-cross-linked control cells, representing
the spontaneous EBV lytic activation in Akata cells. Means and SD are
from three independent stimulation experiments with subsequent col-
lection of supernatant and infection of CBMC. t tests were performed
with a 95% confidence interval. *, no wells showed signs of transfor-
mation.
FIG. 4. Overexpression of LMP2B decreases the degree of BCR
stimulation required to induce lytic EBV infection, in contrast to
overexpression of LMP2A. BZLF1 mRNA expression in Akata-vector
control (f), Akata-LMP2A (F), or Akata-LMP2B (Œ) 24 h after BCR
cross-linking using increasing doses of anti-IgG. Means and SD are
from three independent stimulation experiments on one representative
polyclonal population.
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recombinase in the cytosol were stimulated and monitored in
parallel to exclude any epiphenomena due merely to overex-
pression which could influence calcium mobilization. Calcium
mobilization reached up to 3-fold, 3.3-fold, and 3.5-fold peaks
compared to baseline levels after BCR cross-linking in Akata-
vector control cells, Akata-cre cells, and Akata-LMP2B cells,
respectively (Fig. 7). Next, we generated double transfectants
by electroporation of Akata-LMP2B cells transiently with the
vector pEneo-LMP2A (2B  At) as described in Materials and
Methods and measured the calcium mobilization after BCR
cross-linking. We observed not only a decrease of calcium
mobilization from 3.5-fold to 1.9-fold in Akata-LMP2B cells
but also a decrease of responding cells from 90% to 74%.
These results are in agreement with previous studies (20–22).
The calcium mobilization in Akata-LMP2A cells revealed the
same low calcium mobilization and percentage of responding
cells as observed in the double-transfected 2B  At cells (1.8-
fold and 77%, respectively). To address the question of
whether it is possible to rescue the phenotype of Akata-vector
control cells, we transiently transfected Akata-LMP2A cells
with the vector pEneo-FLAG-LMP2B (2A  Bt). Interest-
ingly, the calcium mobilization was restored to Akata-vector
control cell levels from 1.8- to 2.9-fold after BCR cross-linking.
Additionally, responding cells increased from 77% to 82% in
double-transfected 2A  Bt cells (Fig. 7).
DISCUSSION
In this work, we investigated the impact of LMP2B on the
potential of LMP2A to maintain EBV in its latent state. We
demonstrate that LMP2B increases the magnitude of EBV
switching from its latent to its lytic form upon BCR cross-
linking, lowers the degree of BCR cross-linking required to
provoke this switching, and is involved in augmenting signaling
via calcium mobilization upon BCR cross-linking in Akata cells
harboring functional EBV. These observations suggest a neg-
ative regulatory effect of LMP2B on the ability of LMP2A to
block BCR signaling, thereby preventing EBV from switching
from latent to lytic infection in B cells.
Although LMP2A and LMP2B are similar in their structure,
the lack of the signaling amino-terminal domain in LMP2B
indicates distinct functions for these two proteins. Indeed, the
overexpression of LMP2B in Akata cells resulted in higher
mRNA expression of immediate-early and early lytic EBV
genes upon BCR cross-linking, whereas the overexpression of
LMP2A results in lower mRNA expression in these genes.
FIG. 5. LMP2B coimmunoprecipitates with LMP2A. Whole-cell protein lysates of Akata-LMP2B pool 2 (2B-2) and the Akata-vector control
were immunoprecipitated (IP) with anti-LMP2A (A). The IPs were separated on a SDS gel and immunoblotted (IB) against FLAG and LMP2A.
The heavy band in the LMP2A immunoblot represents the heavy Ig chain of the mouse antibody used for pull-down, whereas the lower, narrow
band represents the equal amount of LMP2A pulled down in 2B-2 and vector input lysates. (B) The input lysate of 2B-2 was split into IPs without
antibody, against c-myc, and FLAG and immunoblotted (three dilutions; 1, 0.2, 0.04) against FLAG. No unspecific pull-down with anti-c-myc
was observed due to the overexpression of FLAG-LMP2B. (C) The same IPs as those used in panel B were loaded on a SDS gel and
immunoblotted against c-myc to verify that the IP was working. The upper band (65 kDa) and the lower band (63 kDa) in the input lysate of 2B-2
represent two forms of c-myc.
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Moreover, LMP2B overexpression leads as well to production
of more EBV envelope protein gp350/220 and functional virus
than do LMP2A-overexpressing or control Akata cells upon
BCR cross-linking. These findings are compatible with our
previous observation that silencing of LMP2B in Akata cells
reduces the susceptibility of these cells to undergo EBV lytic
activation induced by BCR cross-linking (27). Thus, our cur-
rent and previous data provide evidence that LMP2B is in-
volved in the regulation of EBV switching from latent to lytic
infection EBV in B cells harboring the whole virus in its latent
form.
The overexpression of LMP2B did not result in spontaneous
switching of latent to lytic EBV. Nevertheless, the higher mag-
nitude of EBV lytic activation in LMP2B-overexpressing Akata
cells than that in control Akata cells upon BCR cross-linking
with similar doses of anti-IgG suggested that LMP2B exerts its
mode of action through lowering the required degree of BCR
cross-linking and thus BCR signaling needed. Since LMP2A
blocks BCR signaling (5, 6, 12, 15, 21, 29, 30, 35), we addressed
the fundamental question of whether the magnitude of EBV
lytic activation at given expression levels of the LMP2s de-
pends on the dose of anti-IgG required to cross-link BCR, i.e.,
the degree of BCR cross-linking. Indeed, although increasing
doses of anti-IgG elevated the levels of activation of lytic EBV
in LMP2A-overexpressing Akata cells until they reached a
plateau, peak levels of induced lytic EBV in these cells were
around at least 10-fold lower than in control Akata cells or
around 30- to 50-fold lower than in LMP2B-overexpressing
Akata cells. This result suggests that both endogenous and
overexpressed LMP2A is able to reduce BCR signaling very
effectively and cannot be completely counteracted, even by
saturated levels of anti-IgG added for cross-linking. Thus, the
amount of overexpressed LMP2B was able to decrease the
activity of endogenous LMP2A on BCR signaling but could
not abolish it completely in whole-EBV-containing cells.
An important question to be addressed was if there is an
interaction of LMP2A and LMP2B in Akata cells harboring
EBV and, if so, where the two isoforms of LMP2 colocalize.
The physical interaction between LMP2A and LMP2B was
verified by pulling down FLAG-LMP2B with endogenous
LMP2A. Our immunostaining results suggest an accumulation
of LMP2B in intracellular compartments and to a lesser extent
on the plasma membranes of Akata cells harboring whole
EBV. Lynch et al. (17) reported that transiently expressed
LMP2B localized to perinuclear regions and colocalized with
transiently or constitutively expressed LMP2A in EBV-nega-
tive BJAB cells or LCL B95-8CR, respectively. Studies using
HEK 293 cells overexpressing full-length or deletion mutants
of LMP2A revealed a clustering signal of LMP2A at the C
terminus leading to homodimerization (18). As LMP2A and
LMP2B share eight exons and the C terminus, Rovedo and
Longnecker (29) hypothesized that LMP2B colocalizes with
LMP2A, forming heterodimers, and subsequently negatively
regulates LMP2A activity, leading to decreased degradation of
FIG. 6. Overexpressed LMP2B and LMP2A colocalize before and after BCR cross-linking. (A) Negative control for secondary antibodies.
(B) To investigate where LMP2B and LMP2A localize, we transiently transfected Akata-LMP2A cells with FLAG-LMP2B (2A  Bt) and stained
for LMP2A and FLAG-LMP2B. To determine if there occurs a relocalization of LMP2A or LMP2B upon BCR cross-linking, we stained the
double-transfected Akata cells (2A  Bt) for FLAG-LMP2B and for LMP2A (C) and for BZLF1 and LMP2A (D) 3 h after BCR cross-linking
(E). DAPI, 4,6-diamidino-2-phenylindole.
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the tyrosine kinase Lyn. A more-recent study showed that
when tagged LMP2B was overexpressed in BJAB cells or HEK
293T cells, LMP2B was found exclusively in intracellular peri-
nuclear compartments (29, 37), a result which is in apparent
contrast with the results of the aforementioned study. When
LMP2B was truncated at any domain, it resulted in localization
to the cell surface. Based on these results taken together, one
can hypothesize that the major impact of LMP2B on LMP2A
takes place in endosomes, where it interferes either with the
activity of LMP2A and subsequent ubiquitination and degra-
dation of Lyn or with the trafficking of LMP2A back to the
plasma membrane.
An immunofluorescence analysis of LMP2A and LMP2B
suggested a colocalization of LMP2A and LMP2B in Akata
cells overexpressing both proteins. We detected a rather mod-
est shift of LMP2B and LMP2A into the cytosol, which sug-
gests their internalization after BCR cross-linking. Neverthe-
less, a large amount of both LMP2s remains detectable on the
plasma membrane, demonstrating an intact turnover process.
Moreover, this experiment allowed us to exclude the possibility
of misfolded and degraded protein in the endoplasmic reticu-
lum due to overexpression, as has been reported in earlier
studies (10, 19). It is known that LMP2A aggregates in lipid
rafts, assembling as a signalosome which enables a transient
interaction with the tyrosine kinases Syk and Lyn with a sub-
sequent block of the BCR signal (5–7, 15, 16, 21, 25, 26, 35).
One can hypothesize that after BCR cross-linking, the anti-
IgG/BCR complex is internalized together with closely located
lipid rafts and LMP2A signalosomes. If there is an additional
function of LMP2A in preventing the whole complex from
being transported again to the cell membrane, in this way
blocking continuous stimulation, one can hypothesize that
there is a loss of LMP2A at the cell surface and an accumu-
lation in endosomes located in the cytosol after BCR cross-
linking. LMP2B, which is found in cytosolic compartments,
may intervene in this step, disrupting homodimerized LMP2A
and restoring the turnover.
As demonstrated here for the first time, calcium mobiliza-
tion upon BCR cross-linking is dependent on the expression
level of LMP2B in EBV-harboring Akata cells. As expected
from previous reports (20–22), we observed virtually no cal-
cium mobilization in LMP2A-overexpressing cells upon BCR
cross-linking. By contrast, after transient transfection of
LMP2B into LMP2A-overexpressing Akata cells, calcium mo-
bilization after BCR cross-linking is increased to levels com-
parable to those observed for Akata cells overexpressing
LMP2B. Conversely, we measured a reduced calcium mobili-
zation in LMP2B-overexpressing Akata cells transiently trans-
fected with LMP2A. As transiently transfected vectors express-
ing the gene of interest lead to high levels of protein, the
dominant effect on the stably transfected Akata cells was pre-
dictable. Three different signaling pathways which are acti-
vated upon BCR cross-linking in Akata cells have been ana-
lyzed: (i) calcium mobilization through phosphatidylinositol
3-kinase, (ii) c-Jun N-terminal kinase activation through Syk
and Lyn signaling, and (iii) ERK1/2 phosphorylation through
the RAS protein (4). Nevertheless, whether LMP2B is involved
partially or throughout all these signaling cascades, taking a
key regulatory function upstream, remains unknown. Rovedo
and Longnecker showed recently that in the EBV-negative
B-cell line BJAB, ectopically expressed LMP2B decreases the
activity of LMP2A by alteration of the phosphorylation status
(29). Thus, LMP2B would function at an initial step of BCR
signaling to restore BCR signal transduction which was
blocked by LMP2A. As a more downstream read-out, they
chose to measure the calcium mobilization in BJAB cells upon
BCR cross-linking. As has previously been shown, the overex-
pression of LMP2A nearly abolished calcium mobilization (20–
22). According to the hypothesis of BCR signal restoration by
LMP2B, ectopic overexpression of both splice variants of
LMP2 together resulted in the phenotype of BJAB transfected
with vector control only.
LMP2B may have important functions not only in the mod-
ulation of latent and lytic EBV infection in tumor cells or
FIG. 7. LMP2B restores calcium mobilization in LMP2A-overex-
pressing Akata cells. Calcium levels were determined before and after
BCR cross-linking, and the kinetics were measured for 5 min. Upper
panels, calcium mobilization after BCR cross-linking in Akata control
cells and, as an additional control, in Akata cells with epigenetic
overexpression of an unspecific protein in the cytosol (see Materials
and Methods). Middle panels, calcium mobilization after BCR cross-
linking in Akata-LMP2B cells without (2B) and with (2B  At) tran-
siently transfected LMP2A. Lower panels, calcium mobilization after
BCR cross-linking in Akata-LMP2A cells without (2A) and with (2A
Bt) transiently transfected FLAG-LMP2B. Baselines were measured
just before BCR cross-linking. The percentage of responding cells was
calculated as described in Materials and Methods.
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memory B cells in the periphery. As was reported previously,
LMP2A is expressed in newly infected naı¨ve B cells before
latency is established and serves as a tonic signal for survival.
This scenario might be true for B cells with crippled or a total
loss of BCR expression, leading in the worst case to Hodgkin’s
lymphoma (11, 13). In contrast, if a naı¨ve B cell which has a
functional BCR is newly infected and receives the survival
signal, the additional signal of LMP2A might resemble in total
an activated BCR, forcing EBV to lytic infection. In the pres-
ence of LMP2B, the signal of LMP2A would be downregu-
lated, not leading to activated lytic EBV as was suggested
previously for high levels of LMP2A (32).
In conclusion, the data presented here provide evidence that
LMP2B is involved in the regulation of switching from latent to
lytic EBV in B cells harboring functional EBV. Based on our
present and previous findings for Akata cells (27) together with
observations made for the EBV-negative cell line BJAB (29),
we suggest that LMP2B has an impact on the activity of
LMP2A, resulting in increased susceptibility to induction of
lytic EBV infection through modulation of BCR and down-
stream signaling.
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